Selection of novel antigens from Leishmania spp. and design of live recombinant salmonella vaccines against experimental visceral leishmaniasis by Schroeder, Juliane
  
 
Selection of novel antigens from Leishmania spp. 
and design of live recombinant salmonella vaccines 




D i s s e r t a t i o n 
 
zur Erlangung des akademischen Grades 
d o c t o r  r e r u m  n a t u r a l i u m 
( Dr. rer. nat.) 
 
 
im Fach Biologie 
 
eingereicht an der Mathematisch-Naturwissenschaftlichen Fakultät I 
der Humboldt-Universität zu Berlin 
 
von 
Diplom-Ingenieurin (FH) Juliane Schroeder 
 
 
Präsident der Humboldt-Universität zu Berlin 
Prof. Dr. Dr. h.c. Christoph Markschies 
 
Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I 
Prof. Dr. Lutz-Helmut Schön 
 
 
Gutachter:  1. Prof. Dr. R. Lucius 
2. Prof. Dr. Tamás Laskay 
3. Dr. Maurice Gallagher 
 
 
Tag der mündlichen Prüfung: 29.09.2010 
 
   II 
Acknowledgement 
 
First, I would like to thank Dr. Toni Aebischer for giving me the great opportunity to 
do my PhD in his lab at the University of Edinburgh. 
 
Furthermore I would like to thank the members of the Leishmania lab, but especially 
Dr. Athina Paterou and Dr. Toni Aebischer, without whom I would still be sitting at 
the bench homogenizing foot pads and who both read and corrected my thesis and my 
English. I also would like to thank Anna Lehle for excellent lab work. 
 
It has been a pleasure to work at the 3IR at Edinburgh University and I would like to 
thank everyone for providing such a friendly working atmosphere. Special thanks are 
going to Dr. Graeme Cowan for showing me the magical world of protein 
purification, Dr. Martin Waterfall for showing me how to work the LSR, Dr. Dianne 
Murray for work at the confocal microscope, the collaborators at the University of 
York, Prof. Paul Kaye and Dr. Najmeeyah Brown and finally the guys from the 
animal house. Bette Boyle, who as lab fairy did provide me not only with clean lab 
ware, tip boxes and solutions, but also with an open ear for the everyday lab sorrows, 
a friendly word or the every so often chit-chat between experiments. 
 
Mein besonderer Dank gilt meinen Freunden und meiner Familie, speziell meiner 
Mutter, die mir das Studium in erster Linie ermöglicht hat, aber auch für die seelische 
und moralische Unterstützung während der Doktorarbeit, auch wenn es bedeutet auf 
mich des Öfteren verzichten zu müssen. 
 
And last but certainly not least I would like to thank Andrew for his patience and 
tolerance towards a very busy and stressed PhD student and also for providing me 







                                                                                                Table of contents 
   III




1. INTRODUCTION................................................................................................... 1 
1.1 LEISHMANIA LIFE CYCLE ........................................................................................ 1 
1.2 LEISHMANIA RELATED DISEASES............................................................................ 2 
1.2.1 CUTANEOUS LEISHMANIASIS..................................................................................... 3 
1.2.2 VISCERAL LEISHMANIASIS ........................................................................................ 4 
1.3 TREATMENT OF VISCERAL LEISHMANIASIS ........................................................... 5 
1.4 IMMUNOLOGY OF LEISHMANIASES......................................................................... 6 
1.5 LEISHMANIASES – A GROWING PROBLEM?............................................................ 8 
1.6 ANTI-LEISHMANIAL VACCINES ............................................................................... 9 
1.6.1 REQUIREMENTS......................................................................................................... 9 
1.6.2 LEISHMANIZATION .................................................................................................. 10 
1.6.3 ANTIGENS................................................................................................................ 11 
1.6.4 ADJUVANT AND DELIVERY SYSTEMS ...................................................................... 11 
1.7 ATTENUATED LIVE SALMONELLA AS VACCINE CARRIERS.................................. 12 
1.8 LOCALISATION OF ANTIGEN IN THE SALMONELLA CARRIER ............................. 14 
1.9 OBJECTIVES ........................................................................................................... 16 
2. MATERIALS AND METHODS ......................................................................... 17 
2.1 ELECTRICAL LABORATORY EQUIPMENT ............................................................. 17 
2.2 CHEMICALS AND REAGENTS ................................................................................. 18 
2.3 MEDIA..................................................................................................................... 19 
2.4 BUFFERS AND SOLUTIONS...................................................................................... 21 
2.5 BIOLOGICALS......................................................................................................... 26 
2.6 MOLECULAR BIOLOGICAL METHODS................................................................... 30 
2.6.1 SITE-DIRECTED MUTAGENESIS AND PRIMER DESIGN .............................................. 30 
2.6.2 PREPARATION OF DNA FOR LIGATION ................................................................... 30 
2.6.3 PCR PURIFICATION.................................................................................................. 31 
2.6.4 DNA SEQUENCING .................................................................................................. 31 
2.6.5 LIGATION................................................................................................................. 31 
2.6.6 PREPARATION OF CHEMICALLY COMPETENT CELLS ............................................... 31 
2.6.7 TRANSFORMATION .................................................................................................. 32 
2.6.8 AGAROSE GEL ELECTROPHORESIS........................................................................... 32 
2.6.9 DNA EXTRACTION FROM GELS ............................................................................... 32 
2.6.10 COLONY PCR .......................................................................................................... 33 
2.7 PROTEIN TECHNIQUES........................................................................................... 33 
2.7.1 AMIDOBLACK PROTEIN QUANTIFICATION............................................................... 33 
2.7.2 SDS-PAGE.............................................................................................................. 34 
2.7.3 WESTERN BLOT ANALYSIS ...................................................................................... 35 
2.8 PROTEIN PURIFICATION ........................................................................................ 36 
2.8.1 INDUCTION OF RECOMBINANT PROTEIN.................................................................. 36 
2.8.2 PURIFICATION OF SOLUBLE PROTEINS..................................................................... 36 
2.8.3 PURIFICATION OF PROTEINS FROM INCLUSION BODIES ........................................... 37 
                                                                                                Table of contents 
   IV 
2.9 PARASITE CULTURES ............................................................................................. 38 
2.9.1 MAINTENANCE OF LEISHMANIA PROMASTIGOTE CULTURES .................................. 38 
2.9.2 FREEZE/THAWING OF LEISHMANIA PARASITES ....................................................... 38 
2.10 ANIMALS, IMMUNISATION AND PROTECTION EXPERIMENTS.............................. 39 
2.10.1 MICE........................................................................................................................ 39 
2.10.2 PREPARATIONS OF FROZEN SALMONELLA STOCKS FOR IMMUNISATION................. 39 
2.10.3 PURIFICATION OF OUTER MEMBRANE VESICLES ..................................................... 40 
2.10.4 DETERMINATION OF BACTERIAL FITNESS BY COLONISATION ASSAY ..................... 40 
2.10.5 INFECTION OF MICE WITH L. MAJOR AND FOOT PAD MEASUREMENTS..................... 41 
2.10.6 DETERMINATION OF L. MAJOR BURDEN IN MURINE ORGANS .................................. 41 
2.10.7 DETERMINATION OF HEPATOSPLENOMEGALLY AND L. DONOVANI BURDEN IN 
IMPRESSION SMEARS ............................................................................................... 42 
2.10.8 GIEMSA STAINING ................................................................................................... 42 
2.10.9 BLOOD COLLECTION AND SERUM PREPARATION .................................................... 42 
2.11 IMMUNOLOGICAL METHODS................................................................................. 43 
2.11.1 ELISA ..................................................................................................................... 43 
2.11.2 FLOW CYTOMETRY (FACS) .................................................................................... 44 
2.11.3 STAINING OF LEISHMANIA PARASITES FOR FLUORESCENT MICROSCOPY................ 44 
2.12 STATISTICAL ANALYSIS ......................................................................................... 45 
3. RESULTS .............................................................................................................. 46 
3.1 IN SILICO SELECTION OF NOVEL ANTIGEN CANDIDATES FROM  
LEISHMANIA SPP..................................................................................................... 46 
3.2 CONSTRUCTION OF OPTIMISED LIVE VACCINES .................................................. 51 
3.2.1 SURFACE EXPRESSION PLASMIDS ............................................................................ 51 
3.2.2 INTRODUCTION OF MUTATIONS INTO THE RIBOSOMAL BINDING SITE..................... 53 
3.2.3 CYTOSOLIC EXPRESSION PLASMIDS ........................................................................ 54 
3.2.4 EVALUATION OF VACCINE STRAINS AND SELECTION OF SUITABLE CANDIDATES  
FOR PROTECTION STUDIES IN MICE.......................................................................... 56 
3.2.5 PURIFICATION OF RECOMBINANT ANTIGENS FROM E. COLI .................................... 62 
3.3 PRE-CLINICAL EVALUATION OF NOVEL LIVE VACCINE CANDIDATES ................ 67 
3.3.1 RE-EVALUATION OF GENERAL AND SYNERGISTIC VACCINATION EFFECT OF 
SELECTED VACCINE STRAINS................................................................................... 71 
3.3.2 EVALUATION OF VACCINE EFFICIENCY IN C57BL/6 MICE ...................................... 74 
3.3.3 EVALUATION OF VACCINE CANDIDATE STRAINS IN THE L. DONOVANI  
MOUSE MODEL......................................................................................................... 76 
3.3.4 DETERMINATION OF VACCINE INDUCED CELLULAR AND HUMORAL IMMUNE 
RESPONSES .............................................................................................................. 80 
3.3.4.1 T cell response ......................................................................................................... 80 
3.3.4.2 Antibody response to vaccination ............................................................................ 83 
3.4 EXPLOITING OUTER MEMBRANE VESICLES TO AUGMENT ANTIGEN-S 
PECIFIC IMMUNE RESPONSES ................................................................................ 85 
3.5 STRUCTURAL AND FUNCTIONAL ANALYSIS OF LINJ08.1140 .............................. 93 
3.5.1 PREDICTION OF LINJ08.1140 SECONDARY STRUCTURE .......................................... 93 
3.5.2 GENERATION OF A POLYCLONAL ANTIBODY AGAINST LINJ08.1140 ...................... 95 
3.5.3 MAPPING OF MHC-I SPECIFIC EPITOPES USING IN SILICO PEPTIDE PREDICTION ..... 99 
4. DISCUSSION ...................................................................................................... 103 
4.1 IN SILICO SELECTION OF NOVEL ANTIGEN CANDIDATES ................................... 104 
4.2 DISCOVERY OF TWO NOVEL PROTECTIVE ANTIGENS TO VACCINATE  
AGAINST L. MAJOR AND L. DONOVANI................................................................. 105 
                                                                                                Table of contents 
   V
4.3 VACCINE-INDEPENDENT FACTORS TO INFLUENCE AND MODULATE  
VACCINE INDUCED IMMUNE RESPONSE .............................................................. 109 
4.4 ATTENUATED SALMONELLA AS LIVE CARRIER VACCINE AGAINST  
VISCERAL LEISHMANIASIS................................................................................... 111 
4.5 RECOMBINANT OUTER MEMBRANE VESICLES TO AUGMENT VACCINE- 
INDUCED IMMUNE RESPONSES ............................................................................ 116 
4.6 OUTLOOK ............................................................................................................. 119 
REFERENCES .................................................................................................................... 121 
LIST OF FIGURES............................................................................................................. 133 
LIST OF TABLES............................................................................................................... 134 
SUPPLEMENTARY MATERIAL I.................................................................................. 135 



























                                                                                                      Abbreviations 




AIDA Autotransporter involved in diffuse adherence 
AIDS Acquired immunodeficiency syndrome 
AmpR Ampicillin resistance 
APC Allophycocyanin 
APC Antigen presenting cell 
APS Ammonium persulfate 
BCG Bacillus of Calmette and Guerin 
bla beta-lactamase 
BMI Body-mass index 
BSA Bovine serum albumin 
CAI Codon adaptation index 
CD Cluster of differentiation 
CFU colony forming unit 
CL cutaneous leishmaniasis 
CLA Cutaneous lymphocyte antigen 
cm centimeter 
CMV Cytomegalovirus 
CTB-SP cholera toxin B signal peptide 
CTL Cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T lymphocyte antigen 4 
CV column volumes 
DAPI Diamidino-2-phenylindole 
DC Dendritic cell 
ddH2O didestilled water 
°C degree centrigrade 
DNA Deoxyribonucleic acid 
dNTP deoxynucleoside triphosphates 
DTH Delayed-type hypersensitivity 
E. Escherichia 
ECL Enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
e.g. exempli gratia (for example) 
ELISA Enzyme linked immunosorbant assay 
et al. et alii 
etc et cetera 
EtOH Ethanol 
FACS Fluorescent cell sorting 
FCS Fetal calf serum 
fig figure 
FPLC Fast performance liquid chromatography 
FT flow through 
GFP Green fluorescence protein 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
gp63 Glycoprotein 63 
h Hour 
H. Helicobacter 
HA Haemophilus influenzae hemaagglutinin 
HASPB1 Hydrophilic acylated surface protein B1 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid ) 
HIV Human immunodeficiency virus 
HLA Human leukocyte antigen 
                                                                                                      Abbreviations 
   VII
HRP Horseradish peroxidase 
Hsp60 Heat shock protein 
ICS Intracellular cytokine staining 
i.e. id est (that is) 
IFN Interferon 
i.g. intra gastric 
IgG Immunoglobulin G 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
i.p. Intra peritoneal 
IPTG Isopropyl-β-D-thiogalactopyranoside 
i.v. intra venous 
KDa Kilodalton 
KMP-11 Kinetoplastid membrane protein 
L. Leishmania 
L (l) litre 
LACK Leishmania homologue of receptors for activated C kinase 
LB Luria-Bertani 
LDU Leishman-Donovan unit 
LeIF Leishmania elongation initiation factor 








MCS multiple cloning site 
MEM Minimum essential medium 
MHC major histocompatibility complex 
MIF Migration inhibitory factor 
min Minutes 
MOPS 3-(N-morpholino) propanesulfonic acid 
MPL-SE Monophosphoryl lipid A-stable emulsion 
mRNA messenger ribonucleic acid 




NK cells Natural killer cells 
NRAMP1 Natural-resistance-associated macrophage protein 
OD Optical density 
OMV Outer membrane vesicle 
orf Open reading frame 
ori Origin of replication 
OVA Ovalbumin 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PE  Phycoerythrin 
Pen/Strep Penicillin/Streptomycin 
PerCP Peridinin chlorophyll protein complex 
PKDL post kala-azar dermal leishmaniasis 
PMA Phorbol 12-myristate 13-acetate 
                                                                                                      Abbreviations 
   VIII 
PSA-2 Promastigote surface antigen 2 
PVDF Polyvinylidene fluoride 
RBS Ribosomal binding site 
rpm rounds per minute 
s seconds 
s.c. sub cutaneous 
S. Salmonella 
SDM semi defined media 
SDS Sodium dodecyl sulfate 
SPI-2 Salmonella pathogenicity island 2 
TBE Tris borate EDTA 
TBS Tris buffered saline 
TCR T cell receptor 
TEMED N,N,N',N'-Tetramethylethylenediamine 
TLR Toll like receptor 
TNF Tumor necrosis factor 
TSA Thiol-specific-antioxidant 
T3SS Type III secretions system 
TRYP Tryparedoxin peroxidase 
UK United Kingdom 
US$ US dollar 
UV ultraviolet 
V. Vibrio 
v/v volume per volume 
V Volt 
VL visceral leishmaniasis 
w/v weight per volume 
WHO World Health Organisation 


























                                                                                             Zusammenfassung 
   IX
Zusammenfassung 
 
Leishmaniosen gehören zu den tropischen Krankheiten und bedrohen geschätzte 350 
Millionen Menschen in 88 Ländern weltweit. Die schwerste Form, viszerale 
Leishmaniose, betrifft die ärmsten Bevölkerungsschichten und ist die Ursache für 
circa 50 000 Todesfälle pro Jahr. Es wird angenommen, dass die Entwicklung eines 
Impfstoffs möglich ist, aber trotz aller Bemühungen, steht derzeit noch kein Impfstoff 
zur Verfügung.  
Im Rahmen dieser Arbeit wurde ein Impfstoff gegen viszerale Leishmaniose 
entwickelt und in vivo auf pre-klinischer Ebene getestet. Des Weiteren wurden 
rekombinante Membranvesikel konstruiert, um ein Boostreagenz zu erhalten. Die 
Herstellung sowohl des rekombinanten Salmonellenimpfstoffs als auch der 
Membranvesikel sollte, trotz des geringen Handelspreis, ökonomisch praktikabel sein, 
was besonders wichtig ist für Menschen in den betroffenen Entwicklungsländern. 
Der erste Schritt war die Auswahl neuartiger Antigenkandidaten aus einem 
Proteomics Datensatz, in dem beide Leishmania Lebensformen verglichen wurden. 
Der Schwerpunkt wurde auf abundante, hypothetische Proteine gelegt, die sowohl in 
Pro- als auch Amastigoten identifiziert wurden, in Leishmanienarten hochkonserviert 
sind aber gleichzeitig keine Sequenzhomologien zu humanen und murinen Proteinen 
besitzen. Diese Antigene wurden in unterschiedlicher Menge auf der Oberfläche und 
im Cytoplasma von S. typhimurium SL3261 und auch auf Membranvesikeln 
exprimiert. Impfstämme wurden selektiert in Hinsicht auf ihre bakterielle Fitness und 
Antigenexpression.  
Es konnte gezeigt werden, dass LinJ08.1140-, LinJ23.0410-exprimierende 
Impfstämme oder eine Mischung dieser in der Lage waren besonders anfällige 
BALB/c Mäuse vor L. major und wichtiger L. donovani Infektion zu schützen. 
Analyse der humoralen Immunantwort deutet darauf hin, dass der Impfschutz das 
Ergbnis einer TH1 Antwort war.  Erste Schritte zur Aufklärung struktureller und 
funktioneller Eigenschaften von LinJ08.1140 wurden unternommen. Es wird 
allgemein angenommen, dass antigenspezifische CD4+ und CD8+ T-Zellen am Schutz 
beteiligt sind. Daher wurde für LinJ08.1140 potentielle MHC-I Epitope mit Hilfe von 
bioinformatischen Programmen vorhergesagt. Zusätzlich deuten Fluoreszenz-
färbungen mit antigenspezifischen Antikörpern in L. major Promastigoten darauf hin, 
dass LinJ08.1140 eine Rolle bei der Zellteilung spielt. 
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Summary 
 
Leishmaniasis is a neglected tropical disease and currently an estimated 350 million 
people in 88 countries around the world are at risk. Its most severe form, visceral 
leishmaniasis, affects the poorest people in a population and causes an estimated 
50 000 deaths every year. Vaccination is thought to be feasible but despite all efforts, 
no vaccine is yet available. Vaccines will mainly be targeted for people in developing 
countries such as India, thus focus has to be placed on affordability. 
In this thesis a vaccine against visceral leishmaniasis was designed and evaluated in 
vivo at pre-clinical level. Furthermore, recombinant outer membrane vesicles were 
developed in an attempt to create a booster reagent. Both, the recombinant salmonella 
vaccine and the preparation of outer membrane vesicles should be commercially 
viable, and can still be sold at low prices, which is crucial for people in developing 
countries. 
First, novel antigen candidates were selected using proteomics data comparing 
leishmania life stages. Abundant and hypothetic proteins, which have been identified 
in both parasite life stages and have high sequence homology throughout Leishmania 
species while lacking homologues in human and mouse, were selected. These 
antigens were differentially expressed on the surface or in the cytosol of 
S. typhimurium SL3261 and in the form of outer membrane vesicles. A two step 
procedure was developed to select optimised vaccine strains based on bacterial fitness 
and antigen expression. 
Selected salmonella strains expressing LinJ08.1140, LinJ23.0410 or an admixture of 
these strains are shown to protect susceptible BALB/c mice by reducing 
visceralisation of L. major and more importantly L. donovani infections. Analysis of 
vaccine specific antibody responses suggests that protection resulted from induction 
of a TH1 response. First steps were undertaken towards resolving functional and 
structural properties of the most protective antigen LinJ08.1140. Putative MHC-I 
epitopes of antigen LinJ08.1140 were predicted using bioinformatics since antigen-
specific CD4+ and CD8+ T cells are believed to be required. In addition, 
immunofluorescent staining of LinJ08.1140 in L. major promastigotes suggested a 
functional role for this antigen in parasite cell division, since especially dividing cells 
emmited a strong fluorescence signal. 
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1. Introduction 
 
1.1 Leishmania life cycle 
 
Leishmania are uniflagelated protozoan parasites which belong to the class of 
Kinetoplastida, order of Trypanosomatida and the genus Leishmania. These parasites 
have a digenic life cycle, involving two hosts, the sand fly vector and the vertebrate 
host. The parasites are transmitted by the bite of infected female sand flies of the 
genus Phlebotomus (Old World) or Lutzomyia (New World). 
Two life forms of Leishmania parasites are existent, which differ highly in 
appearance. Immotile amastigotes are mainly found in mammalian host cells and are 
of 2-4 μm oval shape. Promastigotes are larger, measuring up to 20 μm and have a 





















Fig. 1.1: Digenic life cycle of 
leishmania species 
(Reprinted by permission 
from Macmillan Publishers 
Ltd: Nature Reviews 
Microbiology (Chappuis et 
al.), copyright (2007)) 
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Female sand flies need blood as a protein source for egg development. After uptake of 
blood from infected mammals, leishmania parasites develop in the midgut of the sand 
fly where they undergo major transformation from amastigote to promastigote states. 
After proliferation and maturation, highly infective metacyclic promastigotes move to 
the salivary glands of the sand fly, from where they are transmitted during the blood 
meal into mammalian hosts. In the skin parasites are ingested by neutrophils, which 
then undergo apoptosis and are subsequently taken up by macrophages for disposal. 
This has been shown for L. major (reviewed by Peters and Sacks, 2009; Laskay et al., 
2008; Ritter et al., 2009) as well as L. donovani (Gueirard et al., 2008). In 
macrophages parasites evade killing, transform into amastigotes and begin to 
proliferate. Highly infected macrophages burst and release amastigotes which in turn 
infect more macrophages. During the blood meal from another sand fly amastigotes 
residing in macrophages are taken up and development into promastigotes 
commences again.  
 
 
1.2 Leishmania related diseases 
 
Early descriptions of leishmania disease date back to 15th and 16th century, when 
seasonal agricultural workers returned from the Andes with ulcers. Due to these 
disfigurements the disease was called “white leprosy”. In 1901 William Leishman 
identified organism in smears from a spleen of a patient who died from Dum-Dum 
fever. Two years later, in 1903, Captain Charles Donovan described these organisms 
as a new species. The link between parasites and disease was finally established by 
Major Ronald Ross, who named the new species after its two discoverers Leishmania 
donovani (www.who.int/leishmaniasis/history_disease/en/index.html, 2009). 
 
To date more than 20 Leishmania species have been identified as the causative agent 
to a wide spectrum of human diseases. Currently an estimated 12 million people are 
infected, while 350 million people in 88 countries from all over the world are at risk 
to develop one of the diseases associated with Leishmania parasites 
(www.who.int/leishmaniasis/disease_epidemiology/en/index.html, 2009; (Desjeux, 
1996).  
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Fig. 1.2: Leishmania species cause a wide spectrum of diseases 
A: skin lesion from cutaneous leishmaniasis, B: mucocutaneous leishmaniasis,  
C: visceral leishmaniasis 
 
 
1.2.1 Cutaneous leishmaniasis 
 
Leishmaniasis of the skin is caused by parasites belonging to the L. (vianna) 
brasiliensis and L. mexicana complex in the New World and L. major and L. tropica 
in the Old World. It is mainly a zoonotic disease, the reservoir ranging from small 
rodents (e.g. gerbils) to bigger mammals (e.g. opossum, sloth), but can be 
anthroponotic in case of L. tropica. An occurrence of 1-1.5 million new cases every 
year has been estimated. The disease affects mainly the skin of exposed areas (e.g. 
face, arms and legs) and can remain sub-clinical. After several weeks first symptoms 
occur with the development of papules which progress to nodules and later to lesions 
(fig. 1.2A). These lesions are normally painless and heal spontaneously after several 
months, often resulting in scars and disfigurements. Further complications include the 
development of satellite lesions, disseminating to the lymph nodes and even 
visceralisation. 
 
Mucocutanous leishmaniasis, also known as espundia is a dreaded complication of 
cutaneous leishmaniasis (CL) and leads to the progressive destruction of mucosal 
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1.2.2 Visceral leishmaniasis 
 
The most severe form is visceral leishmaniasis (VL), also known as Dum-Dum fever 
or kala-azar in India and can be found in Latin America, the Mediterranean Basin and 
Asia. An estimated 500 000 new cases and 50 000 deaths are reported every year and 
90 % from countries like Bangladesh, Nepal, India, Sudan, Ethiopia and Brazil 
(Chappuis et al., 2007). This systemic disease is caused by L. chagasi in  
 
Fig. 1.3: Distribution of visceral leishmaniasis world wide 
Regions highlighted in red show endemic areas of VL 
(Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology (Chappuis et al.), copyright (2007)) 
 
the New World and L. infantum and L. donovani in the Old World. VL is mainly 
zoonotic with dogs being the main reservoir, however, transmission in areas endemic 
for L. donovani (e.g. India and Sudan) is anthroponotic. In many cases infection 
remains asymptomatic, but dependant on circumstances can become acute or chronic. 
Then a sub-clinical incubation period between two and six month is followed by first 
symptoms like fever, fatigue, weight loss, weakness, which are accompanied by 
hepato-splenomegally (enlarged liver and spleen) and anaemia caused by internal 
bleeding. Untreated patients may die from bacterial co-infections, massive internal 
bleedings and anaemia (reviewed by Chappuis et al., 2007; Herwaldt, 1999).  
 
Post kala-azar dermal leishmaniasis (PKDL) is a complication of VL which develops 
0-6 month (Sudan) or 2-many years (India) after recovery. The disease presents itself 
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in different forms, mainly as a maculopapular, nodular or papular rash which spreads 
from face to the whole body, dependant on the grade of disease (Zijlstra et al., 2003). 
These rashes harbour high numbers of profoundly infective parasites which are 
serving as a reservoir for the anthroponotic cycle.   
 
 
1.3 Treatment of visceral leishmaniasis 
 
While CL normally heals spontaneously, VL can be fatal without treatment. Visceral 
leishmaniasis is a disease which affects the poorest populations. Olliaro and 
colleagues estimated the financial cost to manage one episode of visceral 
leishmaniasis for a household in India. Cost taken into account included lack of 
income due to illness, cost for medical treatment and transportation, which altogether 
averaged at 9420 rupies (209 US$). This accounts for more than four times the 
monthly average household income, which was estimated to be 2200 rupies (49 US$) 
(Olliaro et al., 2009).  
Chemotherapeutic treatment is available, but due to high toxicity and adverse effects, 
lower doses are often administered, encouraging the emergence of parasite resistance 
(Polonio and Efferth, 2008). Pentavalent antimonials have been the treatment of 
choice for more than six decades. These are now considered as lost, due to the 
increased resistance of L. donovani especially in the Indian state of Bihar (Sundar et 
al., 2000; Lira et al., 1999). The replacement Amphothericin B deoxycholate is highly 
effective but also has intolerable toxic side effects including cardio- and 
nephrotoxicity and even death. The toxic deoxycholate part has been replaced with 
different liquid formulations, resulting in AmBisome®, which is a registered drug 
against VL in India. Although the price of the drug has been reduced from 200 US$ to 
20 US$ per vial, treatment cost remain expensive, as a single dose is less effective. In 
addition a high relapse rate of 80-100 % has been found in immunosuppressed 
patients (Meyerhoff, 1999). Miltefosine is the first drug to be taken orally, reducing 
toxicity to mild or moderate symptoms. Major drawbacks are the prolonged treatment 
period, often enhancing failure due to inconsistencies in adherence to treatment plan, 
high drug cost (between 53 and 85 US$ per pack) and teratogenic effects of 
Miltefosine, contraindicating its use in pregnant women or generally women of child-
bearing age. Its prolonged half-life is the reason for concerns regarding the emergence 
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of resistance (Olliaro and Sundar, 2009; Sundar and Chatterjee, 2006; Olliaro et al., 
2009). A newly registered drug is Paromomycin, which is given as intra-muscular 
injections over a period of 21 days. Low drug cost of 10 US$ per adult and 5 US$ per 
child making this drug the cheapest available so far. In respect to the low household 




1.4 Immunology of leishmaniases 
 
The work of Mosmann and Coffman led to the TH1/TH2 paradigm for protection or 
susceptibility to intracellular pathogens (Mosmann et al., 1986; Stevens et al., 1988).  
Figure 1.4 shows a simplified model of susceptibility and resistance in mice. 
However, while control of leishmaniases remains TH1 (IL-12, IFNγ, TNFα, IL-2) 
dependant, there is compelling evidence for L. major and L. donovani, that typical 
TH2 cytokines IL-4 and IL-13 can enhance protection by inducing IL-12 production in 
macrophages and dendritic cells (Basu et al., 2005; Murphy et al., 1998; Stager et al., 
2003a; Hochrein et al., 2000; reviewed by Alexander and McFarlane, 2008; 
Alexander and Bryson, 2005). Furthermore, IFNγ and IL-4 producing T cells have 
been found in asymptomatic and cured patients. It had been speculated that enhanced 
protection is rather down to an increased frequency of cytokine producing T cells than 
an altered IFNγ/IL-4 balance (Murphy et al., 1998).  
Another TH2 cytokine, IL-10 has been shown to promote parasite residence and 
multiplication in resistant and susceptible mice. Interleukin-10 has anti-inflammatory 
properties and is produced by a wide range of cells, e.g. macrophages, dendritic cells, 
B cells, T cells and epithelial cells. It has been found in high levels in patients with 
VL, where it is thought to limit immune mediated pathogenesis by inhibition and 
down regulation of IL-12 and MHC-II, thus promoting parasite replication and 
disease progression (reviewed by Nylen and Sacks, 2007).  
Furthermore IL-10 has been shown to promote B cell survival, resulting in 
hypergammaglobulinaemia and isotype class switch to IgG1 and IgG3 (Caldas et al., 
2005). A contribution of leishmania-specific IgG in disease promotion has been 
shown (Miles et al., 2005) and hypergammaglobulinaemia is a common parameter in 
patients with active VL. It has been found that the sources of disease promoting IL-10 
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are rather antigen driven Tr1 cells than natural Tregs (reviewed by Nylen and Sacks, 
2007).  
 
Fig. 1.4: Simplified overview of the leishmania immuno-biology paradigm based on 
the murine L. major infection model 
Upper panel shows scenario in susceptible mice. [1] non-activated infected APC 
presents leishmania antigens via MHC-II to CD4+ T cells, [2] the lack of IL-12 leads 
to activation of TH2 T cells and production of anti-inflammatory cytokines [3] IL-4 
secretion induces antibody class switch to IgG1 [4] anti-inflammatory cytokines 
promote uncontrolled parasite multiplication leading to the burst of the host cell [5] 
release of amastigotes, followed by opsonization with IgG1 and Fcγ mediated uptake 
by uninfected APCs. 
Lower panel shows scenario in resistant mice. [6] upon infection APC become 
activated and present parasite antigens via MHC-II to CD4+ T cells, [7] presence of 
IL-12 leads to activation of TH1 T cells and inhibition of TH2, [8] IFNγ secretion 
promotes antibody class switch to IgG2a, [9] pro-inflammatory cytokines up-regulate 
among others iNOS, [10] mechanism including oxidative burst and microbicidal 
activities lead to the killing of the parasite by the host, [11] MHC-I presentation leads 
to activation of  cytotoxic T cells (CD8+) which can kill the infected host cell along 
with the parasites.  
Abbreviations: MHC major histocompatibility complex, IL interleukin, Ig 
immunoglobulin, CD cluster of differentiation, iNOS inducible nitric oxide synthase, 
IFN interferon, DC dendritic cell, Mφ macrophage, APC antigen presenting cell 
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Recent vaccine studies also suggested the contribution of cytotoxic CD8+ T cells in 
vaccine induced protection against experimental visceral leishmaniasis in mice (Basu 
et al., 2007a; Murray et al., 1989; Stager et al., 2003b). 
Genetic factors also play a role in disease progression. Natural-resistance-associated 
macrophage protein (NRAMP1) has been shown to limit the replication of 
intracellular pathogens and susceptibility against visceral leishmaniasis is linked to 
polymorphism in the NRAMP1 gene (Mohamed et al., 2004). 
 
 
1.5 Leishmaniases – a growing problem? 
 
Several factors have been singled out to contribute to the spreading of leishmaniases 
world wide, causing present and future problems and underlining the need for a 
vaccine. 
The main reservoirs for the parasites are dogs and rodents. Dogs have been found to 
carry L. infantum, L. tropica, L. major and L. braziliensis, while L. major is 
predominantly hosted by gerbils and the fat sand rat (Ashford, 1996). Plantation of 
new crops is an attractive food source for rodents, increasing the risk of transmission 
to seasonal workers. Political instabilities, civil unrest and environmental changes 
(e.g. draughts) are the main causes for migration of human populations. Non-immune 
individuals from areas where VL is not common are forced to move to areas endemic 
for leishmaniases, mostly living cramped under bad hygienic conditions in close 
proximity to parasite reservoirs like dogs. This, for example, led to the spread of VL 
endemic areas from Sudan to Ethiopia and Eritrea (www.who.int/leishmaniasis/ 
burden/magnitude/burden_magnitude/en/index.html, 2009; Desjeux, 2001).  
A further threat is constituted by the possibility of global warming, moving the 
maximum northern latitude for sand fly survival further north and increasing the 
number of countries where VL could become endemic (Desjeux, 2001). Indeed, while 
endemic in South European countries, sand flies have been found in central European 
countries like Germany and Belgium since 1999, and are proven or suspected vectors 
of leishmaniasis (Aspock et al., 2008; Naucke et al., 2008). In Germany, eleven cases 
of leishmaniasis, where indigenous origin is likely, were found since 1991, one 
involving an infant (Naucke et al., 2008).  
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The high incidence of canine leishmaniasis in the Mediterranean area makes dogs the 
main reservoir for VL in this region. When treated, these dogs receive Miltefosine or 
AmBisome®, drugs which are used in India to treat human disease. This enhances the 
risk of the emergence of drug resistant parasites, which then due to globalisation and 
tourism threaten to spread to developing countries (Dujardin et al., 2008).  
A further massive problem is the increasing occurrence of VL in patients with HIV. 
Along with African countries co-infections were also frequently detected in South 
Europe (Spain, Portugal, France and Italy), where L. infantum infection is the third 
most common parasitic disease in HIV patients (Alvar et al., 1997). Between 2 and 
9 % of all VL cases are known to be HIV positive, but numbers reach as high as 30 % 
in endemic areas like Ethiopia. 
Co-infection of HIV patients with leishmania parasites is considered a major problem, 
due to the deadly synergy, both pathogens form. Among others, parasites causing VL 
have been found to modulate the virus life cycle and to promote viral replication thus 
resulting in the clinical progression of HIV to AIDS. HIV on the other hand promotes 
the reactivation of latent leishmania infection, due to a declining immune system and 
a decrease in pro-inflammatory cytokines IL-12, IFNγ and IL-18 accompanied by an 
increase in anti-inflammatory cytokines IL-4 and IL-10 (Wolday et al., 2000).  
 
Together with high treatment cost of human VL, toxicity of drugs and the emergence 
of parasite resistance (see section 1.3); the factors described above highlight the need 
for a vaccine against leishmaniasis. 
 
 
1.6 Anti-leishmanial vaccines 
 
1.6.1 Requirements  
 
An ideal vaccine against visceral leishmaniasis needs to fulfil a number of 
requirements. Safety and affordability are top priorities, especially in regard of the 
main vaccination target, populations in developing countries. It should be capable of 
initiating a protective CD4+ and CD8+ T cell response, lacking IL-10, and induce a 
long term immunological memory. Along with prophylactic and therapeutic potential, 
a broad protection against species causing CL and VL would be preferable. Since 
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functional cold chains and infrastructure are not very common in developing 
countries, a stable vaccine formulation which can be stored at room temperature 
would be of advantage.  
The most important requirement of all is feasibility. This is given by the fact that 






To protect individuals from disfiguring facial lesions of CL, virulent parasites from 
active lesions have been deliberately injected into the skin in non-exposed areas of the 
body. Lesions healed spontaneously resulting in an acquired T cell mediated 
immunity against re-infection with CL. This procedure is called leishmanization and 
has been practiced for over a century. In an approach to cover larger geographical 
areas cultured parasites were used in the former Soviet Union, Israel and Iran 
(Greenblatt, 1980). However, the procedure had since been abandoned due to the 
emergence of safety issues, as for example leishmanization in some cases resulted in 
the development of large non-healing lesions, which required treatment, exacerbating 
chronic disease or immunosuppression. Further problems were difficulties in 
standardisation and loss of parasite virulence after several in vitro passages. Studies 
carried out in the 1940s using killed parasites alone or with BCG were considered 
inconclusive and were mainly focussed on CL (reviewed by Khamesipour et al., 
2006; Kedzierski et al., 2006; Coler and Reed, 2005). A further approach currently 
pursued is the development of live attenuated parasites. It is anticipated that 
immunisation with genetically engineered parasites which are lacking genes for long 
term survival in vivo or which are equipped with suicidal cassettes can induce a 
protective immune response, before being cleared. Major drawbacks are the limited 
protection due to rapid elimination of the parasite by the host and the risk of parasites 
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1.6.3 Antigens 
 
On the quest of developing vaccines against cutaneous and visceral leishmaniasis a 
number of parasite antigens have been tested for their potential to induce anti-
leishmania immune responses. Leishmania surface protein gp63 and leishmania 
homologue of receptors for activated C kinase (LACK) have been extensively studied 
in a wide range of adjuvant and delivery systems. Other antigens include 
lipophospoglycan (LPG), hydrophilic acylated surface protein B1 (HASPB1), 
promastigote surface antigen 2 (PSA-2), kinetoplastid membrane protein (KMP-11), 
thiol-specific-antioxidant (TSA) and the polyantigen Leish-111f, to name a few 
(summarised by Kedzierski et al., 2006; Palatnik-de-Sousa, 2008; Coler and Reed, 
2005). In an attempt to tackle leishmania infection at an early stage, salivary proteins 
of the sand fly have also been evaluated for vaccination. Studies in hamsters and dogs 
showed promising results with induction of type I responses and significant IFNγ and 
IL-12 production (Collin et al., 2009; Andrade et al., 2007). 
 
 
1.6.4 Adjuvant and delivery systems 
 
Purified antigens on their own are most often not immunogenic and require the 
addition of adjuvant to induce an immune response. Alum and squalene are the only 
two adjuvants approved for human vaccines. While they are potent inducers of 
humoral immunity, their induction of TH1 responses required for protection against 
VL is considered to be poor. The combination of IL-12 and antigen does induce a 
strong TH1 immune response. However, IL-12 is not recommended for human 
vaccination as it may promote immune disorders and in addition lacks the ability to 
induce immunological memory, as seen in mice immunised with LACK (Gurunathan 
et al., 1997; Coler and Reed, 2005). Further approaches tested in animal models so far 
include DNA vaccination using naked DNA or recombinant Vaccinia virus, which act 
as adjuvant by activation of the innate immune response via non-methylated CPG 
sequences and confer protection by a prolonged intracellular expression of 
vaccination antigen. On top of that production costs are relatively cheap in 
comparison to purified protein. 
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Leishmania parasites are intracellular pathogens and like all intracellular pathogens 
clearance requires a TH1 response. This led to the exploration of attenuated 
intracellular pathogens like Bacillus of Calmette and Guerin (BCG), Salmonella 
enterica and Listeria monocytogenes as delivery systems for foreign antigens 
(summarised by Kedzierski et al., 2006; Palatnik-de-Sousa, 2008; Coler and Reed, 
2005).  
A rather exotic and perhaps less feasible approach is the pulsation of DC with antigen 
or peptide. Although results were promising, large-scale production, provision of 
infrastructure etc. still needs to be addressed.  
 
Despite all effort, no vaccine against visceral leishmaniasis is available to date. The 
polyprotein vaccine Leish11f, comprising of antigens TSA, LmSTI1 and LeIF, in 
combination with adjuvant MPL-SE is the first second generation (i.e. subunit) 




1.7 Attenuated live salmonella as vaccine carriers 
 
The employment of recombinant attenuated Salmonella enterica for delivery of 
foreign antigens in vaccines is a promising alternative to the combination of purified 
antigen and adjuvant. Low production cost and the possibility of lyophilisation, 
allowing vaccine storage at room temperature, make this approach an ideal candidate 
for vaccination in developing countries. Salmonella have been shown to induce a 
strong mucosal, humoral and cellular immune response in vivo and clearance requires 
the activation of type I T cells which produce cytokines IFNγ, IL-2 and TNFα. Recent 
studies have also shown that salmonella are capable of activating cytotoxic CD8+ T 
cells via MHC-I cross-presentation in humans (Salerno-Goncalves and Sztein, 2009; 
Winau et al., 2004). Since visceral leishmaniasis targets in part the same organs 
(spleen and liver) as typhoid salmonella, activation of tissue specific cellular 
responses through vaccination is a desirable feature. In addition, salmonella carry Toll 
like receptor (TLR) ligands such as lipopolysaccharid (LPS) on their surface, which 
permits activation of the immune system e.g. via TLR4. This makes the use of 
potentially toxic adjuvants redundant. 
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S. typhimurium shows similar effects in mice as S. typhi in humans and therefore it 
can be assumed that findings from mouse vaccination experiments can be translated to 
human-S. typhi interaction. Attenuated S. typhi strains Ty21a and CVD908 for 
example have been approved for human vaccination against typhoid fever. Their 
efficiency to carry heterologous antigens from pathogens like Helicobacter pylori, 
Hepatitis B virus and Plasmodium falciparum have been assessed in different clinical 
vaccination trials (Galen et al., 2009; Aebischer et al., 2008). A further advantage of 
using these strains as vaccine carrier is that the target population will not only be 
vaccinated against VL but simultaneously against typhoid fever, a co-endemic 
disease. 
 
Oral administration of attenuated salmonella in general is considered safe and well 
tolerated. Adverse effects are mild and include gastrointestinal disturbance, headaches 
or in rarer cases the appearance of rashes. Bacteria are cultured in large-scale 
bioreactors and the lyophilised product is filled into gelatine capsules, which have 
been coated with organic solutions to ensure that capsules are dissolved in the gut and 
not the stomach (Kopecko et al., 2009). In the small intestine Salmonella are taken up 
by M cells and translocated from the intestinal lumen to Peyer’s patches, lymph node 
like structures of the gut, where they reside for several weeks (Dunstan et al., 1998). 
Attached or in intracellular form, they then disseminate via mesenteric lymph nodes 
to visceral organs like spleen and liver (Mäkelä, 1997). In lymphatic tissue salmonella 
are taken up by macrophages and dendritic cells, which present epitopes of carrier as 
well as vaccination antigen via MHC-II molecules and activate specific CD4+ T cells, 
CD8+ T cells and antibody production.  
 
To test the feasibility of recombinant live salmonella several groups have explored 
them as carrier organism to protect against different forms of leishmaniasis. In the 
early 1990s researchers achieved partial protection of mice after prophylactic 
vaccination with gp63 expressing S. typhimurium (Yang et al., 1990; Xu et al., 1995). 
Antigen expression in these vaccines was then further improved by the use of 
inducible promoters (McSorley et al., 1997). Gonzalez and colleagues expressed gp63 
in a human anti-typhi vaccine candidate CVD908 and tested it in murine models. 
Vaccinated mice elicited a strong TH1 response and gp63-specific cytotoxic T cells 
have been found (Gonzalez et al., 1998). Other approaches included the therapeutic 
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vaccination with salmonella strains individually expressing TH1 cytokines TNFα, 
IFNγ, IL-2 and migration inhibitory factor (MIF), the prime-boost combination of a 
DNA vaccine and recombinant salmonella expressing LACK; both showing 
promising results (Xu et al., 1998; Lange et al., 2004). Furthermore it has been shown 
that the protective effect conferred by salmonella expressing gp63 was dependent on 
the activation of NRAMP through cascade events triggered by bacterial LPS and the 
production of IFNγ by NK or T cells. NRAMP activation led to upregulation of 
TNFα, IL-1β and MHC-II; whereas mutation or polymorphism in the gene resulted in 
the induction of a TH2 response along with susceptibility (Soo et al., 1998). All these 
studies indicate that successful vaccination using recombinant salmonella is feasible, 
but in need of improvement. 
 
 
1.8 Localisation of antigen in the salmonella carrier 
 
For vaccination using recombinant live salmonella, the topology of antigen delivery 
plays an important role. Expression of foreign protein on the surface or in the 
cytoplasm can highly influence the bacterial fitness of the carrier strain, and therewith 
antigen delivery and induced immune responses. Antigen delivery has been improved 
by the application of in vivo inducible promoters such as PpagC, which allow high-level 
protein expression in vivo but show only low activity in vitro (Bumann, 2001). Upon 
entering the phagosome of APC, where low Mg2+/Ca2+ conditions prevail, the 
salmonella PhoP/PhoQ system becomes activated. Aiming at the rapid induction and 
expression of immune and environmental modulating proteins, promoters like PpagC 
become active, not only to express virulence factors but also the protein/antigen of 
interest. However, dependent on the antigen, its intrinsic toxicity or lability in the 
cytoplasm can result in insufficient stimulation of the immune system (Hess et al., 
1996). Alternatively antigens can be expressed on the surface of the salmonella 
carrier. 
 
Autotransporters have evolved to display on or secrete proteins through the outer 
membrane of Gram-negative bacteria. The adhesin involved in diffuse adherence 
(AIDA-I) from enteropathogenic E. coli allowed the surface expression of more than 
105 molecules per cell (Jose, 2006). AIDA fusion constructs consisted of a cholera 
                                                                                                         Introduction 
   15
toxin signal peptide, targeting a protein of interest for secretion through the inner 
membrane, followed by this passenger, a linker domain and the actual autotransporter 
domain. After translation the still cytosolic fusion protein is translocated through the 
inner membrane to the periplasm. Here the cholera toxin signal peptide is cleaved off 
and under formation of a β-barrel pore structure the AIDA autotransporter part inserts 
into the outer membrane. The linker and passenger domains are then transported 
through the pore and displayed on the surface (Maurer et al., 1997). 
This system has been exploited by different research groups to express and display 
proteins and peptides (e.g. heat shock protein Hsp60, cholera toxin B and ureA, a 
subunit of Helicobacter pylori urease) on the surface of Gram-negative bacteria 
(Kramer et al., 2003; Maurer et al., 1997; Rizos et al., 2003). CD4+ T cells isolated 
from mice, orally vaccinated with Salmonella expressing an epitope of Hsp60 on the 
surface via AIDA, did proliferate and produced high amounts of IFNγ in response to 
antigen-specific re-stimulation (Kramer et al., 2003).  
 
 
Fig.1.5: Model of antigen exportation via AIDA-I 
Reprinted by permission from the American Society for Microbiology, Journal of 
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1.9 Objectives 
 
The ultimate goal of this project is the pre-clinical development of a recombinant live 
vaccine against visceral leishmaniasis targeted for the population in India. To reach 
this goal the following objectives were set:  
 
1. In silico selection of novel antigen candidates 
Bioinformatic criteria for the selection of vaccine antigens considered of importance 
for the induction of protective immune responses were to be applied on proteome data 
sets from Leishmania mexicana pro- and amastigotes to identify novel candidate 
antigens. 
 
2. Construction of optimised live vaccines 
Attenuated Salmonella enterica serovar Typhimurium SL3261 was chosen as a live 
carrier to deliver the novel vaccine candidates. Since expression of foreign proteins is 
known to affect bacterial fitness and therefore the efficiency of a live carrier. The next 
objective was to optimize these carriers for vaccine delivery by comparing strains 
engineered to express tuned levels of the novel antigens on the surface or 
cytosolically.  
 
3. Pre-clinical evaluation of novel live vaccine candidates 
A further objective was to obtain proof of concept data that optimized vaccine strains 
would indeed protect against Leishmaniasis by assessing the novel vaccines in 
experimental models of leishmaniasis. Emphasis was to be put on analysis of 
visceralising infection since VL was the target disease. Thus, progressive infection of 
susceptible BALB/c mice with L. major and L. donovani respectively were chosen as 
models. 
 
4. Exploration of outer membrane vesicles (OMV) to augment antigen-specific 
immune responses 
Vaccines often require multiple doses to be effective and prime-boost strategies seem 
promising against many infections (Prieur et al., 2004). Thus, an additional aim was 
to create a versatile cost effective platform to generate a new kind of booster reagent 
based on OMVs. 
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2. Materials and Methods 
 
2.1 Electrical laboratory equipment 
 
ÄKTA prime FPLC system Amersham pharmacia biotech 
Blotting apparatus Bio-Rad 
Centrifuge Heraeus (Multifuge 3 s-r) 
Heat block Thembloc, Selecta 
ELISA plate reader Multiskan Ascent, Labsystems 
Electrophoresis system (DNA) Bio-Rad 
Electrophoresis system (Protein) Bio-Rad 
FACS BD Bioscience (LSRII) 
Confocal microscope Leica SP5 
Incubator (with CO2) STS (Galaxy S) 
Incubator (w/o CO2) Heraeus 
Incubator, shaking New Brunswick 
Magnetic stirrer Fisher Scientific 
Microscope (inverted)  Olympus CKX41 
Microwave Panasonic 
Nanodrop reader ThermoScientific 
PCR machine Bio-Rad (DNAEngine) 
pH meter WTW (Inolab) 
Photo development machine X-ograph Compact X2 
Pipettes (P2, P20, P200, P1000) Gilson 
Pipettes (Multichannel) Eppendorf 
Pipettes (Multidispenser) Eppendorf 
Pipetting aid Integra Bioscience 
Rolling shaker Hecht assistant 
Rotating shaker Labnet (GyroTwister) 
Sonicating water bath Bandelin (Sonorex) 
Spectrophotometer Amersham Bioscience 
Spectrophotometer UV Eppendorf 
Sterile hood NUAIRE 
Table top centrifuge Eppendorf (5415C) 
Ultracentrifuge Beckman 
Ultrasound Soniprep 150 MSE 
Vortex IKA (MS2 Minishaker) 
Water bath GFL 
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2.2 Chemicals and reagents 
 




Ampicillin stock solution 100 mg/ml in ddH20 
Streptomycin stock solution 90 mg/ml in ddH20 
Kanamycin stock solution 50 mg/ml in ddH20 
Gentamycin stock solution 50 mg/ml in ddH20 
Hygromycin stock solution 20 mg/ml in EtOH 




goat polyclonal anti-mouse IgG2a – HRP conjugated (Novus Biologicals) 
goat polyclonal anti-mouse IgG1 – HRP conjugated (Novus Biologicals) 
donkey anti-mouse IgG (H+L) – HRP conjugated (Jackson ImmunoResearch) 
mouse monoclonal (12CA5) anti-HA – HRP conjugated (Roche Applied Science) 
rat anti-mouse TNF – PE conjugated (BD Pharmingen) 
rat anti-mouse IFNγ – AlexaFluor® 647 conjugated (BD Pharmingen) 
rat anti-mouse IL-4 – AlexaFluor® 488 (BD Pharmingen) 
rat anti-mouse CD4 – APC-H7 conjugated (BD Pharmingen) 
rat anti-mouse CD8a – PerCP conjugated (BD Pharmingen) 
anti-mouse CD3 – AlexaFluor® 700 (eBioscience) 
rat IgG1 (κ) isotype control – PE conjugated (BD Pharmingen) 
rat IgG1 isotype control – AlexaFluor® 647 (eBioscience) 
rat IgG2a isotype control – AlexaFluor® 488 (eBioscience) 
mouse anti-08.1140 polyclonal antiserum (this work) 




Alkaline Phosphatase: New England Biolabs 
Benzonase® Nuclease: Novagen 
T4 Quick ligase New England Biolabs 
Lysozyme Sigma 
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Restriction enzymes BglII, BamHI, HindIII, NdeI, NheI, SalI, SpeI, XbaI, XhoI and 





2x SDM (semi defined media) for 10 L 
 
Minimum essential medium powder (S-MEM) with  
Earle’s salts, L-glutamine, w/o sodium bicarbonate 140 g 
M199 medium powder with Hank’ solution,  
L-glutamine, w/o sodium bicarbonate 40 g 
MEM essential amino acids 160 ml 
MEM non-essential amino acids 120 ml 
Glucose 20 g 
HEPES buffer 160 g 
MOPS buffer 100 g 
Sodiumpyruvate 2 g 
L-Alanine 4 g 
L-Glutamine 6 g 
L-Arginine 2 g 
L-Methionine 1.4 g 
L-Phenylalanine 1.6 g 
L-Proline 12 g 
L-Serine 1.2 g 
L-Taurine 3.2 g 
L-Threonine 7 g 
L-Tyrosine 2 g 
Adenosine 0.2 g 
Guanosine 0.2 g 
Glucosamine – HCl 1 g 
Folate 0.08 g 
p-Aminobenzoic acid 0.04 g 
Biotin 0.004 g 
 
Weigh components and fill up with ddH2O to 9.5 L. Adjust pH to 7.0 with NaOH, add 
40 g NaHCO3, readjust pH to 7.3 and fill up to 10 L with ddH2O. Sterile filter solution 
and store at -80 °C. 
 
1x SDM for promastigotes 
50 % (v/v) 2x SDM 
7 % (v/v) heat inactivated FCS 
1 % (v/v) Pen/Strep solution 
42 % (v/v) sterile ddH2O 
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LB-medium 
10 g Tryptone/Peptone 
5 g Yeast extract 
10 g NaCl 
 
Fill up to 1 L with ddH2O and autoclave.  
 
LB-agar 
10 g Tryptone/Peptone 
5 g Yeast extract 
10 g NaCl 
15 g Agar-Agar 
 
Weigh chemicals into a beaker and add 900 ml ddH2O. Adjust pH to 7.0 under 
stirring, fill up to 1 L with ddH2O and autoclave. 
 
5x M9 salt solution 
64 g Na2HPO4 
15 g KH2PO4 
2.5 g NaCl 
5.0 g NH4Cl 
 
Weigh chemicals into a beaker and add 900 ml ddH2O. Adjust pH to 7.2 under 
stirring, fill up to 1 L with ddH2O and autoclave. 
 
M9 minimal medium 
200 ml M9 salts solution 
1 ml 10mM MgSO4 
20 ml  20% Glucose 
10 ml 0.4% Histidine 
50 ml 10% Caseine 
2 ml 2,3 Dihydroxybenzoic acid (100mg in 1ml ddH2O and 1ml EtOH) 
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2.4 Buffers and solutions 
 
10x phosphate buffered saline (PBS) 
80 g NaCl 
2 g KCl 
2.4 g KH2PO4 
11.5 g  Na2HPO4 
 





10x Tris borate EDTA (TBE) 
108 g Tris 
55 g Boric acid 
40 ml 0.5 M EDTA (pH 8.0) 
 
Weigh chemicals and fill up to 1 L with ddH2O, autoclave. For electrophoresis dilute 
1:20 in ddH2O. 
 
6 x DNA loading buffer 
0.09 % (w/v) Bromophenolblue 
0.09 % (w/v) Xylen Cyanol FT 
60 % (v/v0 Glycerol 
60 mM EDTA 
 
 
SDS-PAGE and Western blot 
 
10x SDS running buffer (pH 8.8) 
30 g Tris, 
144 g Glycine 
5 g SDS 
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Coomassie staining solution 
0.25 % (w/v) Coomassie Brilliant-Blue R-250 
45 % (v/v) Methanol 
45 % (v/v) ddH2O 
10 % (v/v) Glacier acid 
 
 
Coomassie destaining solution 
7 % (v/v) Glacier acid 
20 % (v/v) Methanol 
73 % (v/v) ddH2O 
 
SDS-PAGE gel drying solution 
35 % (v/v) Ethanol 
2 % (v/v) Glycerol 
63 % (v/v) ddH2O 
 
4x protein sample buffer 
8 ml 1M Tris/HCl, pH6.8 
4 ml 2-Mercaptoethanol 
16 ml Glycerol 
12 ml 20% (w/v) SDS 
8 mg Bromophenolblue 
 
Add 2-Mercaptoethanol prior use. 
 
4x SDS-PAGE upper gel buffer (pH 6.8) 
30.3 g Tris 
10 ml 10 % (w/v) SDS 
 
Dissolve in ddH2O, adjust pH to 6.8 using concentrated HCl and fill up to 1 L with 
ddH2O. 
 
SDS-PAGE lower gel buffer (pH 8.8) 
90. 10 ml 9 g Tris 
 10 % (w/v) SDS 
 
Dissolve in ddH2O, adjust pH to 8.8 using concentrated HCl and fill up to 1 L with 
ddH2O. 
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10x Transfer buffer (for wetblots) 
60 g Tris 
288 g Glycin 
Fill up to 2 L with ddH2O. 
 
1x Transfer buffer (for wetblots) 
100 ml 10x Transfer buffer (see recipe above) 
200 ml Methanol 
 
Fill up to 1 L with ddH2O. 
 
 
Amidoblack protein quantification 
 
Amidoblack staining solution 
0.5 % (v/v) Amidoblack 
45 % (v/v) Methanol 
45 % (v/v) ddH2O 
10 % (v/v) Glacier acid 
 
Protect from light and store at 4 °C. 
 
Amidoblack destaining solution 
47.5 % (v/v) Methanol 
47.5 % (v/v) ddH2O 
5 % (v/v) Glacier acid 
 
Store at 4 °C. 
 
Amidoblack dissolving solution 
80 % (v/v) Formic Acid 
10 % (v/v) Glacier acid 











10x tris buffered saline (TBS) 
24.22 g Tris 
81.81 g NaCl 
 
Dissolve chemicals in ddH2O, adjust pH to 7.5 using concentrated HCl and fill up to 
1 L with ddH2O. 
 
Blocking solution 
5 % (w/v) skimmed milk powder in 1 x TBS 
 
Substrate buffer 
8.2 g sodium acetate 
ad 1 L with ddH2O, pH to 5.0 with citric acid 
 
o-Phenylene diamine 
10 mg/ml o-Phenylene diamine dissolved in Methanol 
 
Substrate solution 
49.50 ml substrate buffer 
0.5 ml o-Phenylene diamine 
15 µl 30% H2O2 
 
Wash buffer 






0.1 % (w/v) NaN3 




0.2 % (w/v) saponin (Sigma) 
in FACS-PBS (recipe above) 




Lysis buffer (pH 7.5 – 8.0) 
25 mM HEPES 
150 mM NaCl 
0.1 % (v/v) Triton X-100 
1 mM 2-Mercaptoethanol 
5 mM Imidazole 
 
Buffer A (pH 7.5)  
25 mM HEPES 
150 mM NaCl 
 
Buffer B (pH 7.5) 
25 mM   HEPES 
150 mM NaCl 
1 M Imidazole 
 
All buffers are degassed by sterile filtration. 
 
Resuspension buffer (pH 8.0) 
20 mM Tris-HCl 
 
Isolation buffer (pH 8.0) 
2 M Urea 
20 mM Tris-HCl 
0.5 M NaCl 
2 % (v/v) Triton X-100 
 
Binding buffer (pH 8.0) 
6 M Guanidine hydrochloride 
20 mM Tris-HCl 
0.5 M NaCl 
5 mM Imidazole 
1 mM 2-Mercaptoethanol 
 
Wash buffer (pH 8.0) 
6 M Urea 
20 mM Tris-HCl 
0.5 M NaCl 
20 mM Imidazole 
1 mM 2-Mercaptoethanol 
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Refolding buffer (pH 8.0) 
20 mM Tris-HCl 
0.5 M NaCl 
20 mM Imidazole 
1 mM 2-Mercaptoethanol 
 
Elution buffer (pH 8.0) 
20 mM Tris-HCl 
0.5 M NaCl 






Permeabilisation buffer (in PBS) 
0.05 % (w/v) Saponin 
0.1 % (w/v) NaN3 
2 % (v/v) FCS 
0.1 % (w/v) BSA 
 
Blocking buffer (in PBS) 
3 % (w/v) BSA 
0.1 % (w/v) NaN3 
 
 
2.5 Biologicals  
 
Parasites and isolates 
 
Leishmania major 173::DsRed K2 (Sorensen et al 2003) 











SL3261 Salmonella typhimurim, aroA, StrepR  
Source: Stocker (Hoiseth and Stocker, 1981) 
 
 
Escherichia coli JK231 azi-6 fhuA23 lacY1 leu-6 mtl-1 proC14 purE42 
rpsL109 thi-1 trpE38 tsx-67 (ompT-fep) zih::Tn10 
dsbA::Kan 
Source: Jose (Jose et al., 1996) 
 
Escherichia coli BL21 F– ompT hsdS(rB– mB–) dcm+ Tetr gal λ(DE3) endA 
CodonPlus(DE3)-RIPL Hte [argU proL Camr] [argU ileY leuW Strep/Specr] 
Source: Stratagene 
 
Escherichia coli DH5α Φ80, lacZΔM15, recA1, endA1, gyrA96, thi-1, 
hsdR17, supE44, relA1, deoR, Δ(lacZYA-argF) U169 
Source: Promega 
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2.6 Molecular biological methods 
 
2.6.1  Site-directed mutagenesis and primer design 
 
In order to introduce specific point mutations or restriction sites to a construct a PCR 
was performed using specifically designed primers (table 2.1). Amplification was 
carried out using the Platinum® Pfx DNA polymerase kit (Invitrogen) following 
manufacturers instructions. 
 
Template: 0.5 – 1 μl 
10x Pfx Amplifiaction buffer: 10 μl 
dNTPs (10 mM): 4 μl 
Primer (10 μM): 4 μl each 
MgSO4 (50 mM): 2 μl 
Platinum® Pfx DNA Polymerase: 1 μl 
ddH2O: ad 100 μl 
 
The reaction was started with incubation for 5 min at 94 °C. This was followed by 35 
cycles of denaturing 15 s at 94 °C, annealing 30 s at 55 °C and extension 60 s at 
68 °C. The final step was a 7 min extension at 68 °C. 
Gene specific primers were designed using sequence information from GeneDB. At 
least half of the primer sequence was matched with the gene, with at least two 
guanines or cytosines at the 3’ terminus to favour stable annealing. A 5’ restriction 
site was introduced to allow subsequent cloning of the PCR product.  
 
 
2.6.2 Preparation of DNA for Ligation 
 
DNA was digested using 1.5 μl of appropriate restriction enzymes (New England 
Biolabs) in buffer provided with the enzymes in a final volume of 50 μl. Alkaline 
phosphatase (New England Biolabs) was added to the plasmid digest in order to 
remove phosphate residues. All digests were incubated for 1 h at 37 °C. For further 
processing, enzymes were either removed by agarose gel electrophoresis or on 
column using the QIAquick PCR Purification Kit (Qiagen). 
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2.6.3 PCR purification 
 
To remove enzymes off nucleotides after PCR or restriction digestion 5 volumes of 
buffer PBI was added to 1 volume of reaction. The purification was carried out using 




2.6.4 DNA sequencing 
 
Samples were sequenced by the internal SBS Sequencing Service, Ashworth 
Laboratories of the University of Edinburgh. Results were analysed using Chromas 





For ligation the Quick Ligation Kit (New England Biolabs) was used. Briefly, 
different ratios of plasmid and insert were mixed in 9 l H2O with 10 μl 2x ligation 
buffer and 1 μl of Quick T4 DNA ligase. Vector self-ligation control was performed 
by replacing the insert with the same volume of water. The reaction was left at room 
temperature for not longer than 10 min and half of the reaction was used for 




2.6.6 Preparation of chemically competent cells 
 
Two hundred ml of LB media containing the appropriate antibiotics were inoculated 
1:50 with an overnight preculture. The cells were grown at 37 °C for about 3 h till an 
OD600nm of 0.3 was reached. After centrifugation for 10 min at 3000 xg and 4 °C in 
four 50 ml tubes the supernatant was discarded and the pellets were resuspended in 
8 ml of ice cold 100 mM calcium chloride combining cells from two tubes. The cells 
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were incubated for at least 20 min on ice before centrifuged again as above. The 
combined pellets were resuspended in 8 ml of ice cold calcium chloride and left of ice 
over night at 4 °C. The following day 4 ml of ice cold 60 % glycerol were added and 





Two hundred μl of competent cells were added to either 1-10 μl of plasmid or 10 μl of 
ligated DNA. The cells were left on ice for 10 min., then heat shocked at 42 °C for 
90 s and were immediately placed on ice for further 2 min. Eight hundred μl of LB 
medium were added and cells were allowed to grow at 37 °C for at least 1 h. Then 
cells were pelleted for 1 min at 13200 rpm in a table top centrifuge and 800 μl of the 
supernatant was removed. The pellet was resuspended in the remaining 200 μl and 
plated on LB agar containing the appropriate antibiotics. 
 
 
2.6.8 Agarose gel electrophoresis 
 
Agarose was weighed and boiled in 0.5 % TBE according to the required 
concentration (0.8 to 1.5 %). The gel chamber and the combs were assembled. After 
cooling to ~55 °C ethidium bromide (to 0.001 %) was added and the gels (60 ml for a 
small gel, 120 ml for a large gel) were cast. Once the gels settled they were placed in 
an electrophoresis chamber containing 0.5 % TBE. Samples and marker were loaded 
and the gels were run at 95 V (small gel) or 120 V (large gel) for the time required. 
 
 
2.6.9 DNA extraction from gels 
 
After running the DNA samples on agarose gels, fragments of interest were isolated 
from the gel using a clean scalpel and the DNA was extracted using the QIAquick gel 
extraction kit (Qiagen) following the manufacturer’s instructions. 
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2.6.10 Colony PCR 
 
For quick screening of recombinant bacteria, single colonies were picked and 
resuspended in 50 μl PBS. Subsequently the tip with the remaining bacteria was 
streaked on an LB agar plate and incubated at 37 °C over night. From the suspension 
1 μl was pipetted into a PCR tube and the following reagents were added: dNTP-mix 
(0.4 mM), forward and reverse primer (each 100 μM), 10 μl 5x Mango Taq Coloured 
Reaction Buffer (Bioline), MgCl2 (2 mM) and 1.25 U Mango Taq DNA polymerase 
(Bioline). Water was added to make 50 μl of total volume. 
The reaction was started with incubation for 5 min at 94 °C. This was followed by 30 
cycles of denaturing 1 min at 94 °C, annealing 2 min at 54 °C and extension 3 min at 
72 °C. The final step was a 7 min extension at 72 °C. 
 
 
2.7 Protein techniques 
 
2.7.1 Amidoblack protein quantification 
 
This method was used for samples which contain reagents (e.g. SDS, 2-
Mercaptoethanol etc) which are known to interfere with normal protein quantification 
methods (e.g. Lowry, Bradford etc.) (Dieckmann-Schuppert and Schnittler, 1997).  
A cellulose acetate membrane was divided in 1.25 cm x 1.25 cm squares, fixed with 
two clips and hang over a tray. Samples were prepared by boiling equal volumes of 
sample and 2x protein sample buffer for 5 min. A BSA standard dilution series (0, 
0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.5 and 5 mg/ml) in PBS was prepared the 
same way and after boiling and a quick spin 5 μl of sample per square were applied. 
The membrane was dried for 10 min and then covered in Amidoblack staining 
solution for 10 min under shaking. The staining solution was then discarded; the 
membrane rinsed with water and then destained 3x 5 min. The cellulose acetate sheet 
was allowed to dry thoroughly before the squares were cut and placed into 1.5 ml 
reaction vessels. 500 μl of dissolving solution was added and the samples were 
incubated for 30 min at 50 °C under shaking. After the dissolving process, 250 μl of 
samples were pipetted in a 96-well microtitre plate and the absorbance was measured 
at 620 nm (or the nearest wavelength available). From the single values the value of a 
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water control (0 mg/ml) was subtracted and subsequently the protein concentration 





Glass plates were cleaned and fitted into the casting stand. The resolving gel (10 %, 
12 % or 15 %) was prepared (see table 2.2) and poured to approximately 1.5 cm 
below the top, and covered with 100 % isopropanol. After polymerisation the 
isopropanol layer was removed and the stacking gel was prepared and poured on top 
of the resolving gel. A comb was placed in the still liquid stacking gel and the gels 
were allowed to polymerise. Once settled the gels were placed into the tank and 
1x SDS running buffer was added. Samples were mixed in protein sample buffer and 
together with the protein marker were boiled for 5 min and loaded onto the gel. 
 
Table 2.2: Pipetting scheme for SDS-Gels of different percentage 
Resolving gel 10 % 12 % 15 % 
 1 gel 2 gels 1 gel 2 gels 1 gel 2 gels 
H2O 2.5 ml 5.0 ml 2.1 ml 4.2 ml 1.5 ml 3.0 ml 
4x lower gel buffer 1.5 ml 3.0 ml 1.5 ml 3.0 ml 1.5 ml 3.0 ml 
40 % acrylamide 2.0 ml 4.0 ml 2.4 ml 4.8 ml 3.0 ml 6.0 ml 
TEMED 4.5 μl 9.0 μl 4.5 μl 9.0 μl 4.5 μl 9.0 μl 
10 % APS 45 μl 90 μl 45 μl 90 μl 45 μl 90 μl 
total volume 6 ml 12 ml 6 ml 12 ml 6 ml 12 ml 
 
Stacking gel 5 % 
 1 gel 2 gels 
H2O 1.17 ml 2.34 ml 
4x upper gel buffer 0.5 ml 1.0 ml 
40 % acrylamide 0.33 ml 0.66 ml 
TEMED 3.0 μl 6.0 μl 
10 % APS 25 μl 50 μl 
total volume 2 ml 4 ml 
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For focussing gels were run at 70 V till the samples reached the resolving gel. Then 
voltage was raised to 115 V and the samples were run till the bromophenolblue dye 
reached (or ran out of) the bottom of the gel. Gels were removed from the glass plates 
and stained for 15-20 min in Coomassie staining solution (Laemmli, 1970). 
Afterwards gels were destained and dried between cellulose sheets. 
 
 
2.7.3 Western blot analysis 
 
Proteins were separated by SDS-polyacrylamide gel electrophoresis of gels of 
appropriate percentage. After electrophoresis, gels were soaked in 1x transfer buffer 
for 5 min. Using a wet blot system (BioRad) two pieces of pre-cut filter paper and two 
fibre pads were soaked in transferbuffer. A 9 x 6 cm PVDF membrane (Millipore) 
was cut and briefly rinsed in methanol. After another rinse in water, the membrane 
was placed in transfer buffer as well. To assemble the transfer sandwich, one fibre pad 
was put on one site of the blotting cassette followed by a filter paper. The equilibrated 
gel was placed onto the filter paper and trapped air bubbles were removed. Then the 
membrane was laid on top of the gel and the sandwich was completed by another 
filter paper and fibre pad. Air bubbles were removed with help of a pen. The cassette 
was closed and then placed in the module and the buffer tank. The ice unit was added 
and the tank was filled up with transfer buffer. After one hour of transfer at 100 V 
under permanent stirring the sandwich was removed, the membrane was placed in a 
50 ml tube and blocked with PBS/ 5 % skimmed milk powder for 15 min. Antibody 
was pre-incubated in PBS/ 5 % milk (and Salmonella typhimurium lysate when 
required) for 30 min. Afterwards the membrane was incubated for 1 h with the 
antibody solution on a rolling shaker. When incubation with a secondary antibody 
was necessary, the membrane was washed for 3x 10 min with PBS/ Tween 20 
between both incubation periods. Before detection the membrane was washed 
3x 10 min to remove unbound antibodies. Membranes were then placed in a cassette 
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2.8 Protein purification 
 
2.8.1 Induction of recombinant protein 
 
A single colony was picked and used to inoculate 10 ml of LB medium supplemented 
with 50 µg/ ml kanamycin and grown overnight. Five hundred ml of LB medium was 
inoculated with 0.5 ml of an over night culture and was grown at 37 °C, 150 rpm till 
an OD600nm between 0.4 and 0.6 was reached. At this stage 1 ml culture sample was 
removed, bacteria  centrifuged at 20800 xg for 3 min; the resulting pellet was 
resuspended in 50 µl 2x protein sample buffer and boiled for 5 min at 95 °C and 
frozen at -20 °C till later analysis. Recombinant protein expression was induced by 
adding isopropyl-β-D-thiogalactopyranoside (IPTG, 0.4 – 0.8 mM) to the cultures 
which were then incubated at 30 °C for 5 h with shaking. After induction OD600nm was 
measured and 0.5 ml of culture was removed for an analytical SDS-gel. Finally, all 
bacteria were harvested by centrifugation for 25 min at 4500 xg and 4 °C. The 
supernatant was discarded; the pellet was washed once with 30 ml lysis buffer and 
was then transferred into a 50 ml tube. After another spin for 25 min at 4500 xg and 
4 °C the pellets were stored at -80 °C until further processing.  
 
 
2.8.2 Purification of soluble proteins 
 
The bacterial pellets were thawed and resuspended in 5 ml lysis buffer supplemented 
with half a tablet protease inhibitors (Complete Mini EDTA-free tablets, Roche) and 
1 mg/ ml lysozyme (Sigma). Afterwards the suspension was gently shaken at 30 °C in 
a water bath for 1 h till the solution became viscous. Twenty-five units of DNase 
(Benzonase®Nuclease, Novagen) were added and the suspension was allowed to rest 
on ice for further 30 min. The bacteria were then disrupted by sonication on ice (4x 
30 s intervals with 30 s resting between) until the solution became clear. After a 
centrifugation step at 18000 xg and 4 °C for 25 min the supernatant was filtered 
through a 0.22 µm pore sized filter and then purified by affinity chromatography. 
Preloaded nickel columns (GE Healthcare) were equilibrated with 5 column volumes 
(CV) Buffer A at a flow rate of 1 CV/ ml. After sample application columns were 
washed with 20 CV Buffer A : Buffer B (ratio 99:1). Recombinant proteins were 
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eluted on a continuous gradient towards a Buffer A/Buffer B ratio of 50:50, during 
which fractions of 1 CV were collected. Finally the gradient was raised to 100 % 
Buffer B in order to elute the remaining proteins.  
 
 
2.8.3 Purification of proteins from inclusion bodies 
 
The bacterial cell paste was thawed and resuspended in 20 ml resuspension buffer 
supplemented with protease inhibitors (Complete Mini EDTA-free tablets, Roche) 
and 1 mg/ ml lysozyme (Sigma). Afterwards the suspension was gently shaken at 30 
°C in a water bath for 1 h till the solution became viscous. Twenty-five units of 
DNase (Benzonase®Nuclease, Novagen) were added and the suspension was 
incubated on ice for further 30 min. The bacteria were then further disrupted by 
sonication on ice (4x 30 s intervals with 30 s resting between). After a centrifugation 
step at 25000 xg and 4 °C for 10 min the supernatant was discarded and the pellet was 
resuspended in 15 ml cold isolation buffer. The sonication was repeated as described 
above. Afterwards centrifugation, re-suspension and sonication were repeated for a 
second time. The suspension was pelleted again and the precipitate was resuspended 
in 10 ml of buffer without urea (e.g. resuspension buffer). After a final spin at the 
conditions mentioned above the resulting pellets were frozen at -80 °C till further 
processing. 
Frozen pellets were dissolved in 5 ml binding buffer per 100 ml induced culture. 
Samples were incubated for 30 to 60 min at room temperature with gently shaking. 
Insoluble parts were removed by centrifugation (25000 xg, 15 min and 4 °C) and the 
supernatant was passed through a 0.45 µm filter. 
For chromatography affinity columns preloaded with nickel were equilibrated with 
10 CV of binding buffer at a flow rate of 1 CV/ min. Once no protein or other 
contaminations were detectable the sample was applied onto the column. Afterwards 
unbound proteins were washed with 30 CV of wash buffer and the flow through was 
collected. In order to allow complete refolding of the proteins a gradient (wash buffer 
to refolding buffer) of 45 CV was applied and flow rate for this step was reduced to 
0.5 CV/ min. This was followed by further 10 CV of refolding buffer. Refolded 
proteins were eluted with 20 CV of a gradient (refolding buffer to elution buffer) 
during which fractions of 1 CV were collected. Fraction collection was continued 
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5 CV beyond this gradient. The final step was a wash of the column in 10 CV binding 
buffer in order to allow complete removal of remaining protein from the column. 
After the final run, columns were washed with 20 % ethanol and stored at 4 °C. 
 
 
2.9 Parasite cultures 
 
2.9.1 Maintenance of leishmania promastigote cultures 
 
Leishmania promastigotes were grown in 1x SDM with 20 µg/ ml hygromycin 
without CO2 at 28 °C. Once the stationary phase was reached, 100 µl of the old 
culture was used as inoculum for a new 10 ml promastigote culture. In order to 
maintain virulence, parasites were regularly passaged through a host. For that purpose 
mice were infected with 2x 106 promastigotes sub-cutaneously at the tail base. After a 
lesion became visible, mice were sacrificed. The lesion and the draining lymph node 
were removed and transferred into fresh SDM medium to allow growth of virulent 
parasites. After one passage in culture, parasites were frozen at -80 °C. 
 
 
2.9.2 Freeze/thawing of leishmania parasites 
 
For freezing 1x 107 parasites of logarithmic promastigotes culture were spun down at 
1100 xg at 4 °C for 10 min. The supernatant was discarded and the pellet containing 
the parasites was restored in 500 µl cold SDM medium. Five hundred µl cold 15 % 
glycerol solution was added and after mixing, the parasites were transferred into a 
cryo tube. These were then placed in a cryo box and frozen slowly to -80 °C for 24 h. 
Subsequently tubes were transferred into liquid nitrogen to allow long term storage. 
For thawing parasites were quickly thawed in a 37 °C water bath and then transferred 
into a tube containing 10 ml SDM medium. After centrifugation for 10 min at 1100 xg 
and room temperature the resulting pellet was resuspended in 1 ml SDM which was 
then used to inoculate several flasks containing SDM medium with different volumes 
of parasites. After roughly four days in culture parasites were passaged as usual. 
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Female BALB/c or C57BL/6 mice were purchased from Harlan UK, Charles River 
UK or bred at the University animal facilities and maintained under specific 
pathogen-free conditions in individually ventilated cages. Animals were used at 6–9 
weeks of age and were age matched within each experiment. All experiments were 
approved by a Project License granted by the Home Office (U.K.) and conducted in 
accordance with local guidelines. 
 
 
2.10.2 Preparations of frozen salmonella stocks for immunisation  
 
Two hundred ml of LB medium containing the appropriate antibiotics were inoculated 
1:100 with a pre-culture and grown at 37 °C; 150 rpm till an OD600nm of 1.4-1.6 was 
reached. The cultures were centrifuged at 4 °C, 3500xg for 20min and the supernatant 
was discarded. The pellets were resuspended in 10 ml of LB medium and more 
medium was added to a volume of 35 ml. Centrifugation was repeated at 4 °C, 
3500 xg for 15 min, the supernatant was removed and the pellet was resuspended in 
300 μl LB/ 30 % Glycerol. A small sample was diluted to determine OD600nm, the 
suspension was adjusted to a density equivalent to OD600nm = 100, which corresponds 
to approximately 1010 CFU. Suitable aliquots were frozen away in cryotubes at -
80 °C. For exact determination of vaccination doses, an aliquot was thawed on ice, 
serially diluted and dilutions plated on LB agar plates containing appropriate 
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2.10.3 Purification of outer membrane vesicles 
 
One litre of LB medium with the appropriate antibiotics was inoculated with 10 ml of 
a preculture grown from a single colony. When the culture reached an OD600nm 
between 0.6-0.8, 1 ml of sample was withdrawn and sodium propionate to 50 mM 
was added to induce the production of AIDA-fusion proteins on the cell surface. 
Samples were regularly removed to monitor recombinant protein expression and 
release into the supernatant. These samples were centrifuged for 3 min at 20800 xg, 
100 µl of supernatant were taken and the rest discarded. The pellet was dissolved in 
50 µl of 2x protein sample buffer and boiled for 5 min at 95 °C. Pellets and 
supernatant were frozen at 20 °C until further analysis. After approximately 10 h of 
induction 50 µg/ ml gentamycin was added for 30 min in order to increase membrane 
shedding. The cultures were then harvested at 4500 xg for 30 min, the pellets 
discarded and the supernatant was passed through a 22 µm pore size filter unit. This 
was followed by ammonium sulphate precipitation using 390 g/ L ammonium 
sulphate to obtain 60 % saturation. The solution was left to settle over night at 4 °C. 
The next morning the precipitate was harvested by centrifugation for 30 min at 
11000 xg at 4 °C. The pellets were dissolved in 20 ml PBS and spun again for 15 min 
at 16000 xg and 4 °C. Afterwards supernatants were transferred into Beckman 
ultracentrifugation tubes and membrane vesicles were pelleted for 2 h at 100000 xg 
and 4 °C. To determine dry weights, pellets were dissolved in endotoxin free water 
and lyophilised. Vesicles were reconstituted in endotoxin free water (HyCult 
biotechnology bv) to a working concentration of 1 mg/ ml and stored at 4 °C. 
 
 
2.10.4 Determination of bacterial fitness by colonisation assay 
 
Three mice per group were immunized orally with 1 x 1010 CFU of a SL3261 vaccine. 
After seven days mice were sacrificed and Peyer’s patches removed and placed in a 
vial containing 1 ml PBS. Subsequently, Peyer’s patches were homogenized between 
the rough ends of two glass slides and the resulting suspension was transferred into a 
2 ml reaction tube. The glass slides were rinsed with an additional 1 ml of PBS. 
200 μl of the suspension, 100 μl of 1 % Triton X-100 and 700 μl of PBS were mixed 
and 100 μl were plated on a selective LB agar plate in duplicates. Out of this dilution 
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two further dilutions (1:10 and 1:100 respectively) were prepared and also plated on 
LB agar plates. All plates were incubated overnight at 37 °C and colony numbers 
were counted the following day. 
 
 
2.10.5 Infection of mice with L. major and foot pad measurements 
 
L. major promastigotes were grown in 1 x SDM until stationary phase was reached. 
Parasites were counted and adjusted to 1 x 107/ 100 µl in PBS and 20 µl (equal 
2 x 106 parasites) were injected into the left hind foot pad. Foot pad swelling was 
measured using a calliper. To determine the overall swelling, the difference in 
thickness between left infected foot pad and right reference foot pad was calculated.  
 
 
2.10.6 Determination of L. major burden in murine organs 
 
Mice were sacrificed by cerebral dislocation; organs (spleen, liver, draining lymph 
node, foot pad) were removed and placed into tubes containing 1 ml of PBS. For 
processing, organs were forced through a cell strainer using the sterile top end of a 
1 ml syringe. Before this treatment, feet were cut several times with scissors to 
simplify homogenisation. Cell strainers were flushed with 1 ml of PBS and the single 
cell/ parasite suspension was pipetted back into the collection tube. After 
homogenisation volumes in all tubes were adjusted to the same level.  
For the serial dilution assay, sterile 96 well plates were labelled and filled with 100 µl 
1x SDM (supplemented with 20 µg/ ml hygromycin and 50 µg/ ml kanamycin) per 
well. Homogenates of highly infected foot pads and lymph nodes were pre-diluted 
1:100. For serial dilution, 46 µl of cell suspension were added into the wells of the 
first column in quadruplicates and 46 l were serially transferred resulting in a 1:√10 
dilution steps over all 12 wells of a row. The plates were finally sealed with parafilm 
and incubated at 27 °C for 14 days. Parasite growth was then scored microscopically 
and parasite load in the infected organs was calculated using the dilution where at 
least 2 of 4 wells (~37.5 %) of wells were positive (Taswell et al., 1980). The 
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reciprocal of this dilution was multiplied by the total volume (in multiples of 0.1 ml) 
to derive the total number of parasites per organ. 
 
 
2.10.7 Determination of hepatosplenomegally and L. donovani burden in 
impression smears 
 
Mice were sacrificed, weighed, liver and spleen removed and the weight of both 
organs was also determined. The organ-body-mass index (BMI) was calculated as the 
percentage of weight of the single organ to the total body weight of the mouse. To 
determine parasitic burden in spleen and liver, impression smears from cut organs 
were prepared on microscopic glass slides. Slides were fixed in methanol and stained 
with Giemsa. Afterwards the number of parasites per 1000 host cell nuclei was 
counted using a bright-field microscope and an immersion oil lens. Leishman-
Donovan units (LDU) were calculated by multiplying the number of parasites/ 1000 
nuclei by the organ weight. 
 
 
2.10.8 Giemsa staining 
 
Impression smears were briefly fixed in a small volume of methanol. After pouring 
off excess methanol slides were air dried. Giemsa reagent was prepared in a 50 ml 
tube by mixing 3.6 ml Sorenson A (9.5g Na2HPO4/L ddH2O), 1.4 ml Sorenson B 
(9.07g KH2PO4/L dH2O), 45 ml ddH2O and 5.55 ml of a 1:10 dilution of Giemsa 
stain. The staining solution was mixed carefully and poured into staining baths. Slides 
were placed upside down in the staining bath and left for 20 to 30 min at room 
temperature. The stain was then rinsed off under running tap water and slides were 
allowed to dry. 
 
 
2.10.9 Blood collection and serum preparation 
 
Mice were bled by submandibular stab incision in accordance to Home Office 
guidelines. Blood was collected in a 1.5 ml tube and left to clot at 4 °C over night. 
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The following day, clot and serum were separated by centrifugation at 20800 xg for 
15 min and serum was carefully removed and transferred to a new tube, frozen and 
stored at -80 °C till further use. 
 
 




96 well plates were coated overnight with 50 l recombinant antigen (50 µg/ml) or 5-
7.5x 107 bacterial equivalents of Salmonella enterica serovar Typhimurium-OH test 
antigen (TS1611, Sifin) per well. The next day plates were tapped dry and washed 
with PBS/0.05 % Tween-20 for 5 min. Subsequently, free binding sites on plates were 
blocked with 80 µl/ well skimmed milk/TBS for 45 min at 28 °C (alternatively 30 min 
at 37 °C). Master serum dilution plates were prepared by pipetting 2.5 % skimmed 
milk/TBS to each well, adding 40 l of pooled sera of each vaccination group in 
triplicates to the top row and serially diluted to  1:5; 1:20; 1:80; 1:320; 1:1280; 
1:5120; 1:20480; 1:81920. When obtained serum volumes were sufficient, sera from 
single mice were diluted individually omitting technical replicates.   
Blocked, antigen coated plates were washed three times with PBS/0.05 % Tween-20 
and 50 µl of the serum dilutions were transferred from the master plates to antigen 
coated plates. After incubation for 2 h at 37 °C plates were washed three times and 
50 µl of diluted horseradish peroxidase-conjugated detection antibodies (goat anti-
mouse IgG1 or IgG2a, Novus Biologicals, 1:10000 diluted; donkey anti-mouse IgG, 
Jackson ImmunoResearch, 1:2500 diluted) were added to each well. Plates were 
incubated for a further hour at 37 °C. This was followed by another wash and 80 µl of 
substrate buffer was added to each well for 5 min. Plates were tapped dry and 50 µl of 
substrate solution was pipetted into each well. After incubation for 30 min at 37 °C 
reactions were stopped with 10 µl 5 M H2SO4. The absorption was read at 490 nm 
using an ELISA plate reader. For analysis, triplicate values were averaged and the 
absorption at 490 nm against the dilution was plotted. Antibody titres were 
determined by reading the value at half-maximal absorption. Any curves which did 
not reach the half-maximum were classified as below detection limit. 
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2.11.2 Flow cytometry (FACS) 
 
Single cell suspensions from murine spleens were prepared and 1-3x107 viable cells 
were re-stimulated either with 5-20 μg purified antigen (for 18 h), with medium alone 
(for 18 h) or with PMA/Ionomycin (for 6 h). Two hours before harvest, Brefeldin A 
(10 μg/ml) was added to allow accumulation of intracellular cytokines. 
Cells were then harvested by centrifugation (350 xg, 5 min), resuspended in FACS-
PBS and transferred into FACS tubes. For surface staining (CD3, CD4 and CD8a) 
antibody cocktails (0.4 μg of each antibody per sample) were prepared in FACS-PBS 
and added to isotype and ICS samples. Cells were incubated for 30 min at 4 °C in the 
dark and then washed once with FACS-PBS prior fixation with Reagent A (Caltag) 
for 15 min at room temperature. Afterwards cells were again washed in FACS-PBS 
and fixative was removed by centrifugation. All subsequent steps were performed in 
the dark. For intracellular staining (ICS) cells were permeabilised with 100μl Reagent 
B (Caltag), and antibody cocktails for ICS (α-TNFα-PE, α-IFNγ-Alexa®647 or α-IL-
4-Alexa®488) or respective isotype controls were added. After incubation for 45 min 
at room temperature samples were washed in FACS-PBS-saponin twice and were 
resuspended in FACS-PBS for immediate analysis or in 0.1 % paraformaldehyde 
fixative solution then stored at 4 °C in the dark for later analysis.  
Data from 2x 105 to 1x 106 cells were acquired on a LSR II (BD Bioscience) using 




2.11.3 Staining of leishmania parasites for fluorescent microscopy 
 
Parasites from late logarithmic phase cultures were harvested by centrifugation 
(5 min, 1900 xg) at room temperature, the supernatant discarded and the pellet 
washed twice with PBS. The parasites were fixed in 4 % paraformaldehyde/HEPES 
for 30 min at room temperature. In order to quench free aldehydes, fixed parasites 
were washed once in TBS, the resulting pellet was resuspended in 100 μl TBS and a 
droplet each was carefully distributed on Polysine (VWR International) slides and left 
to dry. For intracellular staining parasites were covered in permeabilisation buffer and 
incubated in a wet chamber for 10 min at room temperature. Parasites, which were 
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surface stained only, were treated equally with buffer lacking saponin. Afterwards 
slides were washed once with PBS and blocked with buffer containing 3 % BSA for 
1 h in a wet chamber, then washed again with PBS. Subsequently parasites were 
stained with primary antibody solution (polyclonal mouse anti-08.1140, 1:100 diluted 
in permeabilisation buffer) for 1 h, while surface controls were treated with antibody 
solution lacking saponin. Parasites were washed in PBS again. Anti mouse-Cy2, 
diluted 1:500 was added and incubated for 1 h at room temperature, followed by three 
washes in PBS and subsequently slides were dried. A drop of Mowiol (Calbiochem) 
containing DAPI (Sigma) was given onto a cover slip and was carefully placed onto 
the stained slide avoiding air bubbles. Slides were allowed to dry and were stored at 
4 ºC in the dark. Images were acquired with the Leica SP5 confocal laser-scanning 
system and processed with VOLOCITY software (Improvision) at the PIF (Pathogen 
Imaging Facility of the University of Edinburgh). 
 
 
2.12 Statistical analysis 
 
Statistical analysis was performed using GraphPad Prism Program (Version 3.0, 



















3.1 In silico selection of novel antigen candidates from Leishmania spp. 
 
A bioinformatic analysis was performed to select potential novel antigen candidates 
for an anti-leishmania vaccine from a proteome data set. This data set was derived 
from a comparative study of the proteomes of L. mexicana promastigotes and 
amastigotes (Paape et al., 2008). In the latter study, 509 different proteins were 
identified which corresponded to approximately 6 % or the gene products predicted 
from the L. major reference genome that was used for identification based on the 
mass spectra. In this protein set, all antigens experimentally tested in vaccines 
published to date were recovered. It was thus assumed that the data set was an 
excellent resource for the selection of novel antigen candidates for vaccines. Since 
experimental analysis of all 509 proteins would not have been realistic, a theoretical 
approach was established prioritizing requirements for antigen suitability. Protein 
abundance, sub cellular localization and conservation within the target species had 
already been tested and discussed for Helicobacter pylori (Sabarth et al., 2002), a 
pathogen of similar complexity. Thus, these parameters were applied in the selection 
process for leishmania vaccine antigens. An overview of these criteria is presented in 
figure 3.1 and table 3.1.  
 
Abundance is an important parameter, since only proteins expressed above a certain 
threshold, are likely to be recognized by the immune system. Given the available 
dataset which corresponded to approximately 6 % of the leishmania proteome, the 
509 proteins were considered to represent abundant polypeptides. In addition, since 
selective codon usage had been shown in leishmania to reflect translational bias and a 
codon adaptation index (CAI) had been calculated for each protein (Paape et al., 
2008); this was used to rank the set of 509 possible candidates. All proteins have been 
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Fig. 3.1: Schematic overview of criteria applied in antigen selection process 
 
Antigens may be more likely to be recognized as “foreign” by the immune system of 
vaccinated individuals if they lack homology to proteins in species targeted for 
vaccination (human as final target and mouse as animal model in the present case). In 
contrast, conservation of potential antigens within Leishmania species was strongly 
favoured. Thus, candidate proteins were further analysed bioinformatically for lack of 
homology to human or mouse polypeptides and for high degree of conservation 
between leishmania homologues (table 3.1) 
 
A further criterion was the expression of the potential antigen in different life cycle 
stages. Preference was given to proteins expressed during the intracellular phase of 
infection (amastigotes), but, since early stages of infection after transmission of  
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promastigotes was also considered relevant, vaccination antigen expressed in both life 
cycle stages were also included. In total of six antigens were selected and,  as shown 
in table 3.1, the majority of selected antigens were found in both stages, but 
LinJ23.0410 was only found in amastigotes and KMP-11, which while overly 
expressed in promastigotes, is only present in very little amounts in the amastigote 
stage (Berberich et al., 1998). Finally, potential antigens with unknown function 
(hypothetical proteins) were preferred since the main goal of this work was to search 
and evaluate novel vaccine candidates. An exemption was made for KMP-11, which 
served as a reference as it had been well characterized in previous studies (Basu et al., 
2005).1 
 
Since protein identification was based on the L. major genome database, conservation 
of the proteins within Leishmania spp. was an absolute necessity. Moreover, the 
vaccine would be primarily developed for populations in India affected by visceral 
leishmaniasis, a DNA preparation from a patient isolate of the etiologic agent, i.e. L. 
donovani (MHOM/INI/03BHU-55) was used for gene amplification. Due to the lack 
of genetic information on L. donovani all cloning procedures were planned using the 
L. infantum genetic database (GeneDB) as reference. Homology was analysed by 
comparison with L. infantum, L. braziliensis and both Trypanosoma species, T. cruzi 
and T. brucei using comparison tools on GeneDB (table 3.1) and ClustalW. Figure 3.2 
which shows an example for such an alignment that included the sequence obtained 
for the respective antigen from the L. donovani (MHOM/INI/03BHU-55) isolate. 
Alignments of all other antigens were included in the supplementary section (S-1) of 
this thesis.  
 
In addition to the major selection criteria described above, predicted properties of 
selected proteins were also taken into consideration (table 3.2). Proteins, especially 
when being expressed on the surface of bacteria by means of autotransporters should 
not be too large, so that they are easily transported through the inner and outer cell 
membrane. Furthermore a strong positive charge may hinder transportation, and in the 
presence of a putative transmembrane helix proteins may become stuck in the 
                                                 
1 LinJ09.1180 which, at the time of selection, was listed as hypothetical protein - possibly 
mitochondrial RNA binding protein 2 (MRP2), has now been experimentally confirmed as MRP2 or 
gBP25 (Aphasizhev et al., 2003). 
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membrane, preventing exposure on the bacterial surface. Putative leader sequences 
had to be removed prior cloning, so that proteins will be targeted to the surface using 
the cholera toxin signal peptide from the AIDA construct as explained elsewhere. All 
predicted protein properties of the selected antigen candidates are summarized in table 
3.2. 
 
Fig. 3.2: ClustalW alignment of antigen LinJ08.1140 in different Leishmania 
species 
Small and hydrophobic amino acids are shown in red, acidic amino acids in blue, 
basic amino acids in magenta and amino acids with hydroxyl or amine side chains in 
green.  
"*" means that the residues or nucleotides in that column are identical in all sequences 
in the alignment; ":" means that conserved substitutions have been observed, 
according to the colors explained above. LmjF = L. major; LinJ = L. infantum; LbrM 
= L. braziliensis; L. donovani = isolate MHOM/INI/03BHU-55 
 
Due to the dynamic process of the genome projects and their updating in databases, 
GeneDB changed nomenclature for the selected antigens throughout the duration of 
this project. Table 3.3 gives an overview with the latest update from September 2008. 
In this study antigens were named according to their number in GeneDB from 
December 2006. 
 
Table 3.3: Nomenclature for selected antigen candidates 
L. major ID 
GeneDB 
systematic ID from 
December 2006* 
GeneDB 
systematic ID from 
September 2008 
other previous IDs 
LmjF08.1260 LinJ08.1140 LinJ08_V3.1190  
LmjF09.1120 LinJ09.1180 LinJ09_V3.1180 LinJ09.0840 
LmjF23.0370 LinJ23.0410 LinJ23_V3.0420 LinJ23.0380 
LmjF25.1610 LinJ25.1680 LinJ25_V3.1670 LinJ25.1480 







* Antigens were named according to their number in GeneDB from December 2006 
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3.2 Construction of optimised live vaccines 
 
ORF for the selected antigens were cloned to be expressed on the surface or in the 
cytosol of attenuated Salmonella enterica serovar Typhimurium and thereafter to be 
tested in murine models for visceral leishmaniasis. Expression plasmids allowing the 
expression of vaccine antigens in salmonella from previous studies (Rizos et al., 




3.2.1 Surface expression plasmids 
 
In order to express the selected leishmania antigens on the surface of salmonella 
plasmid pKRI143 based constructs were generated. This plasmid carries an 
autotransporter (AIDA) construct which was previously used for the vaccination 
against H. pylori (Rizos et al., 2003; J. Schroeder, unpublished data). The expression 
cassette consists of a cholera toxin B signal peptide, followed by H. pylori antigen 
ureA, and a HA-tag encoding sequence to allow detection of fusion proteins later, all 
linked to the 5’ sequence coding for the N-terminus of AIDA. The fusion gene is 
under the control of the in vivo inducible PpagC promoter. The UreA cDNA was 
removed from the cassette to create an empty vector ready for insertion of leishmania 
antigen ORFs. For this purpose a new restriction site had to be introduced which 
allowed the positioning of genes of interest between the signal peptide and the HA-tag 
sequences followed by aida (fig 3.3). Primers were designed with the forward primer 
LS_KRI XhoI (F) starting upstream of PpagC and incorporating an XhoI site. The reverse 
primer LS_SpeI/BglII (R) was positioned in a way that allowed incorporation of the 
signal peptide in the PCR product while the 5’ overhang was used to introduce an 
additional SpeI restriction site closely followed by a BglII site (fig. 3.3A). The 
resulting PCR product contained the PpagC promoter, followed by RBS, leader 
sequence and the two restriction sites. Consequently the PCR product was digested 
with XhoI and BglII and ligated into an equally processed pKRI143 plasmid.  
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Fig. 3.3: Cloning of leishmania antigens into surface expression plasmids 
Schematic overview of the cloning process that resulted in the generation of antigen 
free AIDA construct (pAIDA0) ready for insertion of different antigens. The 
subsequent cloning procedure is shown on the example of LinJ08.1140. A: 
Introduction of SpeI and removal of ureA resulting in pAIDA0 (B), C: insertion of 
antigen between SpeI/BglII and mutation of RBS resulting in D. AIDA: 
autotransporter involved in diffuse adherence, bla: beta-lactamase, HA: Haemophilus 
influenzae hemaagglutinin, CTB-SP: cholera toxin B signal peptide, RBS: ribosomal 
binding site 
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The resulting new plasmid contained all parts of a functional surface expression 
system but lacking ureA (fig. 3.3B). With SpeI an additional restriction site was 
introduced which allowed the ligation of leishmania antigen ORFs between SpeI and 
BglII. This new universal plasmid was named pAIDA0 (fig. 3.3). 
For the ligation of antigen ORFs, gene specific primer (see table 2.1) carrying either a 
SpeI (forward) or a BglII site (reverse) at the 5’ end were designed using the L. 
infantum gene sequence (GeneDB). A DNA preparation of L. donovani isolate 
MHOM/INI/03BHU-55 (Bihar, India) served as a template for PCR. The PCR 
products were separated on agarose gels, eluted and digested with SpeI and BglII, 
ligated into pAIDA0 plasmid (fig. 3.3C) and subsequently transformed in to E. coli 
JK321. 
Importantly this strain has a deletion of the dsb A gene, which encodes a 
disulfideoxidoreductase. If present this enzyme is responsible for the formation of a 
stable tertiary structure of the AIDA-antigen complex, resulting in a blockage of the 
translocation through the outer membrane. This would lead to a rapid degradation of 
the fusion proteins in the periplasm. Hence lack of the disulfideoxidoreductase allows 
the AIDA-antigen construct to remain unfolded and be transported through the outer 
membrane to the bacterial surface (Jose et al., 1996).  
Gene insertion, correct size and sequence was confirmed by colony PCR, restriction 
digestion and sequencing, respectively. The resulting plasmids were carrying the 
original RBS and were named accordingly. The nomenclature was psVAC0-antigen, 
with “s” standing for surface, “VAC” for vaccine, “0” referring to the wild type 
ribosomal binding site present and “antigen” was replaced with the relevant antigen 
(KMP11, 08.1140, 09.1180, 23.0410, 25.1680 or 35.0240). 
 
 
3.2.2 Introduction of mutations into the ribosomal binding site 
 
The expression of foreign antigen can highly influence the bacterial fitness of vaccine 
strains often leading to additional attenuation. Therefore protein expression needs to 
be fine tuned by introducing point mutations to the ribosomal binding site. These 
mutations lead to either elevated or reduced binding of the transcript to the ribosome 
and subsequently to a higher or lower translation efficiency of the antigen-encoding 
mRNA. This strategy to modulate antigen expression had been explored before and 
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certain point mutations had been tested (Rizos et al., 2003; J. Schroeder, unpublished 
data) and were applied in this study. Since the plasmids for cytosolic antigen 
expression contained already all different RBS, the antigen-encoding sequence simply 
needed to be replaced with one of the ORFs of the selected leishmania antigens, as 
described in section 3.2.1. 
For surface expression strains a mutagenesis PCR was performed using the psVAC0-
antigen constructs as template. The RBS was mutated with help of either of the 
following primer KOR_RBS4 (F), KOR_RBS6 (F) or AIDA RBS_2 (F) and gene 
specific primers for the reverse end. The resulting product was digested with BglII 
and XbaI and ligated into equally digested psVAC0- templates creating mutated RBS 
3, 4 and 5 (fig. 3.3D). All mutations were verified by sequencing. A list of mutations 
and the corresponding RBS number is presented in table 3.4. 
 










also known as, 
other expressions 
0 AGGAG Yes Yes 
psVAC0 
pcVAC0 
1 AGGAA Yes No pcVAC1 
2 GGGAA Yes No pcVAC2 
3 AGCAG Yes Yes 
pcVAC3 
psVAC3 
4 AGGGA No Yes psVAC4 




3.2.3 Cytosolic expression plasmids 
 
For the expression of antigens in the cytosol a series of plasmids derived from 
pBR322 was used (M. Sörensen, unpublished data). Plasmid pMW223 possessed the 
original RBS, whereas its derivates contained mutated versions in order to down 
regulate the expression of foreign antigens whose presence can have a negative 
influence on bacterial fitness. 
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Since these plasmids were initially designed for the expression H. pylori antigens, the 
gene for antigen HP0231 can still be found within the multiple cloning site (MCS) 
and needed to be removed to allow insertion of leishmania antigen encoding ORFs.   
 
Fig.3.4: Cloning of leishmania antigen ORFs into cytosolic expression plasmids 
Plasmid maps of pMW223 before digestion with NdeI/BamHI and the resulting new 
plasmid pcVAC0-08.1140 after cloning the PCR fragment of the antigen 
(LinJ08.1140 in this case) between both restriction sites. ampR: ampicillin resistance 
cassette, RBS: ribosomal binding site 
 
Figure 3.4 shows the cloning strategy on the example of ORF encoding antigen 
LinJ08.1140.  Since none of the leishmania antigen sequences contained an NdeI or a 
BamHI site, all genes of interest were cloned using these two restriction enzymes. For 
that purpose gene-specific primers were designed carrying an NdeI site (forward, also 
containing the ATG start codon) and a BamHI site (reverse, with stop codon). A PCR 
was performed using L. donovani DNA (MHOM/INI/03BHU-55)  as a template, the 
resulting product was purified on an agarose gel, digested with NdeI and BamHI and 
ligated into pMW223 plasmid or its derivates and subsequently transformed into E. 
coli JK321.  
Gene insertion, the correctness of size and sequence was confirmed by colony PCR, 
restriction digestion and sequencing respectively. The resulting plasmids were 
carrying the different mutations in the RBS and were named accordingly. The 
nomenclature was pcVAC0-antigen, with “c” standing for cytosol, “VAC” for 
vaccine, “0, 1, 2 or 3” the ribosomal binding site and “antigen” was replaced with the 
relevant antigen (KMP11, 08.1140, 09.1180, 23.0410, 25.1680 or 35.0240). 
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3.2.4 Evaluation of vaccine strains and selection of suitable candidates for 
protection studies in mice 
 
To induce a protective immune response, antigens need to be administered in 
sufficient amounts. In the context of live vaccines, the total antigen amount delivered 
during vaccination is given by the product of the number of antigen molecules per 
bacterial cell by the number of bacteria reaching the places of antigen delivery, 
processing and presentation (e.g. Peyer’s patches, lymph nodes and spleen). However, 
on the one hand high expression of foreign antigens can impair bacterial fitness and, 
thus, higher expression does not equal better vaccine. On the other hand, low 
expression levels per cell may not reduce fitness but can result in carrier antigens out-
competing the vaccine antigens given the limited capacity of APC to present antigens 
from complex mixtures. Figure 3.5 visualizes the relation between protein expression 







Fig. 3.5: Schematic diagram explaining the 
relation between antigen expression 
and carrier fitness 
Suboptimal conditions (white area), optimal 
conditions (grey area), carrier or antigen can 
be in sufficiency (+) or insufficient (-). 
 
 
For this study six antigens have been selected and salmonella vaccine strains were 
engineered to express the antigens either in the cytosol or on their surface. 
Furthermore, mutations in the RBS sequence were introduced to allow fine tuning of 
antigen expression levels and therefore bacterial fitness. This resulted in altogether 48 
vaccine strains. A two step triage was employed, to evaluate their bacterial fitness in 
vivo, as well as antigen expression levels under in vivo conditions for each of the 
vaccine strains. This approach allowed to pre-select vaccine strains using a small 
number of animals before moving to vaccination experiments with larger numbers. 
Vaccine strains which failed to reach a certain threshold were ruled unfit and were 
eliminated at this stage.  
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The first step was to test the bacterial fitness in an in vivo colonisation assay. Three 
mice per group were oro-gastrically immunised with 1010 CFU of a salmonella 
 
Fig. 3.6: In vivo colonisation ability of “surface” vaccine strains 
Each symbol represents one mouse and symbols refer to groups vaccinated with 
strains carrying expression plasmids with the indicated mutations in the RBS. Control 
(■) was the carrier strain SL3261. Seven days after immunisation mice were 
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Fig. 3.7: In vivo colonisation ability of “cytosolic” vaccine strains 
Each symbol represents one mouse and symbols refer to groups vaccinated with 
strains carrying expression plasmids with the indicated mutations in the RBS. Control 
(■) was the carrier strain SL3261. Seven days after immunisation mice were 
sacrificed, the Peyer’s patches removed, homogenized and plated on selective agar 
plates.  
 
vaccine strain. Seven days later mice were sacrificed and the number of colonising 
bacteria in the Peyer’s patches was determined using selective agar plates. The results 
were plotted onto graphs (figures 3.6 and 3.7). It was estimated that approximately 
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2x 104 colonising bacteria were needed to present a sufficient amount of antigen to the 
immune system.2 This threshold is indicated by a grey line and was ideally exceeded 
by selected candidates. However, expression of certain antigens (e.g. surface 
LinJ25.1680 or cytosolic LinJ23.0410) did overall reduce fitness with all of the strains 
colonizing below the threshold value or just equaling it, e.g. like surface LinJ08.1140. 
In these cases, strains approximating the threshold were also considered, especially 
when the level of antigen expression was high. The empty carrier control SL3261 
showed, as expected, the highest colonisation, thus bacterial fitness. Most other 
strains showed a significant reduction (> 10 fold) in their colonisation abilities. 
However, cytosolic expression of LinJ08.1140, LinJ09.1180, LinJ25.1680 and 
LinJ35.0240 did not lead to a dramatic reduction in bacterial fitness (fig. 3.7). 
Interestingly, surface expression of LinJ23.0410, although significantly impairing 
bacterial fitness, showed no differences between strains harbouring mutations in the 
RBS (fig 3.6). Therefore antigen expression assays under conditions that mimicked 
the in vivo situation were performed in order to study the quantity of protein induced. 
Antigens were expressed under the control of the PpagC promoter. This promoter is 
regulated by the in vivo inducible PhoP/Q system. Upon entering the endosome of 
macrophages or dendritic cells, where low Mg2+ concentrations prevail, the PhoP/Q 
system is activated to initiate the expression of virulence factors and magnesium 
transporters, some of them under the control of PpagC. Using minimal medium, 
supplemented to the needs of aro- salmonella (i.e. with 2,3 dihydroxybenzoic acid), 
and limiting Mg2+, the in vivo situation was mimicked and protein expression was 
determined 3 h, 30 min after induction. Bacteria were harvested lysed and total 
protein amount was adjusted and equal amounts loaded onto SDS PAGE gels for 
analysis (“cytosolic” strains, figure 3.8) or Western blot analysis (“surface” strains, 
figure 3.9). 
The analysis of induced cytosolic strains revealed that no antigen expression can be 
seen for LinJ08.1140, LinJ09.1180, LinJ25.1680 and LinJ35.0240, which is 
consistent with the observation that none of these strains showed a reduction in fitness 
compared with the SL3261 control strain.  
                                                 
2 J. Schroeder, Diploma thesis (2003) Konstruktion und in vivo Evaluation von recombinanten 
Salmonella-Impfstoffträgern zur Optimierung eines anti-Helicobacter pylori Lebendimpfstoffs. 
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Fig. 3.8: Cytosolic protein expression after activation of PpagC 
Bacteria were lysed and 20 μg whole cell lysate per lane was applied, gels were 
stained with Coomassie. Negative control was the empty carrier control SL3261; 
black arrowheads indicate protein of interest. 
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Therefore, these strains were excluded from further analysis. KMP-11 and 
LinJ23.0410, however, are antigens for which cytosolic expression was seen (fig. 3.8, 
arrowheads), although they were running slightly below (~6.5 kDa) their predicted 
size (~11 kDa), which might be down to altered running performance of either marker 
or antigen. While the pcVAC0 version of both antigens showed the highest amount of 
induced antigen, the in vivo colonisation was rather poor. The introduction of a point 
mutation in the RBS of pcVAC1 or pcVAC2 resulted in less induced antigen per cell, 
and therewith higher bacterial fitness (fig. 3.7 and fig 3.8). Both pcVAC1 strains were 
selected for follow up in protection studies.  
 
Fig. 3.9: Surface protein expression after activation of PpagC 
Bacteria were lysed and 20 μg whole cell lysate per lane was loaded onto SDS gels.  
Immunoblots were developed with an antibody against the HA-tag. Negative control 
was the empty carrier control SL3261; black arrowheads indicate protein of interest. 
 
Induced expression of antigens on the surface of salmonella was visualized by 
detection with antibodies against an HA-tag which had been included in the construct 
in Western blot analyses. SL3261 itself showed two cross reactive bands at 
approximately 68 and 90 KDa, which were seen to be partly interfering with some of 
the antigen-AIDA constructs, for they have a similar molecular weight. Protein 
expression for LinJ35.0240 was below detection limit, although some of the strains 
displayed a reduced fitness. Therefore psVAC5-35.0240, which colonized on average 
with 2x 104 CFU, was selected as a representative for this antigen.  
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Consistent with the colonisation data, all strains expressing LinJ23.0410 showed a 
band with the same intensity, indicating that for unknown reasons all strains 
expressed similar amounts of antigen. Hence, only one strain (psVAC0-23.0410) was 
selected for further analysis. Induction of LinJ25.1680 on the cell surface resulted in 
high amounts of protein, with several degradation products. This would also explain 
the suboptimal colonisation ability of those strains. Two representatives (psVAC0-
25.1680 and psVAC5-25.1680) have been selected to proceed into protection 
evaluation. Strain psVAC5-08.1140 has been selected for showing higher protein 
induction than psVAC3, while bacterial fitness remained level. Antigen LinJ09.1180 
was highly induced in psVAC4, which unfortunately resulted in colonisation below 
the detection limit of 200 CFU. Therefore, psVAC3 was selected to progress into 
protection studies, since this strain displayed the highest bacterial fitness while 
expressing a detectable amount of antigen. For KMP-11 two representatives 
(psVAC0-KMP and psVAC3-KMP) were selected.  
 
Altogether 10 out of 48 strains were selected for analysis of their potential to protect 
susceptible BALB/c mice from visceral leishmaniasis. An overview is presented in 
table 3.5 below. 
 








3.2.5 Purification of recombinant antigens from E. coli 
 
The antigens selected (section 3.1) were cloned and expressed in salmonella carrier 
strains. The ability of the candidate antigens to induce a protective immune response 
in animal models was determined using these strains. Due to their novelty, 
immunological reagents like specific antibodies or purified protein were unavailable. 
Antigen Surface Cytosol 
KMP-11 2 1 
LinJ08.1140 1 0 
LinJ09.1180 1 0 
LinJ23.0410 1 1 
LinJ25.1680 2 0 
LinJ35.0240 1 0 
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Therefore it was necessary to express and purify those antigens, to enable analyses of 
the immune response like detection of specific antibodies from serum, re-stimulation 
of antigen-specific T cells isolated from vaccinated individuals or for better 
characterization of the antigens, generation of specific polyclonal antibodies. The 
following section describes the antigen purification process, i.e. the generation of 
expression plasmids, the induction of recombinant proteins and their purification. 
 
Fig. 3.10: Overview of cloning of LinJ08.1140 into pET28(+) expression plasmids 
Shown are plasmid maps (A) before and after insertion of LinJ08.1140 gene into the 
expression plasmids. Below the maps the cloning site sequence is depicted (B), with 
promoter, operator, RBS, His-tags, gene and terminator sequences marked. Note: due 
to the stop codon in the gene of interest the second His-tag was lost. 
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To avoid the time-consuming process of determining purification strategies based on 
physical properties which may differ for each antigen, it was decided to add to 
antigens a hexahistidine tag which allowed purification using nickel affinity columns. 
For this, antigens were excised from the cytosolic expression plasmids (see section 
3.2.3) using NdeI and BamHI restriction enzymes, ligated into another expression 
plasmid pET28(+) (Novagen) which provided an N-terminal His-tag (fig. 3.10) and 
subsequently transformed into E. coli XL-1. All constructs were confirmed by PCR, 
restriction digestion and sequencing. 
For antigen expression, these constructs were transformed into E. coli strain BL21 
CodonPlus (DE3)-RIPL (Stratagene), in which induction of expression by IPTG was 
tested on three colonies. Positive colonies showing strong protein expression were 
then selected to prepare bacterial stocks. All subsequent protein induction 
experiments were performed using these stocks. Figure 3.11 shows SDS PAGE gels 
of bacterial lysates prepared before and after the addition of IPTG. 
 
Fig. 3.11: IPTG induced expression of leishmania proteins  
Recombinant protein expression was induced by addition 0.4 mM IPTG and samples 
were taken before (-) and after (+) induction. Samples were boiled in protein sample 
buffer and applied onto either 12 % SDS-gels (LinJ09.1180, LinJ25.1680) or 15 % 
SDS-gels (KMP-11, LinJ08.1140, LinJ23.0410, LinJ35.0240) 
 
Titration experiments showed that most of the antigens were inducibly expressed but 
this required up to 1mM of IPTG. However, LinJ35.0240 antigen did not show any 
expression induction even at this concentration of IPTG. Furthermore, incubation at 
lower temperatures (22 ºC) or variation of IPTG concentration did not lead to any 
detectable protein expression (data not shown).  
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Purification of the His-tagged antigen using FPLC under native conditions was only 
successful for KMP-11 (see figure S-3 in Supplementary material), which was then 
dialysed against PBS to remove imidazole and concentrated by ultrafiltration. 
 
Fig. 3.12: Purification of recombinant leishmania antigens from inclusion bodies 
Shown is the chromatogram of the purification of LinJ08.1140 from inclusion bodies. 
Fractions were collected and those representing the first peak (grey box) were applied 
on an SDS gel. Fractions with higher protein content were pooled and further 
processed. FT: flow through 
 
The amount of protein was determined and aliquots were frozen at -80 ºC. All other 
antigens did not show an absorption peak during elution and consequently no positive 
fractions were detected by Coomassie staining of SDS PAGE gels despite being 
highly inducible with IPTG. It was concluded that overexpression of LinJ08.1140, 
LinJ09.1180, LinJ23.0410 and LinJ25.1680 resulted in the formation of inclusion 
bodies. After lysis, treatment with ultrasound did not dissolve the protein sample as 
seen with KMP-11. Instead, little round bodies were visible by light microscopy (data 
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not shown). Alterations in growth conditions, e.g. less IPTG, different induction times 
and bacterial density did not prevent the formation of inclusions (data not shown). 
Therefore it was decided to purify the inclusion bodies and dissolve them in urea and 
guanidine hydrochloride. The dissolved and denatured proteins were applied on a 
nickel packed affinity column and bound proteins were re-folded on-column. Eluted 
fractions were tested for the presence of protein by an SDS PAGE and positive 
fractions were pooled. An example for a successful purification of proteins from 
inclusion bodies is shown in figure 3.12. 
Imidazole has immuno-stimulatory properties and can influence the response of T 
cells in re-stimulation assays. To avoid this in future experiments, dialysis against 
TBS was performed. Unfortunately, once imidazole was removed from the solution, 
most of the proteins aggregated and became insoluble. However, T cell activation is 
mediated via MHC-peptide/TCR complexes, hence natural conformation of the 
antigen is not required. Therefore, the denatured protein was stored in 50 % glycerol 
at -20 ºC and was used for subsequent T cell assays. 
In contrast, for the detection of host antibodies against vaccination antigens, it is 
important to have the antigen in its natural state, since antibodies are also produced 
against conformational determinants. In this case, imidazole was not expected to 
influence antigen-antibody interaction, therefore its removal was not necessary and 
positive fractions from the FPLC were pooled for subsequent ELISA tests. After 
determination of protein concentration, ELISA plates were coated with 2.5 μg antigen 
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3.3 Pre-clinical evaluation of novel live vaccine candidates 
 
The most authentic animal model of experimental VL described to date (Melby et al., 
2001) is the syrian golden hamster infected L. donovani, the agent causing human VL 
disease. While these animals develop comparable symptoms to humans (e.g.: 
hepatosplenomegaly, hypoalbuminaemia, hypergammaglobulinaemia, and 
pancytopenia (Rodrigues, Jr. et al., 1998)), in the end succumbing to disease, the lack 
of specific reagents and no access to this model in the UK excluded its choice. 
Other, more convenient models are mice, where immunological reagents are readily 
available. The lack of animal facilities equipped for category three pathogens at the 
university campus prohibited the primary use of L. donovani-mouse infection models. 
However, it is known that the normally cutaneous L. major causes a non healing 
infection in susceptible BALB/c mice characterized by progressive skin lesions and 
visceralization of the parasites to spleen, liver and bone marrow. Therefore, this 
model was chosen to test vaccine efficiency against visceralizing infection.   
 
The 10 selected vaccine candidates were therefore tested in the latter mouse model for 
their ability to prevent or delay visceralisation. A pilot-experiment was carried out, to  
 
Fig. 3.13: Schematic overview of in vivo challenge 
Mice have been immunised orally with 1010 CFU of vaccine strains or with PBS and 
were challenged with an s.c. injection of L. major promastigotes. Serum was collected 
before immunisation, before infection and when mice were sacrificed. 
 
determine if salmonella were a valid carrier concept for targeting visceralisation. For 
this purpose salmonella strains expressing the model antigen KMP-11 on either 
surface or cytosol, an antigen that previously had been identified as protective (Basu 
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et al., 2005; Bhaumik et al., 2009; Delgado et al., 2003), were used to immunise 
susceptible BALB/c mice. Mice received a single dose of 1010 CFU of psVAC0-
KMP, pcVAC1-KMP, the carrier control SL3261 or were given an equal volume of 
sterile PBS. Twenty nine days later all mice were challenged by s.c. injection with 
2x 106 L. major promastigotes into the left hind foot pad. Figure 3.13 gives an 
overview of the experimental set up.  
 
During the course of infection lesions developed in mice of all groups. Surprisingly, 
mice which have been given PBS showed a slow onset of disease, comparable with 
pcVAC1-KMP, whereas mice vaccinated with the carrier control SL3261 displayed a 
rapid progression in lesion development (fig. 3.14A).  
 
Fig. 3.14: Salmonella expressing KMP-11 reduce leishmania visceralisation in 
mice 
A: Lesion development after infection. Error bars show standard deviation, * P≤0.05, 
two tailed Mann-Whitney U test.  
B: Reduction of visceralisation is determined by calculating the ratio of parasites in 
the spleen (visceral) and the foot pad (cutaneous). Low numbers indicate reduced 
visceralisation. The value in brackets has been identified as outlier (Grubb’s test, 
P≤0.05), * P≤0.05, ** P≤0.005, two tailed Mann-Whitney U test. 
 
However, the main target parameter was reduced spreading of the parasite to visceral 
organs. Mice with open lesions were therefore sacrificed and parasitic burden in 
spleen and foot pad was determined in a limiting dilution assay, described in the 
methods section. Effects on visceralisation were assessed by calculating the ratio of 
the parasitic burden in the spleen (visceral disease) and the foot pad (cutaneous 
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disease) for every mouse and this visceralisation index was plotted in figure 3.14B. 
Interestingly, mice vaccinated with KMP-11 expressing salmonella showed 
significant reduction in visceralisation (pcVAC1-KMP, P=0.0097 and psVAC0-KMP, 
P=0.00435) compared to PBS immunised mice. The data point in brackets (pcVAC1-
KMP) has been identified as an outlier by Grubb’s test (P<0.05), hence excluded from 
further analysis. Since a small but significant vaccine effect was detected, the main 
study probing all ten selected strains was initiated.  
 
To remain unbiased; the experimental design was adapted and the experimenters 
blinded. Vaccination groups were therefore coded. Once the first mice were sacrificed 
and analysed (day 48); the code was broken and the identity of the vaccine groups 
was revealed. An overview of this experiment is shown in figure 3.15.  
 
Fig. 3.15: Schematic overview of the in vivo challenge 
Mice had been immunised orally with 1010 CFU of vaccine strains or with PBS and 
were challenged 14 weeks later with an s.c. injection of L. major promastigotes. 
Serum was collected before immunisation, one week before infection, at day 48 after 
infection and when mice were sacrificed 
 
Female BALB/c mice were purchased from Harlan UK and immunised with the 
different salmonella vaccine strains (for overview see figure 3.15) or with PBS 
(naïve). Surprisingly, a few days after vaccination mice showed signs of murine 
typhoid fever (e.g. scrubby fur, weight loss and apathy), although the attenuated 
carrier strain SL3261 was used. Furthermore, one group, later revealed to be 
pcVAC1-23.0410, was exposed to additional stress caused by a defect water bottle 
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and as a result six out of ten mice died. The remaining animals were allowed to 
recover for a prolonged period of time and were subsequently infected with a dose of 
2x 106 parasites s.c. into the left hind foot pad. For the following weeks lesion 
development was monitored. Results are shown in figure 3.16A and in the 
supplementary section (S-2).   
 
During the course of infection individuals of two groups (pcVAC1-23.0410 and 
psVAC5-08.1140) showed a striking reduction in lesion size compared with other 
vaccine and control groups. Furthermore a discrepancy between the two control 
groups SL3261 and naïve (shown in supplementary material S-2) was observed. Mice 
immunised with salmonella showed a higher foot pad swelling than naïve mice. This 
effect was also observed in the preliminary study. Therefore pcVAC1-23.0410 and 
psVAC5-08.1140 were compared to the carrier vaccine SL3261 as a reference. Both 
strains showed a significant protective effect (P≤0.005 and P≤0.0005 respectively) 
until day 48 on lesion development. 
Two investigate parasitic burden in foot pad, draining lymph node and spleen, three 
mice per group were randomly selected (lottery) at day 48 after infection. Mice of 
group pcVAC1-23.0410 were not analysed, as their number was already reduced to 
four. The results of this analysis are shown in figure 3.16B. While no parasites were 
detected in the spleen of mice from group psVAC5-08.1140 and psVAC0-23.0410, 
and only in a limited number in mice immunised with pcVAC1-KMP, all other groups 
showed a higher parasitic burden and also a high variation within the group. A similar 
effect was observed for parasite numbers in the lymph nodes. Interestingly, mice 
vaccinated with psVAC5-25.1680 showed exacerbation of foot pad swelling and 
increased parasite numbers in spleen and lymph node. Because of the small number of 
animals sacrificed (n=3) no statistical analysis was performed. Nevertheless a trend 
that some vaccine strains conferred a protective effect was evident and therefore it 
was decided to investigate vaccines psVAC5-08.1140, pcVAC1-23.0410 and 
psVAC0-23.0410 further.  
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Fig. 3.16: Evaluation of candidate vaccine strains   
A: Lesion development in the foot (selected strains). Error bars show standard 
deviation, * P≤0.05, ** P≤0.005, *** P≤0.0005 two tailed Mann-Whitney U test. 
B: Parasitic burden in foot pad, lymph node and spleen. Mice (n=3) were selected at 
random. The detection limit was 65 for spleen and 6500 for lymph node and foot. 
 
 
3.3.1 Re-evaluation of general and synergistic vaccination effect of selected 
vaccine strains 
 
In the above vaccination experiments, two antigens were standing out as they 
significantly delayed onset of disease and were partially protecting mice from 
visceralisation of L. major. The group immunised with pcVAC1-23.0410 showed 
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particularly low foot pad swelling until day 48. Since this group suffered additional 
stress by the accidental lack of water, the vaccine effect was re-evaluated under 
normal conditions. Concomitantly, the positive vaccination effect of psVAC0-
23.0410 and psVAC5-08.1140 were reassessed to confirm the protective nature of 
these vaccine strains. Both antigens reduced spreading of the parasites and since 
multicomponent vaccines are generally thought to be more effective, vaccine strains 
expressing these antigens were also combined to test for synergy. 
Thus, 10 mice per group (bred at the animal facility) were immunised with either the 
carrier control SL3261, the vaccine strains pcVAC1-23.0410, psVAC0-23.0410, 
psVAC5-08.1140, or a combination of all three vaccine strains in equal amounts, in 
the following named vaccine allstars. A further 10 mice were treated with sterile PBS 
only. Blood was taken prior immunisation and upon termination of the experiment. 
Approximately nine weeks after immunisation mice were injected with L. major 
promastigotes. An overview of the experimental set-up is depicted in figure 3.17. 
 
Fig. 3.17: Schematic overview of re-evaluation experiment 
Mice had been immunised orally with 1010 CFU of vaccine strains (a combination of 
all vaccine strains (3x 1010 CFU) for vaccine allstars) or with PBS and were 
challenged 9 weeks later by s.c. injection of L. major promastigotes. Serum was 
collected before immunisation and when mice were sacrificed. 
 
During the course of infection, lesion development was significantly delayed in mice 
which had been vaccinated either with psVAC5-08.1140 or with the vaccine allstars 
(fig 3.18A). Strain psVAC0-23.0410 showed a tendency to delay the onset of disease, 
and mice vaccinated with this vaccine showed  significantly reduced foot pad swelling 
at day 34 (P = 0.0097). Immunisation with the combination of all vaccine strains 
reduced foot pad swelling even more (P = 0.0003, day 24; P = 0.0011, day 28; 
P = 0.0006, day 31 and P = 0.0009, day 34), than psVAC5-08.1140 (P = 0.0015, day 
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24; P = 0.0057, day 28; P = 0.0076, day 31 and P = 0.0041, day 34). In contrast to 
previous studies, mice which received PBS showed similar onset of disease as 
SL3261 treated animals and showed the highest parasite burden in the spleen. 
 
 
Fig. 3.18: Re-assessment of protective vaccination effects and testing for synergy 
A: Lesion development in the infected foot. Error bars show standard deviation, * 
P≤0.05, ** P≤0.005, *** P≤0.0005 two tailed Mann-Whitney U test.  
B: Parasitic burden in foot pad, lymph node and spleen. Mice (n=5) were selected at 
random. The detection limit was 65 for spleen and 6500 for lymph node and foot pad. 
* P≤0.05, ** P≤0.005, *** P≤0.0005 two tailed Mann-Whitney U test. 
 
Before measurements commenced, five mice per group were randomly selected 
(lottery) for analysis of the parasitic burden in foot pad, the draining lymph node and 
the spleen at day 34. None of the mice cleared parasites from foot pad completely. 
Nevertheless a tendency in parasite reduction was observed in all vaccinated groups, 
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especially for psVAC5-08.1140 and the vaccine allstars (fig. 3.18B). Similar results 
were observed for parasite numbers in lymph nodes, but statistical analysis revealed a 
significant reduction in the case of psVAC0-23.0410 vaccinated mice. 
However, splenic parasite burdens were dramatically reduced (up to three log) in mice 
vaccinated with either psVAC5-08.1140 (P = 0.0159) or the combination of all strains 
(P = 0.0079); of which 50 % showed no detectable parasites. Again a synergistic 
effect was observed, as the mean parasitic burden in the spleen of the vaccine allstars 
were more reduced than in any of the single vaccine groups (> 3.3 times for psVAC5-
08.1140, > 31.5 for psVAC0-23.0410 and > 34.7 for pcVAC1-23.0410). Taken 
together this experiment showed that the vaccination effects of psVAC5-08.1140 and 
to a smaller extent psVAC0-23.0410 and pcVAC1-23.0410 were reproducible and 
moreover both antigens seemed to work in synergy in BALB/c mice. 
 
 
3.3.2 Evaluation of vaccine efficiency in C57BL/6 mice  
 
Protection against leishmaniasis is cell-mediated and requires the activation of T cells 
via MHC/peptide complexes. The last two studies showed that antigens LinJ08.1140 
and to a certain extend LinJ23.0410 expressed by salmonella vaccines partially 
protected susceptible BALB/c mice from infection with L. major. This shows that 
there is a possibility that these antigens display epitopes which are recognized by 
MHC class I and/or II molecules of the haplotype d. A major requirement of vaccines 
in general, is that they protect the majority of a population, which normally displays a 
high diversity in MHC haplotypes. For that reason, a small study was performed using 
C57BL/6 mice which express MHC molecules of the haplotype b. Ten mice (obtained 
from Harlan UK) per group were orally immunised with 1010 CFU of SL3261, 
pcVAC1-KMP, the vaccine allstars from the previous study or with PBS. Mice were 
bled prior to immunisation, before infection and upon termination of the experiment. 
As seen in some of the previous experiments mice displayed signs of typhoid fever for 
approximately 2-3 weeks. They were put on a special diet in order to quicken the 
recovery process. Once the mice appeared fit enough (five weeks after immunisation), 
they were challenged with 2x 106 L. major as previously described.  
C57BL/6 mice are naturally resistant against L. major and infection normally causes 
only transient symptoms (lesion development and visceralisation) and is self-healing. 
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Effective vaccines are expected to reduce these symptoms in comparison with control 
groups. Figure 3.19A shows the lesion development over the time. Groups showed a 
peak either at day 53 (both vaccine groups) or at day 57 (control groups). Again a 
discrepancy between the two control groups was observed. Effects on lesion 
development however were not statistically significant.  
 
Fig. 3.19: Vaccination has only minimal effects in C57BL/6 mice 
A: Lesion development in the infected foot. Error bars show standard deviation,  
* P≤0.05, two tailed Mann-Whitney U test.  
B: Parasitic burden in foot pad (solid), lymph node (striped) and spleen (chequered). 
Mice (n=5) were selected at random. The detection limit was 65 for spleen and 6500 
for lymph node and foot. Error bars show standard deviation. 
 
At day 37 after infection, five mice were randomly selected (lottery) for analysis of 
the parasite numbers in foot pad, draining lymph node and the spleen (fig. 3.19B). In 
mice vaccinated with the vaccine allstars and surprisingly in mice who received PBS 
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no parasites were detected in the spleen, whereas up to 1000 parasites were found in 
mice immunised with pcVAC1-KMP or the carrier control SL3261. No statistically 
significant differences were seen between the groups. Interestingly, groups that 
received salmonella orally showed higher parasite numbers in the foot pad (solid bar) 
than in the lymph node (striped bar), whereas in naïve controls it is vice versa. 
Taken together, a small but not significant vaccine effect in regard to foot pad 
swelling and parasite burden in the spleen can be seen in mice immunised with 
pcVAC1-KMP or the allstars, respectively, when compared to the carrier control 
SL3261. 
 
In conclusion, through in vivo protection studies two new antigens, LinJ08.1140 and 
LinJ23.0410, were identified which when expressed by salmonella carrier strains, 
particularly on the cell surface, partially protected susceptible BALB/c mice and also 
showed a tendency to reduce parasitic numbers in resistant C57BL/6 mice. To further 
test their suitability as vaccines against visceral leishmaniasis, another animal model 
utilising the agent of human VL, L. donovani, was investigated.  
 
 
3.3.3 Evaluation of vaccine candidate strains in the L. donovani mouse model 
 
Two antigens so far have been identified to partially protect BALB/c mice from 
infection with L. major. This model was chosen as a substitute for visceral 
leishmaniasis due to L. donovani infection because of the visceralising disease that L. 
major causes in these susceptible mice. However, the vaccine eventually is intended 
to protect humans from L. donovani infection. Along with other criterions antigens 
have been selected favouring the ones which are conserved among Leishmania 
species. Thus, the candidate vaccines were also tested in a model of L. donovani 
infection. Animal experiment project license agreements with the Home office UK, 
did not foresee infections with L. donovani. Therefore, vaccines were evaluated in 
collaboration with Professor Paul Kaye’s research group, University of York. 
Ten BALB/c mice (Charles River, UK) per group were immunised with either carrier 
control SL3261, pcVAC1-KMP, psVAC5-08.1140, vaccine allstars or sham-
immunised with PBS as previously described. Before infection with L. donovani 
strain LV9, one mouse was sacrificed to investigate if immunisation with salmonella 
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resulted in splenomegally, as this would interfere with analysis at a later point. 
However, appearance and weight of the spleen was normal (data not shown). Mice 
were therefore infected with 3x 107 amastigotes i.v. six weeks after vaccination. 
Characteristic for L. donovani infection in mice is the transient infection of the liver, 
peaking around day 28 after infection and subsequently declining. Infection of the 
spleen, however, leads to progressive increase in parasite numbers over the course of 
disease. Five mice per group were sacrificed at day 28 after infection and body, spleen 
and liver weights were determined in order to calculate the organ to body-mass index 
(BMI) for both organs (Fig. 3.20A and B). Giemsa-stained impression smears of both 
organs were analysed microscopically and parasitic burden was expressed in 
Leishman-Donovan units (LDU). Figure 3.20C and D show that vaccination 
significantly reduced parasitic burden in liver and spleen. Vaccination with 
salmonella alone reduced the mean of parasite numbers by 15 % in spleen and 44 % 
in liver. Cytosolic expression of KMP-11 further increased protection to 26 % 
(spleen) and 49.6 % (liver). Parasite numbers were even further reduced in mice 
immunised with salmonella expressing LinJ08.1140 (51.2 % spleen, 78 % liver) and 
the vaccine allstars (50.9 % spleen and 66 % liver) comprising strains expressing 
LinJ08.1140 as well as LinJ23.0410. Interestingly, a higher BMI for both organs was 
observed in mice immunised with psVAC5-08.1140 (Fig. 3.20A and B). This may 
have reflected inflammation rather than infection as a response of the vaccinated 
organism to parasitic infection. Moreover, including antigen LinJ23.0410 in the 
vaccine (allstars) seemed to antagonise this effect. 
 





Fig. 3.20: Vaccination significantly reduced L. donovani burden in spleen and liver 
Mice were killed at day 28 after infection and the body-mass index (BMI) for liver 
(A) and spleen (B) was calculated. Parasite count per 1000 nuclei was counted from 
organ impressions and related to the BMI (C and D). Statistical analysis was 
performed using one-tailed Mann-Whitney U test. 
 
The remaining mice were sacrificed and analysed at a later time point (day 68) in 
order to determine if the vaccine is still effective at later stages of infection. Increased 
BMIs were observed for all vaccination groups, but in contrast to day 28 mice 
vaccinated with LinJ08.1140 or the vaccine allstars showed the lowest BMI (data not 
shown). This result is reflected in the LDU data for both organs (fig. 3.21). As 
expected, mean parasite numbers in the liver were declining after day 28. However, 
mice vaccinated with LinJ08.1140 or the allstars showed a significant reduction by 
77 % and 81 %, respecitively, compared to sham-immunised mice. This effect was 
less pronounced in mice vaccinated with the carrier control SL3261 (48 %) or the 
strain expressing KMP-11 in the cytosol (36 %).  
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Fig. 3.21: Vaccination reduces L. donovani burden in spleen and liver over time 
Mice were killed at day 68 after infection and the LDU for liver (left) and spleen 
(right) was calculated. Parasite numbers per 1000 nuclei was counted from organ 
impressions and related to the organ weight. Results from both time points are shown. 
Statistical analysis was performed using one-tailed Mann-Whitney U test. One mouse 
from group SL3261 showed at day 68 abnormally high LDU in the liver (1082) and 
was excluded from analysis, since it was assumed that this was likely the result of an 
underlying health condition (e.g. cancer) other than VL. 
 
Parasitic burden in the spleen increased during the course of the experiment. Carrier 
control SL3261 and vaccine strain pcVAC1-KMP reduced the mean parasitic burden 
in a comparative manner (36 %) which is statistically significant (P=0.0143 and 
P=0.0159, respectively). However, this effect was even more distinctive in mice 
vaccinated with LinJ08.1140 or the vaccine allstars, where parasitic burden was 
reduced by 68.7 % (P=0.0079) and 73.3 % (P=0.0143), respectively in comparison to 
sham-immunised mice. These very encouraging results showed that prophylactic 
vaccination with a single dose of salmonella expressing leishmania antigens 
significantly reduced parasitic burden in liver and spleen compared to controls and 
thus vaccination effects observed against L. major were reproducible when using L. 
donovani, the causative agent of human VL. Measurements of appertaining immune 
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3.3.4 Determination of vaccine induced cellular and humoral immune 
responses 
 
3.3.4.1 T cell response 
 
Resistance against leishmaniasis infection in mice is associated with a type-1 T cell 
response whereas susceptibility is related to type-2 responses. Typical for Th1 
responses is the production of cytokines IFNγ, TNFα and IL-2, ideally by one and the 
same T cell (multifunctional T cells). While IL-2 contributes to the survival of 
activated T cells, IFNγ and TNFα work synergistically on the activation of 
macrophages inducing NO synthase resulting in NO production and thus intracellular 
killing of parasites in infected mouse macrophages.  
 
Ideally, a vaccine induces an antigen/parasite-specific TH1 response which upon 
infection leads to rapid killing of parasites. In order to determine the response of T 
cells from infected or immunised and infected mice, single cell suspensions of spleens 
were prepared and re-stimulated for 18 hours with medium alone, or medium 
containing purified antigen (see section 3.2.5), or, as a control, with PMA/ionomycin 
for 6 h. After the addition of brefeldin A (to prevent secretion of newly synthesized 
proteins) for a further two hours, T cells were harvested and stained for CD3, CD4, 
CD8, and intracellular IFNγ, TNFα and IL-4 using specific antibodies or matching 
isotype control antibodies respectively. It was assumed that spleen cell suspensions 
contained enough APCs to present and process the antigens.  
After acquisition, data was analysed using the gating strategy shown in figure 3.22. 
Cells were first gated for viable lymphocytes, including blasted thus slightly larger 
cells. These were then further analysed for the presence of CD3 molecules and 
positive cells were tested for CD4 and CD8 molecules respectively. CD3+, CD4+ and 
CD3+, CD8+ population were further gated for IFNγ and TNFα single or double 
producers, while no IL-4 was detected. 
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Fig. 3.22: Gating strategy for analysis of flow cytometry data 
 
During acquisition it quickly became apparent that the sensitivity of this assay was 
too low. Most of the samples did not show any IFNγ/TNFα double producing T cells. 
It was noted, however, that mice from group psVAC5-08.1140 showed a higher 
frequency of CD4+ and CD8+ T cells (fig. 3.23). Furthermore, mice from this 
particular group showed  
 
 
Fig. 3.23: Frequency of T cells in the spleen of vaccinated mice 
Single cell suspension from spleens was restimulated with antigen for 18h and surface 
stained. Bars represent 3 mice per group, error bars are standard deviation of the 
mean. 
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Fig. 3.24: Cytokine production of CD3+, CD4+ T cells after re-stimulation 
 
a double IFNγ/TNFα-producing CD4+ population (fig. 3.24), which is statistically not 
significant due to relatively low acquisition numbers if 2-3x 105. Isotype control of 
this group did not show any double positive T cells (data not shown).  
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In addition, mice from this group showed a late onset of disease, while no parasites 
were detected in spleen at day 48 after infection (section 3.3 and fig. 3.16). Analysis 
of CD8+ T cells, however, did not show any significant cytokine production (data not 
shown). 
Thus, vaccination with psVAC5-08.1140 resulted in a higher frequency of CD3, CD4 
and CD8 positive T cells, of which a small fraction of CD4+ cells produced IFNγ and 
TNFα simultaneously upon in vitro stimulation. This indicates that vaccination indeed 
resulted in the development of an antigen specific cellular response. However, firm 
conclusions of the T cell re-stimulation assays remained rather elusive, but may be 
determined with a more sensitive assay set-up. 
 
 
3.3.4.2 Antibody response to vaccination 
 
Another way to determine vaccine-induced immune responses is the measurement of 
antigen-specific serum IgG. During B cell development, T cell help is required and 
cytokines produced by the latter determine isotype switching. In general, the presence 
of IFNγ is correlated with IgG2a generation, whereas IL-4 produced by type-2 T cells 
is correlated with IgG1 isotype switch.  
Mice in each L. major infection experiment were bled before and after challenge with 
L. major and antigen-specific antibodies in serum were determined by ELISA. When 
animals were bled 3-4 weeks after immunisation, immunization induced antigen-
specific antibody titres were generally higher, but were already in decline at week 6 
after vaccination. However, parasite infection in general boosted vaccine antigen-
specific antibody titers in vaccinated mice (LinJ08.1140, cytosolic LinJ23.0410, 
KMP-11; fig. 3.25) and induced vaccine-antigen specific antibodies, e.g. KMP-11 
(mainly IgG1), and to far lesser extent LinJ08.1140 (data not shown).  
Vaccination with pcVAC1-KMP resulted in the induction of KMP11-specific 
antibodies, of which both isotypes IgG1 and IgG2a were detectable with similar titres. 
This was observed in several experiments (fig. 3.25 top panel). Infection with 
L. major did increase specific antibodies; both isotypes were again detected at similar 
titers in most experiments with a slight shift towards higher IgG1 titers in experiment 
D (fig. 3.25 top panel). Mice vaccinated with psVAC5-08.1140 on the other hand 
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only specific IgG2a were detected in their serum, while IgG1 remained below 
detection limits. This is shown  
 
 
Fig. 3.25: Antigen-specific antibody response for three antigens 
Serum was tested for antigen- specific antibodies of different isotypes (IgG1, white 
bar; IgG2a, solid bar) against vaccination antigens. Data without error bars represent 
serum pools of 10 mice; error bars represent standard deviation when individual 
analysis was carried out. n.d. not determined; exp. experiment  
 
for experiment D (figure 3.25) and was confirmed in other experiments (data not 
shown). Infection with L. major, however, seemed to induce a shift in LinJ08.1140 
vaccinated mice towards antigen-specific IgG1, through an unknown mechanism. 
While immunisation with psVAC5-08.1140 delayed onset of disease, the shift 
towards IgG1 which is connected to type-2 responses might indicate that infection-
induced type-2 CD4+ T cells may expand a population of B cells producing IgG1 
which were below detection before challenge. Vaccination with pcVAC1-23.0410 
induced low titers of specific IgG2a. While parasite infection augmented antibody 
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titres, the outcome was highly variable (fig. 3.25 bottom right panel). Interestingly 
surface expression strain psVAC0-23.0410 did not induce any specific antibody 
response in any of the experiments, despite showing a protective effect (section 3.3) 
and also failed to rise significantly after infection with L. major (data not shown). 
In summary, immunisation of mice with salmonella vaccine strains expressing 
different leishmania antigens, led to an induction of specific antibodies. While the 
nature of the antigen seemed to determine the antigen-specific isotype induced, e.g. 
IgG1 versus IgG2a, parasite infection did not only augment these titres, but in some 




3.4 Exploiting outer membrane vesicles to augment antigen-specific immune 
responses 
 
The release of outer membrane vesicles (OMV) is a common feature of Gram 
negative bacteria and in recent years there has been a growing interest in capitalising 
them for the development of affordable vaccines. OMVs have been implicated in 
different processes of e.g. delivery of virulence factors to target cells, intra- and inter-
species communication and bio-film formation. Moreover, purified vesicles from 
pathogens like Neisseria meningitis and Vibrio cholerae have been tried successfully 
in vaccination studies. However, presently there is no evidence that other pathogens 
than Gram- bacteria are capable of OMV production. To take advantage of the 
immune stimulatory features of OMV and in order to combine them with antigens 
from pathogens, other than Gram- bacteria, an inducible platform was developed 
which should allow the expression of heterologous antigens on OMV. 
Autotransporters have evolved to display on or secrete proteins through the outer 
membrane of Gram- bacteria. It was reasoned that proteins targeted to the outer 
membrane via autotransporters could also be targeted to OMVs. AIDA, the 
autotransporter used in this study, had already been used for surface antigen 
expression on salmonella vaccine strains (see section 3.2.1). AIDA fusion proteins in 
these strains were expressed under control of the in vivo inducible PPagC promoter, 
which can also be activated in vitro under Mg2+ limitations. However, in vitro 
induction led to a decrease in bacterial growth (data not shown) and thus would 
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require high volume cultivation for production of OMV at a scale required for vaccine 
production, which disqualified this promoter for antigen expression on OMVs. 
Constitutive promoter activity on the other hand may damage the bacterial 
membranes causing bacterial death due to insertion of pore forming AIDA molecules 
in the outer membrane. It was therefore decided to use a recently developed 
propionate-inducible expression system (Lee and Keasling, 2005,Lee and Keasling, 
2006), kindly provided by J.D. Keasling; to integrate the autotransporter downstream 
of the PprpB promoter.  
The AIDA cassette from pAIDA0 (see section 3.2.1) was amplified using primers 
designed to introduce a NheI restriction site at the 5’ terminus and a SalI site at the 3’ 
terminus respectively. The resulting PCR product was digested and cloned into the 
MCS of an equally treated pPro18 expression plasmid, creating pMV1-AIDA 
(fig. 3.26). The antigens were cloned between SpeI and BglII as already described for 
surface expression constructs (see section 3.2.1). The correctness of the insert was 
verified using colony PCR, restriction digestion and sequencing. The resulting 
constructs were named according to their antigen pMV1-“antigen”.  
 
Fig. 3.26: Map of pMV1-08.1140 as a representative for all pMV1 vectors 
The AIDA cassette was cloned into MCS or pBR322 derived pPro18, providing SpeI 
and BglII restriction sites, which allowed subsequent insertion of genes coding for 
L. donovani proteins. Abbreviations: rrnBT1,2 – part of strong ribosomal rrnB 
terminators, ori – origin of replication, SP – cholera toxin B signal peptide, HA – 
Haemophilus influenzae hemagglutinin tag, aida – autotransporter involved in diffuse 
adherence, orf – open reading frame (figure from (Schroeder and Aebischer 2009)) 
 
For induction experiments constructs were transformed into E. coli JK321. 
Optimisation experiments were carried out to determine the best conditions for 
inducing antigen expression on OMVs of such recombinant E. coli. For that purpose 
time course experiments using different concentrations of sodium propionate were 
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performed with pMV1-KMP and pMV1-AIDA carrying bacteria as a reference. The 
results indicated that a propionate concentration of 50 mM is sufficient to induce 
KMP-11 expression, which reached a plateau after 5 h (data not shown). In these 
experiments, promoter leakiness was observed for the KMP-11 construct, which is 
reminiscent of observations made by Lee and colleagues with the propionate 
inducible promoter.  
All constructs were finally tested for propionate inducible antigen expression. 
Samples were taken prior the addition of sodium propionate and 7 h after induction. 
To enhance vesicle production (Kadurugamuwa and Beveridge, 1997) 50 μg/ml 
gentamycin was added to the culture 30 min prior harvesting. Figure 3.27 shows cell 
lysates of E. coli before and after induction. Black arrowheads indicate induced 
protein, while white arrowhead point out protein detected already before induction 
due to promoter leakiness. A clearly visible antigen expression was seen for KMP-11, 
LinJ08.1140, LinJ23.0410 and LinJ25.1680. However, no expression was detected for 
LinJ35.0240, coherent with previous expression experiments, and LinJ09.1180, which 
could only be detected prior induction as a result of promoter leakiness. Dot blot 
analysis of cell free culture supernatants (fig. 3.27, lower panel) revealed that the 
addition of gentamycin did indeed enhance release of expressed antigens into the 
supernatant and thus, likely, vesicle production. It was concluded that the propionate 
inducible expression system worked for the majority of antigens which can be 
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Fig. 3.27: Inducible expression of AIDA-fusion proteins for recombinant OMV 
production 
Western blot analysis of HA-tagged fusion proteins in cell lysates (20 μg/ lane; top 
panels; white arrows point to protein resulting from promoter leakiness, black arrows 
mark induced fusion protein) and cell-free supernatants (5 μl per spot; bottom panels) 
prior (- -) and 8 h after addition of 50 mM sodium propionate (+ -). MV production 
was stimulated by gentamycin (50 μg/ml) addition for at least 30 min (+ +). Fusion 
proteins were detected with peroxidase-conjugated anti-HA tag antibodies. 
 
Since vaccines containing LinJ08.1140 or LinJ23.0410 were partially protective and 
the KMP-11 served as a reference antigen, it was decided to test the ability of OMV 
expressing these antigens to boost salmonella vaccine primed immune responses. 
OMV were purified using the method of Moe et al., 2002 preparations typically 
yielding the expected 9.3 mg and 11 mg dry weight per litre of spent culture 
supernatant (Alaniz et al., 2007). Western blot analysis suggested that OMV 
preparations contained approximately 2.5-5 μg recombinant fusion protein per mg of 
dry weight (data not shown). 
 
Twenty mice per group were immunised with SL3261, psVAC5-08.1140, pcVAC1-
KMP, pcVAC1-23.0410, psVAC0-23.0410 or sham-immunised with PBS (naïve). 
Three weeks later mice were bled and serum was prepared and equal volumes were 
pooled for later determination of vaccine antigen and salmonella carrier-specific 
IgG2a, IgG1 and  
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Fig. 3.28: Recombinant OMVs boost antigen specific antibodies 
Specific serum antibody titres were determined in mice before (striped bar, n=20) 
OMV application, three weeks after a single subcutaneous booster injection of 100 μg 
OMV (clear bar, n=10) and 6 weeks after immunisation without boost (solid bar, 
n=10). Mice vaccinated with carrier control strain SL3261 were boosted with control 
OMV prepared from E. coli JK321. No cross-reacting antibodies against a mixture of 
KMP-11, LinJ08.1140 and LinJ23.0410 were detected. Bars represent mean antibody 
titres of serum pools of 20 (before OMV application) and 10 mice per group after 
OMV injection respectively. 
 
Mice injected with OMV expressing KMP-11 or LinJ08.1140 showed a 6-40 fold 
increase of antigen specific antibodies, IgG2a as well as IgG1 in comparison to their 
non-boosted counterparts. Salmonella expressing LinJ23.0410 in the cytosol induced 
approximately 10 fold lower specific antibody titers for IgG2a compared to antigens 
KMP-11 and LinJ08.1140, while IgG1 remained below detection limit. Boosting 
resulted in an 8 fold increase of antigen specific IgG2a for this vaccine. The surface 
expressing strain psVAC0-23.0410 did not seem to induce any antigen specific 
antibodies and boosting was also not effective. 
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E. coli is closely related to salmonella (Falush et al., 2003), and boosting salmonella-
immunised mice with recombinant OMV from E. coli may generally increase the 
response to the live vaccine used for priming. Focussing on expanding only the 
antigen-specific response of the vaccine, however, would be preferred. Therefore, the 
relative contribution of antigen-specific and carrier-specific antibody response to the 
overall vaccine induced antibody response was estimated. The respective antibody 
responses were plotted as proportion of their sum (fig. 3.29). The results indicated that 
boosting with OMV selectively expanded the response to vaccine antigens. For 
IgG2a, boosting with OMV carrying antigens LinJ08.1140 and KMP-11 led to an 
increase in the antigen specific contribution of more than 15 % to the total response to 
vaccination. On the other hand, priming with cytosolic LinJ23.0410 resulted in a 
lower specific antibody response; hence antigen-specific contribution to the overall 
vaccine did not exceed 1 %. Antigen-specific IgG1 for LinJ08.1140 was, although 
present, below the required level for titre determination (half maximal). Boosting 
therefore resulted in a proportional increase to 3.6 % of the total response. KMP-11 
on the other hand showed a contribution of 2.5 % after vaccination which was boosted 
to 15 % (fig. 3.29). This indicated that boosting with a single dose of OMV can 
increase antigen specific immune responses. 
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Fig. 3.29: OMV boost specifically vaccine-antigen induced antibody responses 
Antigen-specific antibody titres were related to the overall immunisation-induced Ig 
titre (i.e. the sum of anti-vaccine antigen plus anti-SL3261 carrier response). 
Proportions were plotted as percentage on this overall vaccination-induced antibody 
titre. First bar/ group represents titres three weeks after priming (mean of n=20); 
second bar/group, six weeks after priming without OMV boost (mean of n=10); third 
bar/group six weeks after priming but three weeks after OMV injection (mean of 
n=10). 
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In order to determine if prime-boosting with recombinant salmonella and OMV 
vaccines increased the protective effect of the salmonella vaccines against visceral 
leishmaniasis, primed or primed-boosted mice were challenged with 2x 106 L. major 
promastigotes as described earlier. The results showed that immunisation with 
salmonella expressing antigens LinJ08.1140 or LinJ23.0410 reduced parasitic burden 
in the spleen (fig. 3.30A upper panel), although not statistically significant in this 
experiment. Boosting resulted in slightly increased parasite numbers in spleens of 
LinJ08.1140 and cytosolic LinJ23.0410 vaccinated mice (fig. 3.30A bottom), whereas 
a trend for reduced parasitic burden was seen for KMP-11 and surface LinJ23.0410 
expressing vaccines after boosting; being statistically significant in the latter group.   
 
Fig. 3.30: Boosting with recombinant OMV does not increase vaccine induced 
protection against visceral leishmaniasis. 
A: parasitic burden in the spleen of boosted (bottom, white) and non-boosted (top, 
solid) mice at day 35 after infection. B: antigen specific antibody titres from 
individually mice (IgG2a, top panel; IgG1, bottom panel), error bars reflect standard 
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Analysis of the antigen-specific antibody response showed an increase in both IgG 
isotypes for boosted and non-boosted animals (fig. 3.30B) compared to uninfected 
mice (fig. 3.28), indicating that all vaccination antigens are naturally immunogenic in 
a leishmania infection. Interestingly no difference in antigen-specific IgG1 between 
boosted and non-boosted groups was detected. However, mice prime-boosted with 
antigen LinJ08.1140 showed significantly (P≤0.0001) elevated antigen-specific IgG2a 
titres compared to immunised only mice.  
 
In summary no compelling evidence was found indicating that boosting salmonella 
vaccine primed mice with recombinant OMV increased protection from visceral 
leishmaniasis. This was despite the findings that boosting with OMV increased 
antigen-specific antibody responses significantly. 
 
 
3.5 Structural and functional analysis of LinJ08.1140 
 
LinJ08.1140 emerged from the above experiments to be the most promising, 
protective antigen of those selected for this work. LinJ08.1140 represents a 
hypothetical protein of unknown function and no structural information is available to 
date. Only its sequence and predicted physical properties are known (see table 3.1 and 
3.2). Therefore, in the following section first steps are presented aimed to characterize 
LinJ08.1140 better using bioinformatics and experimental methods. 
 
 
3.5.1 Prediction of LinJ08.1140 secondary structure  
 
The hypothetical protein LinJ08.1140 is highly conserved throughout Leishmania 
species. However, no homologues have been found in other species so far, which 
made the application of comparative methods for the prediction of secondary 
structures impossible. Therefore secondary and tertiary structures of LinJ08.1140 
were predicted with ab initio methods. These methods are aimed at the prediction of 
secondary structure elements in proteins and are based on the prediction of solvent 
accessibility of amino acid side chains. The resulting accessibility patterns are then 
compared to patterns that are typically associated with certain secondary structures. 
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Two methods were used to analyse LinJ08.1140, the PHD method (Rost and Sander, 
1993; Arnold et al., 2006) and PSIPRED (Jones, 1999). Both methods led to similar 
results. Figure 3.31 shows the secondary structure predicted by PSIPRED. 
LinJ08.1140 is likely to comprise three partly interrupted α-helices, linked by coil 
structures. 3D modelling using TasserLite (Zhou and Skolnick, 2007) resulted in a 
similar prediction (fig. 3.32). 
 
Fig. 3.31: Solving the secondary structure using ab initio prediction programs 







Fig. 3.32: 3D model of LinJ08.1140 using TasserLite 
Alpha-helices are highlighted and colour ranges from blue (N-
terminus) to green (C-terminus) 
 
Taken together, protein structure prediction programs indicated that antigen 
LinJ08.1140 is a small protein comprising three α-helices and appears as a compact, 
globular domain. 
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3.5.2 Generation of a polyclonal antibody against LinJ08.1140 
 
One mouse was immunised orally with psVAC5-08.1140 as described before. The 
mouse was left to recover and was several weeks later boosted with an emulsion of 
purified 08.1140 antigens in Freund’s complete adjuvant (Sigma). Several weeks later 
the mouse was bled and the serum was tested for antigen-specific antibodies by 







Fig. 3.33: Determination of polyclonal 
anti-08.1140 serum IgG 
 
Figure 3.33 shows that very high antigen-specific antibody titres were detected in the 
serum of the prime-boosted mouse. A dilution of 1: 104 still gave maximal absorption 
of 0.8 at 490 nm. Subsequently the specificity of this anti-serum was tested on a range 
of different antigen preparations associated with this project e.g. salmonella vaccine 
strains expressing LinJ08.1140 or strains used for protein expression and purification. 
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Fig. 3.34: Testing the polyclonal 
antibody to detect different 
variants of antigen 
LinJ08.1140 
The ability to detect soluble antigen (A) 
and the AIDA-08.1140 fusion protein 
(B) was tested. A: E. coli lysates before 
and after induction with IPTG; left panel 
coomassie stained SDS gel, right panel: 
western blot using anti-08.1140 (1:104) 
and secondary peroxidase labelled anti-
mouse IgG. B: Salmonella lysates after 
induction of PpagC, left panel: western 
blot using peroxidase labelled anti-HA 
antibody, right panel: western blot using 
anti-08.1140 (1:104) and secondary 
peroxidase labelled anti-mouse IgG. 
Anti-08.1140 was additionally blocked 
with 100 μg SL3261-lysate. 
 
Figure 3.34A shows a coomassie stained gel (left panel) of lysates of recombinant E. 
coli cells before and after induction of antigen-expression using IPTG (see section 
3.2.5). Induced protein is clearly visible around the 11 KDa mark. Lysates were 
blotted onto PVDF membranes (right panel) and antigen was detected using anti-
08.1140 (1: 104) and a peroxidase-labelled anti-mouse secondary antibody. To prevent 
unspecific binding of salmonella carrier specific antibodies, 100 μg of salmonella 
lysate was added to the primary antibody. Two bands became visible after detection, 
one at 11 KDa likely corresponding to monomeric LinJ08.1140 and another one just 
below 25 KDa suggesting dimer formations. Only a slight cross-reaction with E. coli 
protein around the 18 KDa mark was detected. Figure 3.34B shows Western blot 
analysis of cell lysates of salmonella vaccine strain expressing LinJ08.1140 on the 
surface and the control SL3261 after induction of vaccine-antigen expression by 
culture in minimal medium with low Mg2+ concentration (see section 3.2.5). 
Detection using anti-08.1140 antibody revealed a single band of the expected size for 
the AIDA-08.1140 fusion protein (right panel). The cross-reacting bands typically 
seen after detection using anti-HA antibody (left panel) were absent. However, 
detection of LinJ08.1140 in L. major lysates was not successful (data not shown). It 
was possible that, despite extensive washing, residual FCS used for leishmania 
cultivation was interfering with proper transfer and prevented transfer of leishmania 
proteins to the PVDF membrane. 
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The polyclonal anti-08.1140 antibody from mice prime-boosted with LinJ08.1140 
recognised specifically the antigen from serum-free preparations such as bacterial 
preparations (fig. 3.34) and can therefore be used for the detection of the antigen in 
the parasites using fluorescence microscopy. 
In order to visualise antigen LinJ08.1140 in parasites, a late log-phase promastigote 
culture of L. major 173::DsRed K2 was harvested and fixed on glass slides for 
subsequent staining. Parasites were permeabilised with saponin and stained either 
with the polyclonal antibody against LinJ08.1140 (1:50) or an equal concentration of 
an antiserum from a mouse immunised with SL3261 as control. To prevent cross-
reaction both antibodies were blocked with salmonella lysate and detection was 
performed using a Cy2-labelled anti-mouse IgG antibody (1:500). As an additional 
control some parasites were stained with secondary antibody only. Pictures were 
acquired with the Leica SP5 confocal laser-scanning system and processed using 
VOLOCITY (Improvision) software. Figure 3.35 shows that while controls did not 
show any significant signal, a strong signal was observed in promastigotes stained 
with the anti-08.1140 antibody.  
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Interestingly parasites which appear to be in the process of cell division (fig. 3.35, 
arrows) exhibited the strongest signal, whereas the fluorescence signal in non-
dividing parasites was much weaker. In the majority of dividing cells with bright 
signals nuclei appeared to have already separated (not shown) while the flagellum was 
not fully developed and cells were still attached to each other. This indicated that the 
expression of antigen LinJ08.1140 by leishmania promastigotes may be cell cycle 
dependent and suggested a functional role in this process. 
 
 
3.5.3 Mapping of MHC-I specific epitopes using in silico peptide prediction  
 
Antigens are presented via molecules of the major histocompatibility complex 
(MHC). External antigens are processed in the phagolysosome of antigen presenting 
cells (APC) and loaded onto MHC class II molecules. After transport to the surface 
the MHC-II/peptide complex is presented to CD4+ helper T cells. Antigens located in 
the cytosol, however, are processed in a proteasome-dependent fashion and resulting 
peptides subsequently are transported into the ER and loaded onto MHC class I 
molecules for presentation to cytotoxic T cells (CTL). The involvement of CD8+ T 
cells in resistance against visceral leishmaniasis has been acknowledged in several 
studies (Basu et al., 2007a; Murray et al., 1989; Stager et al., 2003b). Moreover, 
salmonella-induced cross-presentation has been reported (Winau et al., 2004; Salerno-
Goncalves and Sztein, 2009). Therefore, it was assumed that salmonella vaccine 
strains expressing leishmania antigens will, along with CD4+ T cells, also activate 
specific CD8+ T cells.  
LinJ08.1140 is a newly discovered antigen, which has been shown here to be 
potentially protective in mouse models of leishmaniases when delivered by 
recombinant salmonella vaccine strains. Furthermore it would be of interest to try this 
antigen in other more epitope based vaccine formulations, since they allow precise 
initiation, regulation and control of immune responses. LinJ08.1140 comprises 99 
amino acids, thus 91 putative peptides (nonamers) for MHC-I presentation. However, 
not all of these peptides will be immunogenic and experimental evaluation of all 
peptides is cost and labour intensive. Therefore, epitope prediction programs were 
employed to examine putative MHC-I binding peptides in LinJ08.1140 and, for 
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reference, KMP-11, since epitopes for the latter were predicted and tested 
experimentally (Basu et al., 2007b). 
More than 30 prediction programs based on different algorithms are available on the 
internet. A comparative study published last year (Lin et al., 2008) assessed 
performance and reliability of MHC prediction programs using a set of model 
antigens. The study revealed that matrix based programs (e.g. BIMAS and 
SYFPEITHI) were outperformed by non-linear predictors like NetMHC which is 
based on artificial neural networks (ANN). Therefore analysis of LinJ08.1140 and 
KMP-11 was performed using NetMHC (Buus et al., 2003; Nielsen et al., 2003; 
http://www.cbs.dtu.dk/services/NetMHC/).  
Another obstacle is the choice of appropriate MHC-I haplotypes/alleles. Genes of the 
MHC family are highly polymorphic with several hundred variants reported to date. 
Analysing all of them would exceed the scope of this work and therefore it was 
decided to focus on a set of haplotypes considered relevant for the major vaccine 
target, the population of India.  
The population of India is, however, highly diverse with several thousand 
endogamous groups, 325 functioning languages and 25 scripts (The Indian Genome 
Variation Consortium, 2005). Moreover, cultural aspects like the cast system, religion 
and migration highly contributed to genetic diversity. However, visceral leishmaniasis 
is endemic in only three states in the North of India. Focussing only on Bihar, where 
90 % of all cases of VL are reported, eastern Uttar Pradesh and West Bengal (Bora, 
1999), the composition of ethnic populations could be better defined. Within the 
framework of the Indian Genome Variation Consortium it was established that the 
majority population of these states is Caucasian (Uttar Pradesh, Bihar and admixture 
in West Bengal) and Australoid (West Bengal) with mongoloid influence. This was 
further confirmed by another study involving Asian Indians of the Delhi area. It was 
suggested that the Indian population is, although essentially Caucasoid, in reality a 
mixture of Caucasian and oriental haplotypes/alleles (Mehra, 2000). According to this 
review the most common HLA class I alleles in the Indian population were A*02, 
A*24, A*11, A* 33 in the HLA-A locus and B*07, B*35, B*40, B*57 and B*58 in 
the B locus. Thus, for the purpose of predicting vaccine antigen-derived epitopes and 
it was decided to restrict the analysis to these most common haplotypes. Interestingly 
the most ubiquitous Caucasian allele  





                                                                                                                             Results 
 102
A*0201 is absent in the Indian population and hence was replaced with the more 
frequent A*0211.  
The result of the epitope prediction is shown in figure 3.36. Analysis of KMP-11 
(bottom half) generates a cluster of binding peptides in the N-terminal region of the 
protein, with one classified as strong binder (black, threshold affinity ≤ 50 nM) 
starting at position 2 and a number of weak binding peptides (grey, threshold affinity 
≤ 500 nM) in the region 2-21. The C-terminus in comparison is a lot less represented 
with one strong binder starting at position 78 and a couple of weak binders. This is to 
a certain degree coherent with experimental data (Basu et al., 2007b), which also 
showed clustered binding regions N-terminal (1-30) and C-terminal (71-90). 
Interestingly, the majority of peptides found, did match HLA-A haplotypes, while 
only one weak binder for the chosen HLA-B haplotypes was detected. Due to the 
coherence with experimental data for KMP-11, it was assumed that a similar analysis 
with LinJ08.1140 would be valid. 
Epitope prediction for LinJ08.1140 using the same haplotypes showed a higher 
frequency of peptides with strong and weaker binding ability both for HLA-A and 
HLA-B than KMP-11. A cluster comprising strong binder for HLA-A was found 
between position 17 and 64, while clusters of weak binders were found for both loci 
between position 46 and 78. Additionally one strong binder was found for each of the 
loci starting around amino acid 80. Overall peptide prediction revealed several 
candidate peptides for CD8+ activation, which in a next step will have to be evaluated 

















Leishmaniasis is a grossly neglected tropical disease and currently threatens more 
than 350 million people in 88 countries world wide (Desjeux, 1996). The emergence 
and spread of HIV, migration due to civil unrest and the phenomenon of global 
warming contribute to the rise of leishmaniasis (www.who.int/leishmaniasis/en/). 
Treatment is available, but expensive, toxic or prone to resistance development in 
parasites, underlining the need for a vaccine. The concept of vaccination is feasible 
and during the past decades a lot of effort has been invested to understand parameters 
like immune responses linked to susceptibility or resistance or genetic factors 
associated with disease. In order to reach the ultimate aim, a vaccine against different 
forms of leishmaniasis, several strategies such as whole live or dead organism, single 
antigens in combination with different adjuvant and recombinant delivery systems 
have been more or less successfully tested (Khamesipour et al., 2006; Kedzierski et 
al., 2006; Coler and Reed, 2005; Palatnik-de-Sousa, 2008). Some of these vaccines 
progressed to clinical studies, but despite all effort no such vaccine has become 
available yet. 
The immunisation with attenuated live pathogens in order to induce a protective 
immune response in the host has had a long tradition. A major drawback of this 
approach is that under certain circumstances attenuated strains may gain virulence and 
become pathogenic again. This is especially in regard to the severity of visceral 
leishmaniasis not acceptable. A solution to this problem is the use of sub-unit 
vaccines, instead of the whole organism, with the ambition to induce a protective 
immune response but not disease. A live vaccine using recombinant, attenuated 
S. typhimurium has been developed and described in this thesis. Furthermore, novel 
antigen candidates have been identified and evaluated using different in vivo models 
for visceral leishmaniasis. In an attempt to further improve the vaccine effect 
achieved, outer membrane vesicles have been engineered to inducibly express 
leishmania antigens and consequently have been tested for their potential to augment 
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4.1 In silico selection of novel antigen candidates 
 
Several methods to successfully identify putative antigens candidates have been 
described in the literature. Melby and colleagues, for example, screened a cDNA 
library which has been generated from L. donovani amastigotes. An estimated 30 000 
constructs have then been tested in pools and the most protective ones have been 
further analysed in sub-pools. A major finding was, however, that the sub-pools were 
less protective. The resulting decrease in protection has been attributed to the loss of 
synergistic effects of some of the cDNAs. Altogether, the authors describe this 
method as very laborious and no particular cDNAs have been singled out as vaccine 
candidates (Melby et al., 2000). A further method, involving the fractionation of 
L. major lysate on SDS-Gels and subsequent transfer to PVDF membranes has been 
described (Zeinali et al., 2007). Immunoreactive proteins were identified by 
incubation of the membrane with serum from patients who recovered from CL and 
subsequently eluted from the membrane for identification. Serum from healed and 
immunocompetent patients is also used in immunoproteomics. Lysates of pathogens 
were separated on two-dimensional electrophoresis and potential antigen candidates 
are subsequently identified using the anti-sera from patients with healed or active 
infection and reactive protein spots were then analysed by mass spectrometry. This 
approach has been used for a number of pathogens such as Neisseria meningitides, 
Chlamydia, H. pylori and L. donovani (Williams et al., 2009; Karunakaran et a.,l 
2008; Haas et al., 2002; Forgber et al., 2006; Theinert et al., 2005). The disadvantage 
of this method is the requirement of patient serum, which is not always available in 
excess and more importantly not all protective antigens are immunogenic during 
disease. 
For that reason it was decided to use an in silico method to identify and select novel 
antigen candidates from proteomics data derived by comparative analysis of L. 
mexicana life cycle stages (Paape et al., 2008). The majority of these antigens were 
also detected in another study (table 3.1) using leishmania proteomics but was only 
published in 2008 (Rosenzweig et al., 2008) that is after this thesis project had started. 
The proteomic approach took advantage of the completion of sequencing projects for 
L. major and L. infantum, respectively (Ivens et al., 2005; Peacock et al., 2007). The 
sequencing of the L. major Friedlin strain led to the prediction of 8272 proteins. Five 
hundred and nine of these open reading frames have been identified in the 
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comparative proteome project (Paape et al., 2008). This is equivalent to 6.2 percent of 
the whole proteome and reflects the most abundant proteins present in both life cycle 
stages.  
The in silico selection of antigens for vaccine development has been successfully 
described for the gastric pathogen H. pylori (Sabarth et al., 2002), which led to the 
confirmation of HP0231, an antigen which was previously discovered by 
immunoproteomics (Haas et al., 2002) and was later included in a clinical vaccination 
study (Aebischer et al., 2008). According to Sabarth et al. it was presumed that 
vaccination against abundant protein from pathogens facilitates recognition and thus 
response by the immune system. For the purpose of the development of an anti-
leishmania vaccine, it can be assumed that the 6.2 % of proteins identified in the 
proteomics study are representing the most abundant proteins.  
Genetic diversity clearly exists for Leishmania species (Ivens et al., 2005; Peacock et 
al., 2007). Therefore it was considered important to favour antigens which are highly 
conserved among Leishmania spp. A comparative sequence analysis using ClustalW 
has been done for all antigens selected in this thesis (fig 3.2 and supplementary 
material), which showed a high grade of homology. Furthermore, it is known that 
vaccination with proteins can induce autoimmune reactions and suboptimal immune 
responses, due to cross-reactivity with host proteins. Therefore it was of importance 
that the antigens in question have no homologues in humans or mice. None of the 
selected antigens showed any homologies. Taken together, five antigens have been 
selected for this thesis using the in silico approach. Two of them have been shown to 




4.2 Discovery of two novel protective antigens to vaccinate against L. major 
and L. donovani 
 
Five antigens have been selected to be tested in murine models of VL. In addition 
KMP-11 was chosen to serve as a reference control. Its immunogenic potential as 
antigen in prophylactic and therapeutic vaccines against VL has been shown in 
previous studies using KMP-11 expressed by Toxoplasma gondii (Ramirez et al., 
2001), KMP-11 DNA vaccine (Basu et al., 2005) and a KMP-11 transfected hybrid-
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cell vaccine (Basu et al., 2007a). Due to the encouraging results of these studies 
KMP-11 is currently being developed for clinical studies (T. Aebischer, personal 
communication).  
 
However, results of vaccination of susceptible BALB/c mice with KMP-11-
expressing S. typhimurium SL3261 and subsequent challenge with L. major were 
disappointing. Lesion development for the cytosolic expression strain was comparable 
with the SL3261 carrier control (fig. 3.16A and 3.30A) in several experiments and a 
reduction in parasitic burden in the spleen was only transient (fig. 3.16B). 
Interestingly, expression of KMP-11 on the surface of salmonella resulted in an 
increased parasitic burden compared to control mice (fig. 3.16B). Bhaumik and 
collegues have shown that vaccination of BALB/c mice with KMP-11-encoding 
plasmids required the addition of IL-12 to induce a protective immune response, 
which is in contrast to L. donovani, where this kind of vaccination alone was 
sufficient for protection (Bhaumik et al., 2009). This could be an explanation for the 
failure of KMP-11 formulated as a recombinant salmonella vaccine; hence results 
from a challenge with L. donovani were expected to be more promising. However, 
data obtained after L. donovani challenge reflected and confirmed the previous 
observations. Mice vaccinated with cytosolic expression strain pcVAC1-KMP 
showed reduced parasite burdens in spleen and liver at day 28 and 68 after infection 
(fig. 3.21) compared to sham-immunised mice but no differences were detected in 
comparison to the carrier control SL3261. Determination of antigen-specific antibody 
titres in serum showed IgG1 and IgG2a of similar levels in the L. major model, which 
indicated the presence a mixed TH1/TH2 response considered to be of advantage for 
protection against L. donovani (Basu et al., 2005; Basu et al., 2007a; Stager et al., 
2003a). KMP-11 vaccinated mice from the L. donovani study however produced more 
IgG1 (data not shown), thus were biased towards TH2 response. Interestingly, mice 
from both negative control groups (naïve and carrier control SL3261) showed a 
similar antibody response after infection, with high levels of KMP-11-specific IgG1. 
Overall these findings suggest that despite promising results for KMP-11 in DNA 
vaccines and cell-hybrid vaccines, salmonella were presumably not the ideal vaccine 
carrier for KMP-11, although the novel antigens described in this study were highly 
protective when delivered by recombinant salmonella. This shows that not only the 
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nature of the antigen is of importance for vaccine development but also the way of its 
delivery. 
Two out of five antigen candidates initially selected for this study have delivered 
promising results against both pathogens L. major and L. donovani. LinJ23.0410 is a 
small protein of unknown function, which can be expressed in the cytosol as well as 
the surface of S. typhimurium. Mice that had been vaccinated with either variant 
showed a delayed onset of disease, although surface expression of LinJ23.0410 did 
deliver better results. Throughout the studies, animals vaccinated with the cytosolic 
strain, pcVAC1-23.0410 produced antigen-specific IgG2a, whereas IgG1 was below 
detection limit. After infection however, the ratio IgG1 versus IgG2a varied between 
different experiments, but overall titres remained relatively low (~100) in comparison 
with other antigens (~1000 for KMP-11 and LinJ08.1140). Interestingly, the surface 
expression strain did not elicit any detectable antibody response against LinJ23.0410. 
Purification experiments have shown this protein to be very hydrophobic. After 
extraction from inclusion bodies and on-column refolding the protein was eluted in 
buffer containing imidazole for stabilising purpose, which had to be removed in a 
dialysis step. This resulted in rapid precipitation of the protein shortly after. In 
salmonella transportation of this highly hydrophobic protein to the bacterial surface 
may have resulted in precipitation and thus blockage of the AIDA-pore. Furthermore, 
pore blockage might be an explanation for the observation that wild type as well as 
RBS mutant strains showed similar levels of protein expression and bacterial fitness 
(fig. 3.6 and 3.9) indicating limited toxicity.  
 
The second and particularly protective antigen was LinJ08.1140. Similar to 
LinJ23.0410 it is a hypothetical protein of unknown function, selected from the 
comparative proteome analysis. Surface expression of this antigen resulted in a 
significant reduction of parasitic burden in the spleen and a significant delay in lesion 
development after challenge with L. major. Serum analysis of L. major infected mice 
showed that the initially TH1 biased immune response was averted towards TH2, 
which is in agreement with the observation that vaccination did not fully prevent 
disease and with the fact that progressive disease in BALB/c mice has been correlated 
with a TH2 type immune response. In the L. donovani study however, the majority of 
LinJ08.1140 vaccinated mice show a TH1 biased response (data not shown) on day 28 
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which persisted till later stages of infection at day 68 and reflected the fact that 
disease did not progress in vaccinated mice.  
Elevated organ weights for spleen and liver were observed in LinJ08.1140-vaccinated 
mice at day 28 after infection. This was very likely a result of vaccine-induced 
inflammation and recruitment of immune cells in response to parasite infection. A 
similar observation was described in resistant C57BL/6 mice where the effect was 
attributed to the presence of IL-12, which promoted rapid development of granulomas 
(Satoskar et al., 2000), and in BALB/c mice when function of CTLA-4, a negative 
regulator of T cell activation was blocked (Murphy et al., 1998). This hypothesis was 
supported by the low LDU numbers measured in spite of the elevated organ weight.  
Overall, the level of protection observed for this particular antigen, LinJ08.1140, is 
considered to be very good. A similar protection status was achieved after vaccination 
of mice with recombinant antigen HASPB1 (Stager et al., 2000). As a result HASPB1 
is included in a clinical study which is currently in preparation (T. Aebischer, 
personal communication). 
 
Most studies using single vaccine antigen formulations did not report sterile 
immunity, a fact that has also been observed in this thesis. It therefore can be assumed 
that vaccination against VL will require more than one antigenic target to achieve 
sterile immunity if ever possible. LinJ08.1140 and LinJ23.0410 were the most 
protective antigens studied in this work. Like for many other antigens vaccination 
with these proteins significantly delayed onset of disease and reduced parasitic burden 
in visceral organs. In order to test for synergy, the respective salmonella vaccine 
strains emerging from the first in vivo evaluation psVAC5-08.1140, psVAC0-23.0410 
and pcVAC1-23.0410 had been combined to one vaccine, called “vaccine allstars”. 
Both antigens seemed to synergize (see figure 3.18), enhancing the vaccination effect 
against L. major significantly. In the L. donovani model, no difference between the 
vaccine allstars and the single expression strain psVAC5-08.1140 was found. Both 
formulations showed a remarkable reduction in parasitic burden in spleen and liver. 
Interestingly, an increase in liver and spleen weights, as seen in LinJ08.1140 
vaccinated mice, was not observed, when LinJ08.1140 was combined with 
LinJ23.0410, thus suggesting a counterbalancing effect of the latter with respect to 
inflammation. Due to the hypothetical nature of both antigens the mechanism leading 
to this synergy remains unclear. Synergy can be due to additive effects of 
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immunogenic antigens or to the immuno-modulatory properties of one or more 
antigens. This kind of effect has been previously demonstrated for Leish-111f, a 
recombinant poly-protein, proven to be effective against L. infantum. Two of its 
components, TSA and LmSTI1 have been shown to elicit a protective immune 
response in BALB/c mice when administered with IL-12. The third component, LeIF 
was only partly protective (Skeiky et al., 1998), but found to be a strong TH1 inducer 
stimulating the immune system to produce IL-12, IL-18 and IFNγ, thus making the 
co-administration of IL-12 redundant (Coler and Reed, 2005; Coler et al., 2007). 
Another vaccine, combining protective antigens KMP-11 and HASPB1, is currently 
in development (T. Aebischer, personal communication). Thus, the novel candidates 
discovered here may be incorporated into a future multi-component vaccine. 
 
The remaining three antigen candidates tested during the course of this thesis did not 
confer any significant protection and were not further analysed. Immunisation with 
salmonella expressing LinJ25.1680 on the surface (psVAC5-25.1680) led to 
significant exacerbation and rapid disease progression in mice after challenge with 
L. major. Interestingly a second vaccine strain (psVAC0-25.1680) expressing far 
more LinJ25.1680 antigen under in vivo conditions (fig 3.9) did not show 
exacerbation but similar results as the SL3261 carrier control. The mechanism leading 
to that observation remains unclear though potentially interesting.  
 
 
4.3 Vaccine-independent factors to influence and modulate vaccine induced 
immune response 
 
Unspecific immuno-stimulatory effects such as additional stress, carrier effects and 
the nutritional status of the mice can modulate the response to vaccination, as 
observed in this thesis. 
Stress can highly influence the immune system and therefore mice are held under 
equal conditions to allow comparative analysis of immunological data. However, 
during one experiment, mice suffered additional stress originating from a broken 
water bottle in that particular cage. Mice from this cage were previously immunised 
with cytosolic expression strain pcVAC1-23.0410 and were highly protected from 
L. major challenge. Stress related hormones affect major immune functions and are 
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known to shift immune responses towards an anti-inflammatory TH2 response. This 
would mean a major disadvantage for these mice. However, it has also been shown 
that stress, especially short term, can enhance skin delayed-type hypersensitivity 
(DTH) reaction in rodents, due to rapid infiltration of immune cells from the blood to 
the skin (summarised by Elenkov and Chrousos, 2006). This reaction might be a 
possible mechanism and explanation for the delayed onset of disease after 
subcutaneous injection of L. major parasites. 
Dependent of the source of mice; oral administration of the aroA- salmonella strain 
SL3261 had a major impact on their health. Despite attenuation of the salmonella 
strain, mice displayed symptoms typical for typhoid fever in mice, such as scrubby 
fur, weight loss and apathy, and recovery could take up to four weeks. Lowering the 
CFU of salmonella to 1x 109, a dose which is normally well accepted did not lead to 
any improvement. These severe symptoms were only observed in mice purchased 
from Harlan UK and it was speculated that nutrition and an altered intestinal flora 
played a major role in the apparently enhanced virulence of the attenuated vaccine 
strain. Similar observations were recently discussed by Round and collegues (Round 
and Mazmanian, 2009). As a result mice which received SL3261 carrier control 
showed a faster lesion development and disease progression than their PBS 
counterparts. This might also be an explanation for the observation that immunisation 
of C57BL/6 mice (Harlan UK) with the vaccine allstars in general did not yield the 
same level of protection as observed with BALB/c mice (bred at University facilities 
or purchased from Charles River UK). 
Vaccination with live carrier such as salmonella alone can confer protection against 
experimental infection to certain extends. This effect has been observed in mice from 
other sources than Harlan UK, which did not encounter salmonella-induced disease as 
described above. Carrier effects are quite common and are very likely due to 
unspecific stimulation or the presence of leishmania parasite cross-reactive antigens 
expressed by the salmonella carrier. 
In addition, contamination of the animal facility with murine pathogens occurred 
during the course of the present studies. One of these pathogens, pinworm Syphacia 
obvelata, is known to induce a TH2 response with the production of IL-4, IL-13 and 
specific IgG1 (Michels et al., 2006). This, of course, may have modulated the 
outcome of vaccination experiments against leishmaniasis using L. major parasites 
where a TH1 response is required for protection. 
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4.4 Attenuated salmonella as live carrier vaccine against visceral 
leishmaniasis 
 
The heterologous expression of antigens in attenuated S. typhimurium or S. typhi for 
vaccination of mice and humans, respectively, has been studied against a number of 
pathogens (reviewed by Galen et al., 2009). Immune responses are generally dose-
dependent (reviewed by Zinkernagel et al., 1997) and it has been shown in 
S. typhimurium, that abundantly produced proteins are more likely to be recognized 
by the immune system and result in activation of specific CD4+ T cells (Rollenhagen 
et al., 2004).  
Heterologous antigen expression in salmonella can result in the loss of bacterial 
fitness due to toxicity, and therewith impair the delivery of antigen and its 
presentation to the immune system. To overcome this obstacle the in vivo inducible 
PpagC promoter from salmonella was used for this study. The promoter and 
subsequently antigen expression is activated by low Mg2+ concentrations which 
typically prevail in the phagosome of APCs, where antigen can be processed and 
directly loaded onto MHC molecules. Expression of the well studied fusion protein 
GFP_OVA from this promoter showed no effect on bacterial fitness compared to the 
carrier control, as demonstrated by in vivo colonisation assays (Bumann, 2001). Work 
by Bumann showed that this promoter has a low in vitro activity (< 4000 copies of 
GFP_OVA per cell) compared to a very high activity in vivo (> 90 000 copies of the 
protein per cell), thus reducing rapid plasmid loss in vivo. However, here hypothetical 
proteins of unknown function from leishmania were to be expressed. No information 
about potential cytotoxicity or their impact on the metabolic burden of the vaccine 
carrier was available. Over-expression in E. coli showed that four proteins 
accumulated in inclusion bodies, while one; LinJ35.0240 was not expressed at all, 
thus indicating a negative impact on the host strain. Indeed, the majority of these 
antigens were not expressible from PpagC in the cytosol of salmonella under in vivo 
conditions, suggesting that expression of these antigens even at reduced levels in RBS 
mutant strains was not well tolerated.  
Bacterial fitness can be increased by fine regulation of protein expression. One 
possibility to control intracellular expression levels is the selection of promoters of 
different strengths. The disadvantage of such a system is that promoters may react 
different in diverse carrier systems thus complicating transfer of results from one 
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vaccine model to the other (e.g. mouse/S. typhimurium to human/S. typhi). Therefore, 
regulation of antigen expression on a translational level seemed to be the better 
option, as it allowed the use of a single optimised promoter system. This has been 
done by introduction of point mutations into the ribosomal binding site (RBS) in this 
study and elsewhere (J. Schroeder, unpublished data). These mutations influence the 
binding of the ribosome to the mRNA transcript, resulting in altered translation 
efficiency. A study probing different mutations and their influence on bacterial fitness 
was previously carried out using H. pylori antigen HP0231. Bacterial fitness is 
determined by counting the CFU in Peyer’s patches at day 7, which in general shows 
the peak colonisation and has been used as a surrogate for total colonisation. The 
factorial combination of in vivo antigen levels and bacterial numbers fit for antigen 
delivery showed a direct correlation with vaccine-induced immune responses such as 
specific IgG and T helper cell mediated protection against H. pylori challenge (fig. 
4.1, Schroeder et al., unpublished data).  
 
Fig. 4.1: Effect of HP0231 abundance on salmonella antigen delivery, bacterial 
fitness and immunogenicty 
A: Peyer’s patches colonization of salmonella expressing various amounts of HP0231 
at day 7 post immunization. Based on these colonization data and the estimated in 
vivo HP0231 levels, the total amount of HP0231 was calculated (solid triangles). 
Means and SEM’s for group of 3 to 7 mice are shown. B: Serum anti-HP0231 IgG 
titres (open triangles) seven weeks after immunization with salmonella expressing 
various HP0231 amounts, and Helicobacter pylori stomach loads three weeks after 
challenge infection (and ten weeks after immunization; open circles).  
 
Therefore this strategy was also applied for the expression of leishmania antigens 
during this project. For example antigen LinJ23.0410 expression reduced bacterial 
fitness to a minimum, as no in vivo colonisation was detectable at day 7 after oral 
vaccination. The introduction of a single point mutation in the RBS resulted in a 
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reduced antigen expression but higher bacterial fitness. This strain, pcVAC1-23.0410 
was consequently included in protection studies and was able to reduce parasitic 
burden in mice. However, antigens LinJ08.1140, LinJ09.1180, LinJ25.1680 and 
LinJ35.0240 could not be expressed by either wild-type or RBS mutated strains. This 
was most likely due to toxicity, favouring the outgrowth of strains carrying amber 
mutations in the cDNA coding the antigen.  
However, these antigens were successfully expressed on the surface of salmonella and 
protection studies resulted in the discovery of psVAC5-08.1140 which was 
particularly protective. Antigen localisation plays an important role for the induction 
of an immune response (reviewed by Zinkernagel et al., 1997) and surface 
presentation presumably eases access of proteolytic enzymes in the phagosome of 
macrophages and loading of peptides onto MHC-II molecules (Verma et al., 1995; 
Hess et al., 1996). Furthermore it is known that, like all Gram negative bacteria, 
salmonella undergo constant membrane shedding. The release of outer membrane 
vesicles intra- and extracellularly may activate the MHC-II machinery, thus allowing 
loading of antigenic peptides derived from OMVs.  
 
Leishmania parasites are released into the skin by their sand fly vector. Starting from 
the site of infection, parasites remain local in case of CL or disseminate to internal 
organs in case of VL. No sterile immunity after challenge with L. major or 
L. donovani was achieved in this study or in any other (Yang et al., 1990; Xu et al., 
1995; McSorley et al., 1997; Lange et al., 2004) using salmonella-based or other 
vaccines. This poses the question whether oral vaccination with recombinant typhoid 
salmonella is a good strategy to address early infection at the site of transmission, or 
what is needed to improve the vaccine. Oral administration of vaccine strain S. typhi 
Ty21a, registered for human vaccination against typhoid fever and proposed as one of 
the possible carrier strains for heterologous antigens, was shown to induce mainly gut 
homing lymphocytes. A vast majority (99 %) of responding lymphocytes carried gut 
homing receptor α4β7 integrin, whereas L-selectin responsible for homing to 
peripheral lymph nodes and spleen was found on 42 % and cutaneous lymphocyte 
antigen (CLA) for skin homing was found only on 1 % of specific circulating T and B 
lymphocytes (Kantele et al., 1997; Salerno-Goncalves et al., 2005; Kantele et al., 
2003; Lundin et al., 2002). However, intra-muscular injection of formalin-killed 
salmonella resulted in L-selectin expression on 86 % of cells, whereas 58 % were 
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positive for α4β7, indicating that the intra-muscular route of immunisation is able to 
activate the against VL important systemic immune response (Kantele et al., 1997). 
The same research group investigated the effect of administering multiple doses of 
salmonella via different routes. Oral re-immunisation led to an up-regulation of skin 
homing receptor CLA by 34-48 % of reactive lymphocytes independent of the 
priming route. The group proposed a possible connection between gut and skin in 
association with food allergies, where skin homing lymphocytes are also up-regulated. 
They further discuss that the skin area of the body comprises less than 2 m2, whereas 
the intestinal surface is estimated to be 400 m2. Consequently, more specific T cells 
are required to cover the considerably larger intestinal area. This would be an 
explanation for the different percentages in homing receptors expressed after 
salmonella uptake as excessive accumulation of T cells in the skin might be harmful 
(Kantele et al., 2003). For vaccination against VL as demonstrated during this project 
it can be argued that this one percent skin homing and the 42 % spleen homing is 
sufficient to significantly reduce parasitic burden in the foot pad (CL) and in the 
spleen (VL), but that by combining intra-muscular priming with oral boost, the 
vaccination effect might be further improved.  
Protection against leishmaniasis is cell mediated and a relevant vaccine is required to 
activate antigen-specific CD4+ and CD8+ T cells. Oral vaccination of mice in this 
study resulted in the activation of CD4+ T cells, as measured by flow cytometry and 
indirectly by ELISA. The T cell response monitored by cytometry was not 
compelling, despite indication that psVAC5-08.1140 mediates the activation of 
IFNγ/TNFα double producing CD4+ T cells. This was most likely due to the low 
sensitivity of the re-stimulation assay, lacking the addition of fresh antigen presenting 
cells, or the choice of fluorescence-labelled antibody, especially against IFNγ, or the 
number of cells acquired, factors which all might improve sensitivity of the assay. 
Activation of specific CD8+ T cells was not detectable at all and is in coherence with 
other studies (Yang et al., 1990; Lange et al., 2004). However, antigen-specific 
activation of CD8+ T cells against intracellular parasites would be of advantage.  
 
Several possibilities to exploit salmonella live vaccine carrier to target CD8+ T cells 
have been published. Xiang and collegues used S. typhimurium as a DNA-delivering 
vaccine against cancer. The cancer specific antigen CEA was expressed from a CMV 
promoter and oral vaccination resulted in the activation of antigen specific CD8+ T 
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cells and their production of IFNγ, IL-12 and GM-CSF, which more importantly was 
also detected in the spleen (Xiang et al., 2001). This would be a good method for non-
cytotoxic antigens like KMP-11 or LinJ23.0410. The most protective antigen of this 
LinJ08.1140, however, cannot be expressed in the cytosol of S. typhimurium. 
Moreover, expression from mammalian DNA vaccine vector pcDNA3.1 did not result 
in any detectable protein in HeLa and P815 cells, despite the presence of specific 
mRNA (data not shown). This characteristic might exclude LinJ08.1140 for DNA 
vaccination, unless smaller potions such as epitope coding regions are used.  
Another attractive method to enhance CD8+ T cell response is the employment of the 
S. typhimurium type III secretions system (T3SS). Genes encoded by salmonella 
pathogenicity island 2 (SPI-2) are up-regulated upon entry to the phagosome of 
macrophages. Fusion of heterogeneous proteins or epitopes from Listeria 
monocytogenes to substrates of the T3SS such as SifA and sspH2 resulted in their 
appearance in the cytosol of host cells 6 to 24 h after oral administration. This led to 
the activation of CD8+ T cells and also the induction of effector memory T cells and 
central memory T cells in spleen and blood (reviewed by Panthel et al., 2008; Galen 
et al., 2009). An essential requirement for CD8+ activation is the presence of MHC-I 
epitopes on the antigen. An in silico analysis for the protective LinJ08.1140 has 
therefore been conducted in this thesis. Prediction programs for MHC analysis have a 
limited reliability. However, a comparative analysis revealed NetMHC to be the most 
reliable server available online (Lin et al., 2008). Simultaneously to LinJ08.1140, 
KMP-11 was analysed and the results were compared with experimental data for 
KMP-11 (Basu et al., 2007b). Some of the experimentally confirmed epitopes for 
KMP-11 were also predicted by the server. However, the online prediction seemed to 
be less sensitive, as not all of the experimental epitopes were recovered. The study by 
Basu was conducted in Germany and the blood donors used were very likely of 
Caucasian origin. The MHC I allele A*0201 is highly prevalent in European 
populations but is completely absent in the Indian population (Mehra, 2000). 
Presumably, A*0201 specific epitopes were among the experimental data, thus were 
not included in the in silico prediction which used A*0211 instead. Nevertheless, 
more MHC-I epitopes and especially more strong binding peptides have been 
predicted for LinJ08.1140 than KMP-11 which is consistent with experimental 
observations in mouse protection studies. Interestingly no MHC-I epitopes have been 
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predicted for BALB/c (H-2d) or C57BL/6 (H-2b) mice, which may explain the lack of 
detectable of CD8+ T cell activation.  
 
 
4.5 Recombinant outer membrane vesicles to augment vaccine-induced 
immune responses 
 
Outer membrane vesicles are a common feature of Gram-negative bacteria and have 
been exploited for vaccine development against a number of pathogens such as 
N. meningitides, Vibrio cholerae and S. typhimurium (Holst et al., 2005; Schild et al., 
2009; Schild et al., 2008; Alaniz et al., 2007). It has been demonstrated that intra-
peritoneal injection of purified salmonella OMVs drastically reduced bacterial burden 
in mice that have subsequently been intra-veneously challenged with S. typhimurium 
(Alaniz et al., 2007). It was reasoned that OMVs carrying respective leishmania 
antigens could reduce parasitic burden and increase protection against VL. To date 
only homologous OMVs were produced for vaccination. There is no reason, however, 
not to produce recombinant OMVs carrying heterologous antigens.  
It was assumed that antigens targeted to the surface will automatically appear on 
OMVs. Therefore the AIDA autotransporter system, already described for salmonella 
surface expression was used. The in vivo inducible PpagC promoter showed very low 
activity in vitro (Bumann, 2001) and was hence replaced by a recently developed 
plasmid based propionate inducible system using the PprpB promoter (Lee and 
Keasling, 2005; Lee and Keasling, 2006). Sodium propionate is an inexpensive 
chemical used as food preservative (Glass et al., 2007) and as such is non-toxic in 
contrast to the for protein induction more commonly used IPTG (Figge et al., 1988). 
Vaccination trials against meningococcal infections in humans have shown that a 
single dose of OMV corresponding to 25 μg total protein is immunogenic (Gorringe 
et al., 2009). This is close to the 5 to 10 μg doses used in respective mouse 
experiments (Moe et al., 2002; O'dwyer et al., 2004). OMVs prepared from one litre 
of culture routinely yielded about 10 mg of protein, and in that context provide more 
than 100 immunogenic doses. Therefore, recombinant OMV offer a strategy for the 
development of affordable vaccine combinations since bacterial culture at industrial 
scale in large fermenters is economically viable even if products are sold at very low 
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prices. This is in particular relevant in the context of neglected tropical diseases such 
as leishmaniasis. 
 
Leishmania parasites are released into the skin after exposure to infected sand flies. 
Therefore it was decided to administer OMV preparations as a booster injection sub-
cutaneously in an attempt to attract CD4+ and CD8+ T cells to the primary site of 
infections. In this thesis a salmonella-based vaccine against VL has been developed 
and tested. However, salmonella vaccination predominantly activates gut-homing T 
cells as discussed before. Antibody responses were determined to characterise the 
salmonella-prime/OMV-boost concept, although protection against leishmania 
infection is dependent on the activation of CD4+ and CD8+ T cells. IgG1 and IgG2a 
responses are dependent of CD4+ T cell help and indicative of IL-4 producing TH2 or 
INFγ producing TH1 responses, respectively, the latter being crucial for anti-parasite 
immunity (Murray et al., 2005). Based on the humoral response, KMP-11 expressing 
live vaccines induced both TH1 and TH2 T cell help. Vaccines expressing LinJ08.1140 
and to a far lesser extend LinJ23.0410, however, showed an elevated IgG2a isotype 
titre indicative for a TH1 biased response. As mentioned and discussed before, surface 
expression strain psVAC0-23.0410 did not induce any detectable antigen-specific 
antibodies. Consistent with a recent KMP-11 vaccine study (Bhaumik et al., 2009) 
and results from this work, immunisation of BALB/c mice with the live vaccine alone 
did not confer a significant protective local (foot pad) or systemic (spleen) effect 
against L. major challenge. Only animals boosted with the respective OMVs showed a 
tendency to reduce systemic parasitic burdens, while no improvement was found in 
psVAC5-08.1140 and pcVAC1-23.0410 vaccinated mice. Interestingly, the only 
strain where boosting with the respective OMV led to a significant decrease in 
systemic parasitic burden was the strain expressing LinJ23.0410 on the surface but 
completely lacking the induction of antigen-specific antibodies. Antibodies have been 
implicated in exacerbating leishmania infection (Miles et al., 2005; Anderson et al., 
2002; Buxbaum, 2008). The sub-cutaneous route of application has been chosen 
deliberately not only to attract T cells to the skin but also because the other options 
intra-venous and intra-peritoneal application would not be viable in human 
vaccination. It can be speculated that i.p. application in mice, as done by Alaniz and 
colleagues might have resulted in better protection, since this route targets systemic 
immunity which is required against VL.  
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Nevertheless, recombinant OMVs are a versatile platform to express heterologous 
proteins or antigens for a wide range of applications. For vaccine development 
different requirements such as safety have to be met. OMV-based vaccines against 
meningitis have shown clear, but mostly moderate side effects (Gorringe et al., 2009; 
Lennon, 2007; Nokleby et al., 2007). Immunisation of individuals in a clinical study 
resulted in adverse reactions such as pain and erythema. Systemic reactions were in 
general mild with headache and malaise reported by up to half of the vaccinated 
individuals. Acceptability of these adverse reactions may depend on the disease 
targeted but may be less problematic for veterinary vaccines e.g. dogs in the case of 
VL.  
Purified antigens on their own are most often not immunogenic and require the 
addition of adjuvant to induce an immune response. However, OMVs harbour 
immuno-stimulatory molecules such as lipoprotein, lipopolysaccharide and 
peptidoglycan, which are recognised by TLRs 2 and 4 on APCs. Activation of these 
receptors results in the induction of an inflammatory response and can induce specific 
T and B cells, thus making the addition of adjuvant redundant. This was shown for 
OMVs derived from salmonella (Alaniz et al., 2007) and V. cholerae where, in 
addition, vesicles were shown to be immunogenic when applied orally (Schild et al., 
2009; Schild et al., 2008). In this thesis it was shown that a single injection with 
recombinant OMVs, containing approximately 0.5 μg of the vaccination antigens 
(data not shown), and increased specific antibody titres in mice primed with 
salmonella vaccine strains 6-40 fold. In a similar study, salmonella primed mice were 
boosted with 10 μg of antigen absorbed to alum, which resulted in approximately 50 
fold higher titres (Londono-Arcila et al., 2002). This comparison indicates that 
recombinant OMVs very potently boosted the antigen specific response.  
During the ongoing development of recombinant OMV for this thesis other attempts 
to derive recombinant OMVs have been reported. For example, fusion constructs of 
E. coli cytotoxin ClyA were engineered to study the process of OMV generation (Kim 
et al., 2008) and outer membrane proteins of pathogenic N. meningitides strains were 
expressed in non-pathogenic neisseria to derive recombinant OMV for vaccination 
(O'dwyer et al., 2004). In addition, OMVs of recombinant V. cholerae expressing 
periplasmic PhoA from E. coli were shown to induce PhoA-specific antibodies 
(Schild et al., 2009). This together with the results from this thesis strongly supports 
the use of recombinant OMVs for vaccination purposes. Compared to these 
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approaches, however, AIDA provides a more versatile platform, which allows the 
display of heterologous proteins from different species including Gram-positive 





In this study, two novel antigens have been discovered and prototypic live vaccines 
expressing these antigens have been developed. These vaccine strains conferred 
significant protection in susceptible BALB/c mice against challenge with L. major 
and more importantly L. donovani. It is clear that further improvements are needed 
but the results show that live attenuated salmonella are a valid carrier concept to target 
visceral leishmaniasis. 
 
Dogs are one of the main reservoirs for L. infantum, and vaccination would certainly 
decrease the risk of humans living in close proximity to become accidental hosts. 
Immunisation of dogs with a DNA vaccine encoding leishmania antigens KMP-11, 
LACK, gp63 and TRYP failed to induce protection against L. infantum (Rodriguez-
Cortes et al., 2007). Attenuated S. typhimurium has been used to vaccinate dogs 
against salmonellosis (McVey et al., 2002) and also in recombinant form against 
Echinococcus granulosis (Chabalgoity et al., 2000; Petavy et al., 2008). Salmonella 
expressing antigen LinJ08.1140 showed the highest protection throughout this project 
and as a first measure the prototypic vaccine developed in this thesis can be used to 
vaccinate dogs. Studies by Petavy showed that an attenuated S. typhimurium isolate 
from dogs is more immunogenic than mouse adapted strain SL3261. Due to the 
plasmid based concept applied here, a transfer of the plasmid into a dog adapted 
S. typhimurium strain should be unproblematic. 
 
During this thesis LinJ08.1140 emerged as a particularly protective antigen. It is still 
classified as hypothetical protein and therefore has not been fully characterised yet. 
However, for its safe applications in humans and in order to explore its full potential, 
more research regarding structural and functional properties is necessary. MHC-I 
epitopes have been predicted in this study but experimental confirmation is required, 
so that peptides can be used in other epitope-based vaccine formulations. 
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Leishmania promastigotes have been stained with a polyclonal antibody raised against 
LinJ08.1140. Fluorescence microscopy revealed a strong signal in dividing parasites, 
thus suggesting a role of LinJ08.1140 in cell division. This still needs confirmation in 
amastigotes and further experiments, e.g. Western blots of stage-specific parasite 
lysates need to be conducted. In addition, a genetic knock-out in leishmania would 
certainly contribute towards investigating its relevance for the parasite.  
 
The approach to produce recombinant outer membrane vesicles developed here 
(Schroeder and Aebischer, 2009) may provide an attractive vaccination system in 
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